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Abstract 
Duchenne muscular dystrophy (DMD) is a fatal disease arising from a mutation in 
the dystrophin gene, resulting in the loss of the functional protein. This causes 
the muscle fibres to become extremely prone to contraction induced muscle 
damage, resulting in excessive inflammation and ineffective regeneration. These 
processes ultimately lead to the loss of muscle fibres and expansion of the 
extracellular matrix (ECM). Fibrosis is not just a consequence of the disease, but 
also actively contributes to muscle degeneration.  
In healthy muscles after injury, a transitional matrix is deposited into the area 
which regulates inflammatory and myogenic cells. For repair to be effective the 
synthesis and remodelling of this transitional matrix is crucial. An important 
transitional matrix protein is the chondroitin sulphate proteoglycan, versican, 
which is known to modulate myogenesis, inflammation and fibrosis. Versican is 
highly upregulated in dystrophic muscles and it is hypothesised that this 
persistent upregulation of versican contributes to DMD disease pathology.  
In DMD, muscle function is improved through glucocorticoid treatment. In other 
diseases with a heightened pro-inflammatory and fibrotic state, the synthesis 
and remodelling of the transitional matrix can be regulated by glucocorticoids. 
However, the role of versican in DMD disease progression is unknown. 
Therefore, this thesis explores:  
1. The effect of dexamethasone and excess versican on myogenic processes 
in-vitro.  
2. The physiological relevance of versican in dystrophy using the dystrophic 
mdx mouse model with genetically reduced versican and subsequent 
characterisation of contractile, histological and metabolic properties of 
the diaphragm and hindlimb muscles.   
Glucocorticoids have pleiotropic effects on dystrophic muscles; including 
dampening inflammation, improving regeneration and reducing fibrosis, leading 
to prolonged ambulation in DMD patients. However, the underlying cellular 
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mechanisms are not fully characterised. Results from Chapter 3 confirmed an 
excess of versican in mdx mice, especially in the severely affected diaphragm 
muscles. In-vitro dexamethasone treated C2C12 cells had decreased versican 
gene and protein expression with enhanced myoblast fusion and myotube 
formation, even in the presence of excess versican.  
In Chapter 4, to investigate whether the genetic reduction of versican improves 
mdx diaphragm function, female mdx mice were bred with male heterozygous 
hdf mice, which are haploinsufficient for the versican allele, to generate male F1 
mdx and mdx-hdf pups. The genetic reduction of versican was found to have 
beneficial effects upon the pathology of 21 week mdx-hdf mice, as it increased 
spontaneous physical activity and also the strength, endurance and force 
recovery of isolated diaphragm muscle strips ex vivo.  
As DMD is a paediatric disease which renders fast twitch muscle fibres especially 
susceptible to degeneration, Chapter 5 describes the effects of versican 
reduction properties of the fast twitch EDL and the slow twitch soleus hindlimb 
muscles in male mdx and mdx-hdf mice during periods of growth and maturity. 
Versican synthesis and remodelling is highly upregulated in dystrophic muscles 
during postnatal growth. In growing, 6 week old mice, the genetic reduction of 
versican improved the strength and endurance of soleus muscles, and the 
endurance of EDL muscles. These functional benefits were greatly reduced in 
hindlimb muscles from adult 26 week old mice. Chapter 5 highlights the 
importance of considering fibre type and growth when targeting versican in 
dystrophic muscles. 
Results obtained in this thesis further solidify versican as a potential therapeutic 
target, and is overall beneficial to understanding the processes and 
consequences of a dysregulated matrix in DMD pathology. Together, the highly 
novel findings within this thesis make a significant contribution to the fields of 
fibrosis and DMD. 
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Chapter 1: A review of the literature  
1.1 Overview of skeletal muscle and surrounding matrices 
1.1.1 Skeletal muscle fibre type and organisation  
Striated skeletal muscle is a highly complex structure comprised of numerous 
bundles of individual muscle fibres, satellite cells, tendons, blood vessels, 
capillaries and nerves, held together by a specialised extracellular matrix (ECM) 
(1). There are three layers of skeletal muscle ECM: the epimysium which 
surrounds the entire muscle, the perimysium which surrounds muscle fibre 
bundles, and the endomysium which surrounds the individual muscle fibres. 
Skeletal muscle is structurally and functionally diverse, but broadly all muscle 
fibres can be classified into type I and type II muscle fibres (2). Type I, slow 
twitch fibres are fatigue resistant due to their high concentration of 
mitochondria and capacity for oxidative metabolism (3, 4); however, their force 
output is relatively low (5). Type II, fast twitch fibres are required for strength 
and sprinting, and have a larger cross-sectional area than type I fibres (6). The 
type II fibres can be further classified into type IIa, IIx and IIb. Type IIa have the 
highest oxidative capacity and best endurance (7). Whilst, type IIb have the 
highest force producing capacity, they are very susceptible to fatigue as they rely 
on anaerobic glycolysis (5). Finally, type IIx fibres are an intermediate form of 
muscle fibre compared to type IIa and IIb fibres (5, 7). In human skeletal muscles, 
fast twitch fibres are a combination of type IIa and IIx (8, 9), whereas in skeletal 
muscle of mice, these fibres are primarily IIb (10). Type I and II muscle fibres not 
only have unique metabolic and contractile properties, but the composition of 
their endomysial matrix also differs (11, 12) (see section 1.2.4.2).  
The focus of this literature review and thesis will be upon the endomysium. The 
endomysium lies just above the sarcolemma, enveloping the individual muscle 
fibre and adjoining satellite cells (13). It has an important role in protecting the 
integrity of the muscle fibre during contractile activity, and following muscle 
damage, the remodelling of the endomysium is critical for a carefully regulated 
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and effective inflammatory and regenerative response (13). Given that 
inflammation and regenerative processes contribute to pathology of dystrophy, 
the endomysial matrix is a particularly important focus for research on 
dystrophic pathology. 
1.2 The endomysial matrix of skeletal muscle 
The endomysial matrix of skeletal muscle is a highly complex environment, 
whose structure and function is influenced by age, muscle type, cellular 
processes, and disease. It is therefore important to first understand each phase 
of the matrix before reviewing those implicated during disease.  
1.2.1 The developmental matrix during morphogenesis 
The developmental matrix is crucial for cellular processes and growth to occur. 
Embryonic cells are able to produce a specialised developmental matrix during 
morphogenesis (14). The process of morphogenesis will not be described in 
great detail here as it is beyond the scope of this thesis, however it has 
previously been extensively reviewed (14, 15). Even though matrix components 
have been previously mapped and characterised, the exact role of the muscle 
matrix during morphogenesis is still not fully understood (15). It is important, 
however, to acknowledge that a developmental matrix is one that is very 
different to a mature matrix. This is because there are many processes that are 
occurring during this highly complex transitional period of growth.  
Briefly, this developmental matrix is a loose hydrated matrix that is comprised of 
proteins such as laminins, fibronectin, tenascin (15), as well as hyaluronan (16) 
and versican (17). These proteins are extensively produced and remodelled 
throughout embryonic muscle development. This may be because the 
developmental matrix acts as a scaffold, both nurturing and directing cells such 
that correct proliferation, migration and differentiation can occur. For instance, 
versican can act as a barrier for neural crest cells, preventing them from 
migrating to the wrong area during development (18, 19).  
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Relevant to this thesis, versican, shown to be present within the skeletal muscle 
of the developing murine embryo (17), is also known to increase the 
proliferation of young turkey satellite cells (20), suggesting it plays a crucial role 
in muscle development. It is important to note that some proteins, such as 
versican, are largely upregulated during development, yet are scarce in the 
mature matrix (17). 
1.2.2 Structure and function of the mature skeletal muscle 
endomysium  
The mature endomysium (Figure 1.1) is a highly complex and specialised matrix 
essential to the integrity and function of muscle fibres and the adjacent satellite 
cells. Skeletal muscle contraction requires the transmission of lateral force from 
the contractile apparatus outwards (21), which relies on a fully functional and 
stabilised endomysial matrix, to prevent muscle fibre damage. 
To appreciate how force is dissipated from the contractile apparatus through the 
sarcolemma and into the muscle fibre ECM, it is important to understand the 
structure of the surrounding endomysium. The endomysium contains two 
specialised layers, the basement membrane (comprising the basal and reticular 
laminas) and the interstitial matrix (see Figure 1.1). The basement membrane is 
the immediate matrix that attaches the muscle fibre, and therefore the 
intracellular contractile apparatus, to the surrounding connective tissue. One 
way this link is formed is through an important intracellular protein called 
dystrophin which binds and stabilises the large, multiprotein transmembrane 
dystrophin-associated protein complex (DAPC) on the sarcolemma. Dystrophin is 
needed to stabilise the muscle membrane during contractile activity. Without 
dystrophin the entire DAPC dissociates and the structural integrity of the muscle 
fibre and sarcolemma is severely compromised (22). The DAPC complex is 
comprised of numerous proteins, including dystroglycans, sarcoglycans, 
sarcospan, dystrobrevins and syntrophin (23, 24). This complex plays a major 
role in the transmission of contractile forces within the endomysium, and is also 
important for cell signalling (25). Laminin is present throughout the basal lamina 
(26) and is able to bind to the α subunit of dystroglycan within the DAPC 
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complex, thus providing the critical linkage of the contractile apparatus to the 
surrounding ECM. Laminin is also able to bind to major membrane receptors 
known as integrins, which are equally as important as the DAPC complex, not 
only for their ability to transmit forces, but also for their cell signalling properties 
(27). Integrins can also bind collagen IV, which binds to itself to form a flexible 
ECM network (28-30).  
Laminin and collagen IV are also the major constituents of the basal lamina (31, 
32). Laminin is able to bind and form clustered networks of itself, and through 
additional binding of proteins, such as nidogen (entactin) which binds collagen 
IV, can enable the formation of more complex matrix networks (33). Collagen IV 
networks are also found within the adjacent reticular lamina, along with 
networks of collagen VI (26). Both the basal and reticular laminas, which 
together comprise the basement membrane, contain these non-fibrillar collagen 
networks (26) which are flexible enough to allow for the movement of blood 
through capillaries and migration of inflammatory cells (30), yet are strong 
enough to provide stability to the adjacent sarcolemma during muscle 
contraction. The basement membrane also provides the vital link between the 
sarcolemma and the interstitial matrix (30) through collagen VI rich networks 
(34), which are able to co-localise with fibrillar collagens I and III (21) in the outer 
edge of the reticular lamina (32).  
The collagen isoforms found in the interstitial matrix differ from those found in 
the basement membrane as they do not form networks, instead assembling 
themselves into strong fibrils (26), which run longitudinally above the 
sarcolemma. Therefore, collagen I and III provide additional strength and 
support to the surrounding matrix and muscle fibres. This is important as the 
role of the interstitial matrix is not only bind all muscle fibres, nerves and blood 
vessels to within close proximity to each other, providing structure and support, 
but also helps preserve muscle integrity through the dissipation of force during 
muscle contraction (35). 
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Figure 1.1 A simple overview of the endomysial matrix 
Inside the muscle cell, dystrophin, an integral structural protein in 
muscle, can be seen binding to the DAPC complex, and associates 
with nNOS below the sarcolemma. The sarcolemma expresses 
receptors such as integrins and CD44, from which they bind and link 
the layers of the endomysium. These endomysial layers are highly 
specialised matrices that encompass an individual muscle fibre. The 
basal and reticular laminas together form the basement membrane. 
They are comprised of laminins, nidogen, hyaluronan and versican 
and fibrillary collagens IV and VI, which provide a flexible yet 
structured environment, and allows the dissipation of muscle 
produced force. Note the quiescent satellite cell nestled against the 
sarcolemma, yet underneath the basal lamina. Lying above the 
basement membrane is the interstitial matrix, which is comprised of 
non-fibrillar collagens I and III. These collagens can interact and bind 
with collagens and receptors in the basement membrane, and 
provides structure and support to the cell and surrounding 
environment. Furthermore, versican, a chondroitin sulphate 
proteoglycan, can be found throughout the endomysium and is 
highly upregulated during development or in response to injury. 
Versican, bound by hyaluronan or by itself, can be found interacting 
with CD44 at the cell membrane. Figure has been modified from 
(36) using (21, 26, 37). 
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1.2.3 Proteoglycans associated with developmental and mature 
matrices 
Proteoglycans are another important class of proteins found within the 
interstitial matrix and the basal lamina. Key proteoglycans in skeletal muscle are 
biglycan, decorin, hyaluronan and versican. The expression of these proteins are 
specific and are differentially regulated during development, growth and in adult 
muscle, as well as during regeneration and fibrosis (38-41). Biglycan contains 
chondroitin sulphate (CS) glycosaminoglycans (GAGs) and is known to bind to α-
dystroglycan on the DAPC complex within the basal lamina (42). Decorin contains 
CS and dermatan sulphate (DS) GAGs, and is found within the interstitial matrix 
where it binds collagen (43). Decorin and biglycan are both able to bind 
transforming growth factor beta (TGFβ) (44), a cytokine associated with fibrosis 
and the regulation of muscle precursor cell proliferation and differentiation (45, 
46).  
Another much larger and more complex proteoglycan found in the basal lamina 
and the interstitial matrix is versican (37) (see Figure 1.1). Versican mostly 
contains CS and some DS GAGs (47, 48). These allow for interactions with a 
number of ECM proteins, including hyaluronan (49) which forms a link to the cell 
membrane by binding to CD44 (50). Like decorin and biglycan, versican is able to 
bind various chemokines and cytokines through its GAG side chains (51), 
however TGFβ is bound through its attachment to the core protein (52). When 
the CS GAG chains become oversulphated, they are able to strongly bind L- and 
P-selectin (53) found on inflammatory cells which raises the possibility of 
versican being able to regulate the migration of leukocytes within the interstitial 
matrix (54, 55).  
Regulation of proteoglycan expression within skeletal muscle is highly complex, 
with versican and biglycan being highly upregulated during embryogenesis and 
development, whilst being very scarce in the ECM of healthy adult muscles (17, 
39). Unlike versican and biglycan, decorin is expressed highly towards the end of 
development before spreading throughout the ECM in adult muscle (56). 
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1.2.4 Regions of specialised endomysium 
It is important to note that the endomysium of muscle fibres is a highly complex 
environment, and is not consistent across the entirety of a muscle. There are 
specific niches and regions of function, such as the neuromuscular junction, fibre 
types and even satellite cells. This further highlights the complexity and function 
of the endomysium.  
1.2.4.1 Neuromuscular junction 
For muscle contraction to occur, a motor neuron must be connected to muscle 
fibres via a neuromuscular junction (57). The neuromuscular junction has a 
specialised basal lamina that is continuous between the nerve terminal and the 
muscle endplate. It attaches the nerve to the muscle fibre (58), providing 
specialised support for action potentials to reach muscle fibres in a quick and 
uninhibited manner (57). The protein composition of basal lamina at the 
neuromuscular junction is similar to the mature muscle basal lamina, although 
different matrix proteins are expressed. A well characterised example of this is 
utrophin, a functional homologue of dystrophin (59). Utrophin is highly 
expressed in developing and regenerating muscle fibres (60), however in adult 
muscle, utrophin is found predominately at the neuromuscular junction (61) 
where it is stabilised by biglycan (62). Like dystrophin, utrophin also links the 
intracellular actin to the ECM via the DAPC (59, 60) and is therefore thought to 
be beneficial in stabilising the muscle sarcolemma (63). 
1.2.4.2 Fibre type 
There are also differences in the structure of the endomysial ECM between slow 
and fast twitch muscle. This has implications for force transmission and 
membrane stabilisation during muscle contractile activity. Slow type I muscle 
fibres express more dystrophin (64) and utrophin (65) than fast type II fibres, 
leading to a more stabilized membrane during muscle contractions. Findings 
from rat soleus muscles indicate that type I fibres also contain more collagen IV 
(11), which may lead to a more flexible basement membrane (30). This is 
important as type I fibres are recruited in all muscle contractions, so matrix 
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flexibility is crucial (66, 67). Type II fibres produce the strongest forces within 
muscle (66) and are therefore thought to be more susceptible to contraction 
induced damage (68). Type II fibres from rat rectus femoris muscle have been 
found to contain more laminin than type I fibres (11). This would allow for 
stronger adhesion to the ECM by binding proteins such as nidogen which 
provides a link through the matrix via collagen IV networks, thus helping to 
dissipate contractile forces. 
1.2.4.3 Satellite cells 
Satellite cells reside above the muscle fibre sarcolemma in a specialised niche 
within the basal lamina (69, 70). The satellite cell niche is highly complex and is 
not yet fully understood. Briefly, the niche and its associated matrix proteins 
provide a protective and nurturing environment for the satellite cells, keeping 
them in a quiescent state (71, 72). Satellite cells express various receptors, such 
as integrin α7β1 which binds laminin to provide a stable attachment to the basal 
lamina, and M-cadherin which anchors the satellite cells to the adjoining muscle 
fibre (69). In this manner, satellite cells are kept securely in the niche, in a 
position that nurtures and supports, until they become activated. Satellite cells 
undergo activation through exposure to various stimuli, ranging from contractile 
forces to cytokines and growth factors, produced from the adjacent muscle 
fibres and surrounding matrices upon injury.  
1.2.5 The transitional endomysial matrix during regeneration 
The expression of various developmental proteins is greatly decreased upon the 
formation of a mature matrix, and a similar expression pattern may be seen in 
response to an injury that causes tissue damage. This may happen as part of 
normal muscle adaptation, where the muscle undergoes cycles of degeneration 
and regeneration in order to increase and improve muscle strength, or as a 
consequence of musculoskeletal diseases, such as DMD. When muscle damage 
occurs, as part of the inflammatory and regenerative response, the mature 
matrix is remodelled and a specialised, transitional matrix, similar to that seen 
during development, is synthesised in its place (73). This transitional matrix is 
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comprised of fibronectin, tenascin C, hyaluronan (73), and other proteins, such 
as versican (74). This loose matrix directs the infiltration and behaviour of cells 
such as leukocytes, fibroblasts and muscle progenitor cells, by acting as a 
scaffold and allowing them to embed themselves throughout the injured space 
before beginning to secrete and lay down mature proteins (75-77). In this 
manner, the transitional matrix is able to regulate crucial processes for effective 
tissue repair. 
1.2.6 Dysregulation of the endomysial matrix leads to fibrosis 
The endomysium is a highly specialised matrix whose composition can vary 
depending on the subcellular location of the muscle fibre, on muscle fibre type 
and the stage of muscle development. Collectively, this highlights the 
importance of the endomysium for healthy muscle function as it regulates 
almost all aspects of cellular behaviour. Any cellular signalling event that involves 
receptor-mediated responses or membrane soluble molecules must negotiate 
the matrix. As such, an abnormal endomysial matrix will inevitably result in 
abnormal cellular responses. 
The endomysium regulates cellular behaviour through proteins and their cleaved 
bioactive fragments, formed through extracellular protease activity. These 
include matrix metalloproteinase (MMP) (78), A Disintegrin And Metalloprotease 
(ADAMS) (79), and A Disintegrin And Metalloproteinase with ThromboSpondin 
motifs (ADAMTS) proteases (80). However, to maintain matrix integrity, this 
remodelling needs to be carefully regulated and thus protease inhibitors are also 
very important. These include the tissue inhibitor of metalloproteinases (TIMP) 
1-4 which can inhibit MMP, ADAM and ADAMTS proteases (81, 82). The 
remodelling of the endomysial matrix is functionally significant as it can store 
and regulate the bioavailability of cytokines and growth factors via 
proteoglycans containing heparan (83), dermatan or chondroitin sulphate GAG 
chains (84). Endomysial remodelling, including the synthesis of a transitional 
matrix, is observed during a range of physiological and pathological processes. 
These include embryogenesis and development (14), muscle injury, and in 
neuromuscular diseases such as DMD (85). 
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In a healthy muscle, protein synthesis and degradation are carefully regulated to 
drive appropriate cell behaviour (86). However, if matrix synthesis and 
degradation becomes dysregulated, then fibrosis occurs (87). Fibrosis is the 
permanent expansion of the endomysial matrix, occurring due to the 
unregulated and increased expression of matrix proteases (88), collagens and 
proteoglycans located in the basement membrane and interstitial matrix (40, 89, 
90). Fibrosis is driven by increased inflammation, fibroblast proliferation and 
myofibroblast differentiation, as well as from muscle fibres themselves (87, 91, 
92). Fibrosis not only alters cell behaviour, but also negatively impacts the 
transmission of force during muscle contraction (93).  
Healthy muscle fibres are arranged in neat rows which aids contractile function, 
however when fibrosis is present, muscle fibres become highly disorganised and 
muscle strength deteriorates (94, 95). Increased fibrosis and disorganisation of 
muscle architecture is most prominently seen in muscular dystrophies, of which 
DMD is the most prevalent.  
1.3 Muscle pathology and fibrosis in DMD 
DMD is the most common and severe form of muscular dystrophy, affecting 
approximately 1 in 5000 boys worldwide (96). It is a recessive, X-linked 
hereditary disease caused by a mutation in the dystrophin gene, leading to the 
loss of expression of the functional protein (97). Dystrophin stabilises the 
sarcolemma during contractile activity (see section 1.2.2) (98). Dystrophin binds 
to f-actin in the cytoplasm and to the transmembrane protein β-dystroglycan 
(99), which is part of the DAPC. In DMD, the loss of dystrophin renders 
dystrophic muscles highly susceptible to contraction induced injury through the 
lost connection to the ECM. Aside from a structural role, dystrophin is also 
involved in cell signalling. The best characterised example is the integration of 
dystrophin with neuronal nitric oxide synthase (nNOS), which anchors nNOS to 
the sarcolemma (100). Through the synthesis of nitric oxide (NO), nNOS is able to 
regulate the blood flow to the muscle during contractile activity (101) and 
thereby regulate oxygenation and metabolite transfer (102). When dystrophin is 
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lost and the DAPC disintegrates, nNOS is observed to be localised and act 
differently in dystrophic muscles (103). This change in NOS may cause further 
muscle damage, such as by ischemia (104), leading to oxidative stress and 
further muscle damage (105, 106). 
Aberrant ECM synthesis and fibrosis is seen early in DMD. Muscle biopsies from 
a 2.5 week old newborn infant show a modest expansion of the endomysium 
and minor variations in myofibre size, although the linear arrangement of 
myofibres remains relatively organised (94). Thus, endomysial fibrosis precedes 
any overt signs of muscle degeneration, and increases in volume over time (94, 
107). As a result, by 3 years of age when most boys are diagnosed, significant 
fibrosis and damage, in the form of disorganised necrotic and regenerating 
fibres, is seen in dystrophic muscles (94). Over time, this damage and 
degeneration progresses to severely compromise limb and trunk muscle function 
(108, 109), resulting in muscle weakness, and the loss of ambulation (110).  
Not all muscles are equally affected in DMD. For example, the muscles in the 
fingers remain undamaged, enabling patients to use a joystick to control a 
motorised wheelchair (111). Muscle degeneration also occurs in the diaphragm 
and the heart, compromising cardiorespiratory function and leading to death by 
approximately 30 years of age (109-111). Following contraction induced injury, 
such as from exercise, muscle from a healthy person will undergo effective ECM 
remodelling and successful repair, leading to adaptation and improved function 
(112). In DMD, muscle does not repair efficiently, which leads to muscle loss and 
weakness (Figure 1.2). 
It remains unclear as to why some muscles are more affected than others, 
although it is likely to be a combination of factors rather than a singular cause, 
especially as muscles have different functions and uses. One such cause may be 
due to the defective satellite cells within dystrophic muscles, leading to impaired 
regeneration and weakened muscles (113, 114). Furthermore, as discussed in 
section 1.2.4.2 of this thesis, muscle fibres are known to have differing matrices, 
and this specificity may also extend to the ECM surrounding individual muscles. 
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As such, a dysregulated matrix may also contribute to muscle specific damage. 
This is likely due to the increase in endomysial fibrosis which is present from very 
early in life (94), which is greatly exacerbated by the chronic damage and 
inflammation occurring in dystrophic muscles (115). 
 
 
 
 
Figure 1.2 Comparison of healthy and dystrophic muscle obtained 
from human biopsies. 
These muscle sections were stained with H&E in order to observe 
muscle structure. Upon comparison with A) healthy muscle, B) 
dystrophic muscle has a severe pathology. As the disease 
progresses, the characteristics of dystrophy, such as fibrosis, loss of 
fibres, changes in fibre size and infiltration of adipose tissue, all 
become more aggressive and apparent in the severely affected 
dystrophic muscle. Figure has been modified from (116). 
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It is important to note however, that fibrosis is present in other muscle diseases 
that contain a normal functional dystrophin protein. One such disease is the 
limb-girdle muscle dystrophy type 2Q variant, caused by a mutation in a protein 
called plectin, which has characteristics such as a disorganised muscle structure 
and matrix, and endomysial fibrosis (117). Another muscular disease is systemic 
sclerosis, where increased fibrosis is one of the main pathological features 
affecting the skin, internal organs and skeletal muscle (118). These myopathy 
studies thereby provide evidence of increased fibrosis while having an intact 
dystrophin protein. Indeed, fibrosis itself, and not just dystrophin deficiency, 
actively contributes to the muscle degeneration seen in DMD, thereby making 
fibrosis an important therapeutic target (119). 
There is no cure for DMD and despite significant side-effects, glucocorticoids are 
currently the only treatment with clinical efficacy (120). Briefly, glucocorticoids 
are of particular interest because they lower inflammation (121) and inhibit the 
synthesis of ECM proteins (122, 123). A more detailed review of glucocorticoids 
can be found in section 1.9.2. Any potential therapy for DMD will need to take 
into account the fibrotic state of patient muscles. Therefore, to be effective it is 
imperative that novel treatment strategies commence at a young age due to the 
early onset of endomysial fibrosis (124). DMD is a paediatric disease, and as 
pathology and fibrosis progressively become worse over time, it would be in best 
interests to treat boys with DMD as early as possible to help keep the 
endomysial connective tissue at a more normal level as seen within healthy 
tissues. 
1.3.1 Mouse models used to study DMD 
The DMDmdx (mdx) mouse is the most common animal model used to study 
DMD. Like patients with DMD, these mice have a mutation in the dystrophin 
gene and do not express the functional protein. However, these mice have a less 
severe muscle pathology than humans, with the diaphragm exhibiting a similar 
level of pathology to muscles of DMD patients (125).  
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In hindlimb muscles of mdx mice, there is a severe bout of degeneration and 
inflammation at approximately 3 week of age, which reduces to a steady level by 
8 weeks and persists throughout life (126), with a functional decline in strength 
(127, 128). Hindlimb muscles from adult mdx mice are hypertrophic, have 
ongoing regeneration and degeneration, and reduced tolerance to exercise, 
likely due to increased muscle damage and inflammation, and perhaps because 
of cardiac pathology in older mdx mice (126, 129).  
Like human patients with DMD, differences in susceptibility to damage and 
degeneration is observed in hindlimb muscles of mdx mice (127). In young 3 
week old mdx mice, the slow twitch soleus is the most necrotic muscle (128). 
With age, the soleus is again the most damaged hindlimb muscle, being more 
prone to fibre branching (91), increased necrosis, and increased deposition of 
fibrotic and adipose tissues (130). The soleus is a postural muscle that is highly 
recruited to help to keep the ankle stable during movements such as walking 
(131), so it may be that the damage occurs from the continuous movements that 
it endures through hindlimb locomotion (128, 132).  
Hearts from mdx mice have also been found to have elevated fibrosis present in 
the ventricle walls, along with both hypertrophic and necrotic cardiomyocytes 
(133). Although elevated collagen can be observed in left ventricles of mdx mice 
from as early as 6 months of age (134), they don’t appear to develop a dilated 
cardiac myopathy until 21 months (135), which impairs cardiac function and 
ultimately leads to heart failure (133). This may be why male mdx mice display a 
19 % reduced lifespan when compared to wild type mice (130)  
A second mouse model of DMD called the DMDdko (DKO or double knockout) is 
also available (136). These mice lack utrophin and dystrophin, and display more 
of a true dystrophic pathology to human DMD as they have a very severe disease 
pathology and a greatly reduced lifespan (137, 138). The DMDdko display 
scoliosis, short stature, difficulty breathing and have a waddling gait (136), dying 
when they are just a few weeks old. These mice are less commonly used for 
dystrophic studies as they do not express utrophin, whereas DMD patients and 
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mdx mice express this protein (139). Due to difficulties with breeding, these mice 
were therefore not used in the studies contained within this thesis. 
1.3.2 Loss of dystrophin and skeletal muscle damage 
The loss of the dystrophin protein in DMD causes the sarcolemma to become 
fragile and vulnerable to contraction induced muscle damage. When a 
dystrophic muscle fibre is damaged by contractile activity, the integrity of the 
sarcolemma becomes compromised and leaky. This triggers a series of adverse 
events including an increase in intracellular calcium (Ca2+) which floods into the 
cell through the damaged membrane, as well as an increase in reactive oxygen 
species (ROS) (140, 141). The excessive influx of Ca2+ results in the disruption of 
calcium homeostasis within the cell and leads to calcium-dependent proteolysis 
by activating calpains which degrade muscle protein into peptides (142). These 
peptides can be further degraded to form amino acids by the ubiquitin-
proteasome pathway (143). Excess ROS can damage dystrophic muscle fibres by 
disrupting redox sensitive signalling pathways, and by altering proteins, lipid and 
DNA structure, thereby having detrimental effects on muscle fibre function (105, 
106). 
It is important to note that the whole muscle fibre does not undergo necrosis 
when injured, instead the damaged part can be sealed off and regenerated 
(144). However if muscle damage happens frequently, as it does in DMD, the 
fibres will be inefficiently repaired, leading to an accumulation of branched 
fibres. Branched fibres are highly inefficient, being unable to contract properly 
and, especially in DMD, have a further susceptibility to contractile induced 
injuries (145).  
1.4 Inflammation in DMD 
1.4.1 The initiation of inflammation  
Although inflammation is integral for muscle repair (146), the actual initiation 
and subsequent processes of inflammation, especially in DMD, are still widely 
unknown (147-149). However, regardless if healthy or dystrophic, myofibres that 
become stressed, damaged or undergo cell death, release various stimuli, 
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ranging from danger-associated molecular patterns (DAMPs) (150, 151) to pro-
inflammatory cytokines such as TNFα, IL-6 and IL-8 (152, 153) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) (154), all of which attract 
neutrophils and monocytes from the circulation. Furthermore, these cytokines 
may activate additional cells within the surrounding matrices to intensify the 
chemotactic signals. For instance, TNFα can stimulate tissue resident 
macrophages to release neutrophil chemoattractant and monocyte 
chemoattractant protein 1 (MCP-1) (148) thereby contributing to the onset of 
inflammation.  
The initiation of the inflammatory surge is further amplified by pro-inflammatory 
cytokines, such as TNFα, which upregulate inflammatory cell adhesion 
molecules, such as E- and P-selectin, upon the endothelial surface of blood 
vessels (147, 155). These selectins capture inflammatory cells which roll across 
the endothelial surface, promoting contact with pro-inflammatory cytokines, and 
stimulate the expression of integrins upon the inflammatory cell surface (156). 
This allows the inflammatory cells to bind to endothelial receptors, such as 
intercellular adhesion molecules (ICAMs), and allows for other adhesion 
molecules to interact, such as platelet-endothelial cell adhesion molecule 
(PECAM) (157). These receptors enable neutrophils and monocytes to pass 
through the endothelial blood vessel wall (157).  
1.4.2 Inflammatory cell infiltration of damaged muscle 
Once out of circulation, neutrophils and monocytes are attracted towards 
chemoattractant gradients, comprised of the cytokines and proteins secreted by 
myofibres and resident macrophages, directing their migration to the injury 
(158). Neutrophils and monocytes first need to traverse the endothelial matrix, a 
specialised basement membrane comprised of proteins such as laminins and 
collagen IV, which surrounds blood vessels (159). The migration across this 
matrix is controversial and the exact processes remain largely unknown (160, 
161). 
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Although this matrix is seen to temporarily impede inflammatory cell migration 
(160, 162), the cells eventually locate specific regions containing low amounts of 
matrix proteins, which they then migrate through (159, 163). Additionally, 
observations that neutrophils may require proteases during this step, whereas 
monocytes do not and can freely migrate even without neutrophils present (159, 
163), further highlights a need to investigate the mechanisms of inflammatory 
cell migration through endothelial basement membranes (160, 161). Once the 
neutrophils and monocytes leave the dense venular basement membrane, they 
traverse the interstitial matrix with ease, being able to squeeze and twist 
through tight spaces, and use tension to create temporary openings to move 
through without any damage to the interstitial matrix (161, 164). 
1.4.3 Overview of inflammatory cells during muscle repair 
1.4.3.1 Neutrophils 
Neutrophils are the first inflammatory cell to infiltrate the injured muscle, with 
an increase in numbers seen in as little as 1 to 6 h after muscle damage (165, 
166) and are relatively short lived, approximately 2-5 days (165, 167). The main 
role of the neutrophil is to remove and phagocytose damaged myofibre debris 
(168), which is facilitated by the secretion of a range of proteases (see section 
1.4.4.2). A key component of neutrophil phagocytosis is the respiratory burst, a 
process in which superoxide and hydrogen peroxide levels are increased to 
facilitate the degradation of phagocytosed material (169). 
Neutrophils have been shown to exacerbate contraction induced injuries in 
muscle (170), and are shown to be greatly increased in mdx mice (171), showing 
a link between prolonged production and lifespan of neutrophils with the 
chronic inflammation seen in DMD. Indeed, neutrophils were associated with 
increased myeloperoxidase (MPO), which generates hypochlorous acid (HOCL), 
and exacerbates existing muscle damage, further contributing to degeneration in 
dystrophic mdx mice and golden retriever dogs, another animal model of DMD  
(172, 173).  Furthermore, as part of the continuing inflammatory response, pro-
inflammatory cytokines such as IL-8, released from damaged muscle fibres and 
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surrounding tissue, stimulates neutrophils to release their own cytokines, adding 
to the chemoattractant trail for incoming migratory monocytes (174).  
1.4.3.2 Infiltrating and resident monocytes 
After approximately 8 h, monocytes begin to infiltrate the site of injury (148). 
Monocytes were once considered to be a single cell type that differentiated into 
pro- and anti-inflammatory macrophages (175). This is now known to be more 
complicated. There are different monocyte subsets; in humans there are 
inflammatory classical and non-classical monocyte subsets and in mice there are 
the inflammatory Ly6Chi (Ly6C+) alternative/patrolling and Ly6Clow (Ly6C-) 
monocytes (176, 177).  
The pro-inflammatory Ly6Chi monocyte subset infiltrate damaged muscle in 
approximately 1.5 h, and reaches peak accumulation at around 1-3 days (178, 
179). Once at the site of muscle injury, they are able to phagocytose cellular 
debris and degrade the contents via their own respiratory burst, albeit weaker 
than that observed in neutrophils (180). The inflammatory Ly6Chi subset is 
increased in mdx mice (181), which may further contribute to the excessive 
inflammatory response of dystrophic muscles. Though Ly6Clow monocytes are 
observed to patrol the blood vessels, there is some evidence that they may be 
precursors to resident macrophages in the matrix (182, 183). Furthermore, this 
subset is suggested to play a role in the inflammatory process, potentially 
originating from the inflammatory Ly6Chi subset, as their number steadily 
increased and peaked at day 7 post injury, and they develop an anti-
inflammatory role well suited for muscle repair, while Ly6Chi numbers dropped 
(178, 179).  
Another added complexity, and one that is not very well studied or understood, 
is the resulting fate of these monocyte subsets. One theory is that the 
monocytes are able to differentiate depending on cell type, as the pro-
inflammatory Ly6Chi monocytes are similar to the pro-inflammatory M1 
macrophages, while the anti-inflammatory and reparative Ly6Clow monocytes are 
relatable to the anti-inflammatory M2 subset (178, 182, 184). Another theory is 
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that the Ly6Chi subset gives rise to the resident macrophages (177, 185), while 
others suggest the Ly6Clow are the macrophage progenitors (178, 179). 
Ultimately, through whichever way the process does occur, it is widely accepted 
that monocytes differentiate into another inflammatory cell type called a 
macrophage (175, 186) 
1.4.3.3 Pro-inflammatory M1 macrophages 
After a period of approximately 24-48 h (179), a cytokine influx of IFN-γ, TNFα 
and GM-CSF stimulates the inflammatory monocytes to differentiate into pro-
inflammatory M1 macrophages (87, 187-189). M1 macrophages remove 
myofibre debris via phagocytosis (190), and are able to generate high amounts 
of ROS, nitric oxide and pro-inflammatory cytokines (191-193). M1 macrophages 
can exacerbate existing muscle damage by producing pro-inflammatory 
cytokines such as IL-1, IL-6 and TNF (194), which intensifies the response of 
macrophages as well as recruit additional inflammatory cells. Indeed in DMD, M1 
macrophages remain persistently elevated from a young age, and persist 
through the entire lifespan of the patient (195, 196). This may be due to the 
influx and overlapping of cytokines during the inflammatory response. One 
cytokine example is IFN-γ, which is elevated in DMD and strongly promotes M1 
macrophage inflammation, inhibiting muscle repair in mdx mice (197). M1 
macrophages are actually an important part of the inflammatory process, by 
phagocytosing cellular debris, they prepare the area for muscle regeneration 
(198).  
1.4.3.4 Anti-inflammatory M2 macrophages 
At approximately 3 days post injury, and when most neutrophils have been 
phagocytosed, anti-inflammatory M2 macrophages begin to appear, becoming 
the predominant inflammatory cell at approximately day 5 (199, 200). There is 
debate in the literature regarding M2 macrophage origin and propagation. 
However, current theories suggest that the source of M2 macrophages is 
through the differentiation of M1 macrophages in response to specific cytokine 
signals  (201). 
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A major limitation associated with most research is that the focus is on M2 
macrophages as a whole, but this is actually very inappropriate. The M2 
macrophage population can be further broken down into 3 subsets - M2a, b or c, 
with each subset having a very different and distinct function. 
M2a macrophages, also known as alternately active macrophages, arise through 
an increase in IL-4 or IL-13. The appearance of M2a macrophages is a sign that 
the inflammation is about to switch to a regenerative process, and are 
associated with areas of tissue repair (175). The M2a macrophage population is 
important to repair, because an increase in IL-4, which stimulates M2a 
macrophage activation, also contributes to the deactivation of pro-inflammatory 
M1 macrophages (202). M2a macrophages are also able to supress the ROS 
produced by M1 macrophages and reduce further muscle membrane damage, 
especially relevant in DMD where increased ROS levels are present (201, 202). 
Furthermore, M2a macrophages can secrete TGFβ and fibronectin to promote 
tissue repair and wound healing (203, 204). However this process can be 
dysregulated. M2a macrophages are known to be pro-fibrogenic (205), and have 
been associated with fibrosis in aged diaphragm muscle from mdx mice (206) 
and patients with DMD (207, 208).   
The immunoregulatory M2b macrophages are activated through increases in 
MCP-1 (209) or apoptotic cells (210). The M2b macrophages secrete the anti-
inflammatory cytokine IL-10, but can also secrete the pro-inflammatory 
cytokines IL-1β, IL-6 and TNFα (210, 211). In dystrophic mdx mice, IL-10 
produced by M2b macrophages suppresses the pro-inflammatory M1 
macrophage population and activates the M2c phenotype, thereby dampening 
inflammatory processes and shifting the micro-environment towards muscle 
repair (212). 
The M2c macrophages are strongly activated by IL-10 cytokine secretion by M2b 
macrophages, through interactions with TGFβ1 or glucocorticoids (189, 199). 
They are considered to be anti-inflammatory, and can be further broken down 
into 3 groups: those activated by 1L-10; those activated by both glucocorticoids 
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and IL-10; and those activated by glucocorticoids only (189, 213). Like the M2b 
subset, the M2c macrophages are also able to secrete IL-10, further suppressing 
pro-inflammatory processes and increasing phagocytosis of cellular debris and 
apoptotic cells (213, 214), and hence can potentially attract more M2c 
macrophages. This can be beneficial as the M2c macrophages can promote 
muscle repair in mdx mice by increasing myoblast proliferation (202). 
Additionally, M2c macrophages are able to influence matrix composition during 
repair through the synthesis and remodelling of ECM components, such as 
versican (192, 199). However, they also secrete high levels of TGFβ (215), and 
when large numbers of M2c macrophages are present, this may stimulate 
fibroblasts to produce copious amounts of collagen, and potentially result in 
fibrosis. Indeed, in other diseases, such as obesity, M2c macrophages, along with 
TGFβ and IL-10, are observed to be located in fibrotic areas (216).  
Altogether, when carefully regulated, the inflammatory process is a necessary 
part of effective muscle repair. However, when in excess, as is seen in dystrophic 
muscles, inflammation can be detrimental to muscle health and function, and is 
observed to compromise regeneration and exacerbate damage and fibrosis. The 
role of inflammation in muscle repair is extremely intricate and complex, and 
much is still unknown, both in healthy and dystrophic muscles. Hence, an 
emerging and important area of research is the interactions of the matrix with 
inflammatory cells. 
1.4.4 Inflammatory cell interactions with the ECM 
The endomysial and interstitial matrices of skeletal muscle are complex 
structures (217). In response to muscle damage, the synthesis and remodelling 
of muscle ECM proteins by inflammatory cells is therefore key for an effective 
inflammatory and regenerative response.  
1.4.4.1 Synthesis of ECM by inflammatory cells 
As a part of remodelling the ECM, inflammatory cells synthesise a wide range of 
proteins depending on context and cellular type. Neutrophils are the first 
inflammatory cell to arrive after injury (166), with proteomic analysis being 
23 
 
suggestive that they do not appear to produce or contribute to matrix 
components (218), instead synthesizing and secreting a range of proteases which 
facilitates ECM degradation and phagocytosis of cellular debris after injury (see 
section 1.4.4.2). Neutrophils are well known to interact with the ECM and its 
components (219), and have been observed in areas with high versican 
expression (220). 
Macrophages can also synthesize, secrete and interact with various ECM 
components. For instance, the alternatively activated M2a macrophage can 
secrete fibronectin (204), and anti-inflammatory M2c macrophages can produce 
versican (192). In moderation, these ECM proteins are crucial for a normal 
healthy matrix and tissue repair (81), however when they are overproduced, 
they may contribute to fibrosis in inflammatory diseases. Indeed, fibronectin 
(221) and versican (90) have both been observed, along with tenascin-c, in the 
same fibrotic areas of a lung with idiopathic pulmonary fibrosis (222). 
Surprisingly, these three proteins are known to be components of a transitional 
matrix, upregulated after injury and crucial for muscle repair (73, 74, 77). 
These observations hint at an obvious interaction of versican with inflammatory 
cells. However, these inflammatory cells do not just secrete ECM proteins, they 
also synthesize a variety of specific proteases and inhibitors that allows for the 
degradation and removal of cellular debris after injury, as well as keeping protein 
synthesis in check. 
1.4.4.2 Proteases and inhibitors secreted by inflammatory cells 
By secreting enzymes and proteases, inflammatory cells such as neutrophils and 
macrophages remodel the cellular matrix environment following injury (175, 
223). Neutrophils release proteases such as neutrophil elastase, and matrix 
metalloproteases (MMP-8 and MMP-9) which degrade matrix proteins such as 
collagens (224). Neutrophil elastase is increased within chronically inflamed 
dystrophic muscle, and has been suggested to potentially impair myogenic 
regenerative processes (171). 
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Activated macrophages secrete neutral proteases (eg: MMPs), acid hydrolases 
(eg: hyaluronidase), and lysozymes (225-227). Relevant to this thesis, 
macrophages are also able to secrete ADAMTS1, -4 and -5 (228), which are 
known to degrade versican. In addition to this, macrophages are also able to 
secrete various protease inhibitors, such as furin, which cleaves the pro-domain 
off ADAMTS5 in order for it to become proteolytically active (229, 230). 
Additionally, macrophages also secrete tissue inhibitors of metalloproteinases 
(TIMPs), such as TIMP-3, which inhibits the proteolytic activities of ADAMTS4 
and -5 (175, 231, 232). Therefore, proteases and their inhibitors work in 
conjunction to keep the balance of ECM synthesis and degradation in check. 
Thus, matrix proteases, most importantly the MMPs and ADAMTS (233), are 
capable of remodelling matrix components, such as versican, when required. 
The matrix remodelling by these proteases can release previously bound 
cytokines and growth factors (81). A well characterised example is cleavage of 
the proteoglycan decorin by MMPs, which leads to TGFβ release and increased 
availability (44, 234). This suggests a role for inflammation in the progression of 
fibrosis, particularly in DMD, where levels of TGFβ are high and known to drive 
fibrosis (235). 
Proteases can also create bioactive fragments of matrix components that can 
elicit various effects upon the surrounding cells and signalling pathways (236). A 
well characterised example is the degradation of hyaluronan during 
inflammation. Hyaluronidase, potentially secreted by macrophages (227), and 
ROS are able to remodel the normal, high molecular weight hyaluronan into 
smaller fragments of low molecular weight hyaluronan (236-239). These low 
molecular weight hyaluronan fragments are considered to be pro-inflammatory. 
In activated macrophages, they stimulate increased expression of pro-
inflammatory genes, further potentiating the inflammatory response (240, 241). 
The fragments also increase the expression of macrophage metalloelastase 
(MMP12) (242, 243), further promoting ECM remodelling by selectively cleaving 
basement membrane proteins such as fibronectin and CS proteins (244), as well 
as dampening the inflammatory process (245). Hence, the role of bioactive ECM 
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fragments during inflammation and regeneration is a complex, yet important 
and emerging field of research.  
1.5 Dysregulated muscle repair in DMD 
1.5.1 ECM remodelling and regenerative myogenesis following 
muscle injury 
The intracellular signalling pathways regulating regenerative myogenesis have 
been intensely studied (246). Less understood is the regulation and remodelling 
of ECM during regenerative myogenesis. However, what is clear from DMD 
research is that effective regenerative myogenesis cannot occur if the ECM is 
dysregulated. Briefly, regenerative myogenesis depends on the activation, 
proliferation, migration and fusion of satellite cells with the injured myofibre.  
Satellite cells are located between the basal lamina and the sarcolemma of 
muscle fibres (247) in a quiescent state (248). To maintain satellite cells in this 
low maintenance form, they are surrounded by a specialised niche, a unique 
ECM, which is able to interact and therefore regulate cell behaviour (71) (see 
section 1.2.4.3). Activation of satellite cells has been extensively characterised 
(249, 250) and as such, will not be discussed here in detail. Briefly, in response to 
muscle damage, the quiescent satellite cells are activated and while some of the 
progeny will go back to being quiescent satellite cells and self-renew the 
population (251), the others will go on to repair damaged muscle myofibres. 
Satellite cell proliferation occurs between 24 h and up to a week after the injury 
has occurred (252, 253). Proliferating satellite cells, now referred to as myoblasts 
(254), migrate to the site of injury where they either fuse together to form a new 
multinucleated myofibre, or fuse to damaged fibres in order to repair them 
(255). As such, myoblast fusion is a series of complex processes involving 
numerous signalling pathways (246), however appropriate ECM remodelling 
during these processes is necessary. Versican, for example, can regulate the 
proliferation of myoblasts (20) yet requires cleavage by ADAMTS5 in order for 
myoblasts to fuse together during myogenesis (17). Overall, the processes 
involved in satellite cell activation through to myoblast differentiation allows for 
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the repair of damaged myofibres, and ultimately results in a fully functional 
muscle. 
However, satellite cells can have other roles within muscle. It is well known that 
upon activation, satellite cells subsequently begin to remodel the surrounding 
niche and synthesize proteins (256), such as fibronectin, found to be essential for 
proliferation (257). Furthermore, satellite cells are able to regulate fibroblast 
derived production of collagens and fibronectin in satellite cells (258), potentially 
through the expression of protease inhibitors, as shown in healthy 6 week old 
adult mice (259). Interestingly, the same study showed that age matched, 
dystrophic mdx mice produced a combination of proteases, such as MMP-2 and 
ADAMTS1, along with protease inhibitors such as TIMP-2 and -3 (259), which can 
inactivate ADAMTS1 activity (260). Hence, satellite cells may be linked to fibrosis 
in DMD through the dysregulation of proteases, leading to increased ECM 
production.  
Furthermore, age also can affect satellite cells. In youth, the muscle repair 
processes run smoothly, however with increased age come increased problems. 
For instance, it is well known that increased age correlates with reduced satellite 
cell numbers (261), as well as an increased expansion of the basement 
membrane (262). This may inhibit or potentially impair the muscle regeneration 
process. 
As ECM remodelling still remains largely unstudied, it can be concluded from the 
literature that after damage, muscle repair occurs by first clearing damaged 
fibres, perhaps before activated satellite cells migrate and fuse to repair the 
damage. The basement membrane is subsequently reformed and the muscle has 
completed reparation. However, no studies to date have ever studied this 
process in detail, in youth or with age, or in inflammatory diseases such as DMD.  
1.5.2 ECM remodelling and fibroblast function following muscle 
injury 
As discussed above, ECM synthesis and remodelling are critical for effective 
inflammatory and regenerative myogenesis responses following muscle injury, 
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such that repair is successful and muscle function is restored. Fibroblasts play an 
important role in ECM synthesis and remodelling during muscle repair. 
Fibroblasts regulate the composition of the matrix, during the synthesis of 
transitional proteins, such as versican and hyaluronan (74, 263), as well as 
mature matrix proteins, such as collagens I and III (264). These fibrillar collagens 
are structural proteins that provide support in the interstitial matrix. Fibroblasts 
are also able to produce various ECM proteases, including MMPs and ADAMTSs 
(265, 266), which degrade and remove matrix components, along with their 
inhibitors, such as TIMPs (267) and furin (268).   
Upon muscle injury, fibroblasts are able to infiltrate the site of injury during the 
initial inflammatory wave, alongside neutrophils and monocytes (264). This 
occurs at around 1-8 h after injury (165, 264). Through stimulation by 
chemokines and growth factors, such as IL-1β and TGFβ1, the fibroblasts are able 
to differentiate into myofibroblasts (195, 269). This myofibroblast transition 
occurs in an environment that contains versican (265). Myofibroblasts are able 
to be discerned from fibroblasts by increased expression of protein markers like 
α-smooth muscle actin (αSMA) (270), and by exhibiting changes in phenotype 
and function. (271). 
TGF-β is able to promote α-smooth muscle actin (αSMA) upregulation, which can 
associate with stress fibres by increasing their numbers and thickness (271). This 
is important as the stress fibres provides structure and contractile forces 
required for wound healing after injury (272-274).  
Furthermore, myofibroblasts produce fibrillar collagens I and III found in the 
interstitial matrix, and collagen IV found within the basement membrane (195). 
As the inflammatory response dampens and switches to an anti-inflammatory 
response associated with cellular repair, the cellular signals that stimulate ECM 
production by myofibroblasts are decreased, eventually forcing them to undergo 
apoptosis via IL-1β signalling, leaving behind a healed wound and regulated 
matrix (275, 276).  
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1.5.3 Dysregulation of myogenesis and fibroblast function in DMD 
In DMD, the persistent damage and inflammation causes a dysregulation of ECM 
remodelling (107), due to fibroblast and myofibroblast dysfunction. Fibroblasts 
obtained from dystrophic patients revealed abnormal changes in morphology 
(277-279) and function, skewing the fibroblast population towards a 
myofibroblast phenotype. TGFβ is upregulated in dystrophic muscles (280-282), 
where it potentiates myofibroblast formation (271) and inhibits their apoptosis 
(276). This may contribute to the increased production and accumulation of ECM 
in DMD. This expansion of the matrix is observed in very young infants with 
DMD, in the absence of inflammation, suggesting that fibrosis arises as a primary 
consequence of dystrophy (94). However, as inflammatory pathways are 
activated in infants (281), the possibility remains that inflammation may add to 
the dysregulated nature of fibrosis during the progression of DMD pathology. 
Fibrosis exacerbates dystrophic pathology by increasing the ECM stiffness which 
interferes with normal cellular processes and compromises muscle function (93), 
hence the presence of fibrosis can predict functional decline (94, 283). 
Eventually the fibrotic tissue, along with infiltrating adipose tissue, results in the 
severe muscle weakness seen in DMD patients (107).  
In addition to a dysregulated and expanded ECM, contributing to the poor 
capacity of dystrophic muscles is the fact that muscle damage is chronic. This 
leads to asynchronous regeneration, where multiple bouts of damage, 
inflammation and regenerative processes, at differing stages, happen within 
close proximity (284, 285). This involves the possibility of overlapping cell 
signalling, with the expectation that this environment would include a 
dysregulated ECM. A section of muscle stained with toluidine blue O showed 
that rat muscle underwent asynchronous regeneration by showing two distinct 
stages of differentiation that were occurring within the same area (284). 
Furthermore, like asynchronous regeneration, there are also multiple areas of 
inflammation and degeneration that overlap in dystrophic muscles (286). 
Ultimately, muscle will not be repaired efficiently if the delicate balance 
between inflammation and repair is disrupted. In DMD, the inadequate repair of 
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muscle contributes to the overall disease pathology, resulting in muscle loss and 
fibrosis (107). Together with chronic inflammation and fibrosis, this ultimately 
means that the repair process for a damaged muscle is not as straightforward as 
it seems.  
The dystrophin protein is also integral to satellite cells (114). The loss of 
dystrophin in the activated satellite cells within dystrophic muscle was 
associated with abnormal defects that resulted in the generation of 
dysfunctional satellite cells, further adding to the impaired muscle repair seen in 
DMD (114).  
Further adding to this, as the dystrophic muscle undergoes continuous repair 
and degradation, the regenerative processes will eventually be unable to 
compensate for the damage (287). It is speculated that the supply of satellite 
cells required for muscle repair is exhausted or somehow loses the capacity to 
repair the damaged fibre (87), perhaps due to the loss of dystrophin (114). 
However, a study suggested that the depletion of satellite cells was not the 
primary cause for failed regeneration, casting doubt over the validity of this 
theory (287). It was suggested that failed regeneration in the advanced stage of 
DMD was possibly a result of the inhibition of myoblast differentiation caused by 
an interaction between TGFβ and myogenic regulatory factors (46, 287), 
however this is still largely unknown. Therefore, as myogenesis requires 
remodelling (17), it can therefore be hypothesised that the dysregulation of ECM 
remodelling contributes to the exacerbation of inflammation and muscle 
degeneration in DMD. 
It can be easy to speculate that if one area of muscle is resolving inflammation, 
and a neighbouring area is starting to have an invasion of inflammatory cells, any 
healthy regenerating fibres in between these areas will be affected by the ‘spill 
over’ of cytokines and chemokines from the surrounding degenerating fibres, 
inflammatory cells and the ECM. This chaotic environment worsens 
inflammation, leads to inefficient repair and ultimately results in the permanent 
deposition of fibrotic tissue. Consequently, the damage obtained throughout the 
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course of disease progression is not just due to asynchronous regeneration, but 
also includes the inhibition or impairment of satellite cells, chronic inflammation, 
abnormal cellular signalling, and fibrosis with its highly expressed protein 
components, such as versican. As versican is also able to influence inflammation 
(288), it may prove to be a target, along with its cleaving ADAMTS proteases, in 
future research involving dystrophic muscle.  
1.6 Versican and its remodelling by ADAMTS versicanases 
1.6.1 The structure and regulation of versican 
Versican is a large chondroitin sulphate proteoglycan (289) and an important 
transitional extracellular matrix protein (74), which is found in abundance 
throughout the body. It is located within the endomysial and interstitial matrices 
and is produced by a wide range of cells including myoblasts, fibroblasts and 
inflammatory cells (17, 265, 290). As such, versican is a crucial protein that plays 
a role in many different processes including development, cell maintenance and 
disease. 
1.6.1.1 Versican splice variants  
The different forms of versican arise through the alternate splicing of exons 7 
and 8, which encode the GAGα and GAGβ regions (289, 291). There are five 
major splice variants of versican, designated V0 through V4, with the potential of 
a sixth (V5) variant (48, 289). These variants of versican differ by their structure 
and components. Versican has four known protein domains consisting of a N-
terminal globular (G1) domain, two chondroitin sulphate chain binding regions 
(GAGα and GAGβ), and a C-terminal globular (G3) domain (292) (Figure 1.3).   
1.6.1.2 The G1 and G3 domains of versican 
The domains of versican are important in regulating cellular and matrix 
properties. It is well known that versican can bind to hyaluronan through the G1 
domain (293), which in turn is bound to the CD44 receptor upon the cell 
membrane (50), forming a stable link within the matrix. The G3 domain is equally 
important, being able to interact with macrophages by binding TLR-2 (294) or 
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the P-selectin ligand (295). The G3 domain can also bind proteins, such as 
tenascin-R, and fibulins 1 and 2, providing a link to other proteins with the matrix 
(288, 292), providing matrix stability.  
1.6.1.3 The G2 domain of versican and its CS GAG chains 
The G2 domain of versican is a region comprised of CS GAG side chains (Figure 
1.3). Versican GAG chains are arranged in an array of positions that allows them 
to influence and mediate various matrix and cellular properties. For instance, 
versican can bind directly to CD44 via its GAG chains (296). Furthermore, GAG 
chains have a highly negative charge that attracts water molecules, causing the 
matrix to swell and become more rigid and stiff. This is important to the 
interstitial environment as the GAGs help cushion the forces created during 
contraction (297). As versican accumulates, so would the amount of GAG chains. 
Therefore it is important to note that any effects may not necessarily be from 
the core of the versican protein, but may instead be caused predominantly by 
the GAG chains themselves. The excess accumulation of proteoglycans that 
cause matrix swelling can negatively affect cells, as increased stiffness of the 
matrix may disrupt and prevent cellular processes, such as migration, adhesion 
and differentiation, from occurring (298, 299).  
Additionally, during matrix remodelling, such as during cellular injury, the 
endomysium is able to sequester and regulate the availability of signalling 
molecules from proteoglycans, including versican. Versican GAG chains are able 
to bind and potentially act as reservoirs for a variety of cytokines, chemokines 
and growth factors (51, 84, 300, 301). Furthermore, the CS chains can also bind 
to cell receptors such as L- and P-selectins, allowing for leukocyte and 
macrophage adhesion, which may influence inflammatory processes within the 
endomysium (53, 295).  
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Figure 1.3 The five known splice variants of versican. 
All splice variants of versican contain the G1 and G3 domains. The 
variants differ in appearance by the presence or absence of GAGα 
and/or GAGβ within the G2 domains, therefore the amount of CS 
GAG chains is also different for each variant. Also note the 
truncated GAGβ domain on the V4 variant. 
Figure has been modified from (289), using (302, 303). 
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1.6.1.4 The V0/V1 versican variants 
The V0 and V1 forms of versican are abundant in a range of tissues, particularly 
within skeletal muscle (17). The versican V0/V1 variants differ not only on GAG 
domain type, but also on size and number of CS chains (Figure 1.3). The V0 
variant contains both GAGα and GAGβ domains and is therefore the largest 
versican type, whereas the V1 variant contains only the GAGβ domain (291, 
302). This difference in GAG domains allows these two forms of versican to be 
distinguished, as not only do the GAG domains determine the total size of the 
versican isoform, but they also contain differing number of chondroitin sulphate 
chains. It has been determined that the GAG-α can bind up to 8 CS chains and 
GAGβ can bind up to 15 chains (302). Therefore V0 versican GAG domains can 
contain up to 23 CS chains, while the V1 form contains up to 15 CS chains (Figure 
1.3). This difference in CS chain number may have a potential impact on binding 
properties between these two variants.  Furthermore, the V0 and V1 forms also 
differ through the size and properties of their cleavage products after proteolytic 
processing by ADAMTS (see section 1.6.2.1). 
1.6.1.5 The V2, V3 and V4 versican variants 
Although this thesis focuses only upon the V0 and V1 variants of versican, it is 
important to recognise the other variants that are present in other tissues aside 
from muscle. The V2 and V3 variants have been observed in the mouse brain, 
with the V3 variant also in adult human brains (302, 303). The V2 variants is also 
observed in the central nervous system and neuronal tissues (289, 302, 304). 
Furthermore, the V3 form has also been observed in other human tissues such 
as the adult retina and stomach, and also in foetal livers (303). The newly 
described V4 variant has only been observed in human breast cancer lesions 
(305).  
These variants of versican differ by their GAG domains. The V2 variant contains a 
GAG-α domain with up to 8 CS chains, while the V4 variant contains a truncated 
GAG-β domain with up to 5 predicted CS chains (302) (Figure 1.3). In contrast, 
the V3 variant contains no GAG regions, being comprised purely by the G1 and 
G3 domains only (303) (Figure 1.3). These differences between GAG domains, or 
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absence of, and being tissue specific, is therefore suggestive that these variants 
have very different roles to each other. 
1.6.1.6 The spatio-temporal regulation of versican  
Little is known about the regulation of versican in various tissues or in the stages 
of disease, in particular the spatio-temporal regulation and transcription of 
versican in development and pathology. What is currently known is widely based 
on a general understanding of versican regulation through various signalling and 
transcriptional pathways. However, as it has been extensively reviewed (306), it 
will not be described in great detail here. Briefly though, versican can be 
stimulated through signal transduction pathways such as the receptor tyrosine 
kinase pathway, the phosphatidylinositol 3-kinase (PI3K) – protein kinase B 
(PKB/Akt) pathway, the canonical wingless pathway, and the sonic hedgehog 
pathway (306). The regulation of versican is also dependent on a number of 
transcription factors, such as P53 or the formation of a complex between β-
catenin and T-cell factor/lymphoid-enhancer factor which activates the versican 
promoter (306). Furthermore, the expression of versican can be suppressed 
through the downregulation or inhibition of the various signalling pathways, or 
may be supressed by DNA methylation (306).  
The transcription factors regulating versican gene expression during 
development are not well described, as research has focused on the localisation 
of versican during development and its role in tissue morphogenesis (307, 308). 
In developing skeletal muscle, versican was suggested to act as a barrier to these 
tissues, ensuring that the muscle and nerve patterning occurred in the correct 
positions, with the expression of versican decreasing as the embryo developed 
(307), and being almost non-existent in an adult mouse (17). The specific 
patterning of versican during the embryonic period was determined to be 
regulated by developmental processes (307). In the study, it was suggested that 
V0/V1 versican was involved in the developmental skeletal muscle patterning, 
with V2 versican thought to be staining the developing nerves (307). However, it 
should be noted that staining was performed by using antibodies specific to 
GAGα and GAGβ regions (307), and was therefore not specific staining for 
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individual versican variants. Another study aimed to localise versican during the 
period of growth from 5 days postnatal to 42 day old adult rats (309). This study 
found that versican was differentially expressed at different times and regions of 
the brain (309). However, both of these studies however this study have a 
limitation in that only total versican was assessed, not the individual versican 
splice variants. 
Little is also known about the transcription and regulation of versican in diseased 
states, however emerging roles in respiratory, cardiovascular disease (310-312) 
and cancer (313) are becoming apparent. However, the mediation of versican 
during developmental and regenerative myogenesis, and fibrotic and 
inflammatory processes in DMD will not be included here as they are discussed 
in Section 1.7 of this thesis. 
Overall, these studies indicate that the splice variants of versican are located in 
variant-specific tissues with differential expression patterns highly dependent 
upon age. This is highly suggestive that each variant has a specific purpose in 
each tissue. However more detailed characterisations involving all versican 
variants during developmental, injury and diseased states are required. This 
would allow for better understanding of the differential expression patterns of 
versican and how it’s regulated during these states. Another important state to 
consider however, is the cleavage of versican by proteases. 
1.6.2 The ADAMTS proteases and remodelling of versican 
There are 19 members in the A Disintigrin And Metalloproteinase with 
ThromboSpondin motifs (ADAMTS) protease family (314, 315), however only the 
proteoglycanases ADAMTS1, -4, -5, -9, -15 and -20 can cleave versican (315-319). 
ADAMTS8 belongs to the same versicanase clade (320), and is therefore 
presumed to cleave versican, although this has not yet been proven (321). The 
known ADAMTS versicanases contain multiple domains, however they differ only 
in the number of thrombospondin motifs located at the C-terminal end of the 
protein (322). ADAMTS proteases are secreted in an inactive form as a protective 
mechanism and hence require proteolytic removal of the pro-domain to become 
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active proteases (323). ADAMTS5 for example, can be cleaved by furin on the cell 
membrane, or by pace4 in the extracellular matrix (230, 324, 325), whereupon 
becoming active, can cleave proteins such as versican. 
1.6.2.1 The V0/V1 versican fragments produced by ADAMTS versicanases 
The ADAMTS versicanases can cleave V0 versican at the Glu1428-Ala1429  bond, 
while the V1 form is cleaved at Glu441-Ala442, in order to form bioactive 
fragments (315, 316) (Figure 1.4). The resulting fragments span the G1 domain 
until just before the first CS chain on the GAGβ domains (289). The V0 variant, 
known only as G1-DPEAAE1428, still contains CS chains within the GAGα domain 
(Figure 1.4), and has been observed to differ during injury and repair (321), 
however this versican fragment still remains largely unstudied.  
However, the V1 form, G1-DPEAAE441, now known as versikine, contains no CS 
chains (315) (Figure 1.4). Versikine is the best characterised fragment in regards 
to function. However, the fate of the remaining C-terminus fragments containing 
the rest of GAGβ and the G3 domain is still largely unknown. They may also have 
important signalling roles (326), or they may be endocytosed and lysed internally 
like aggrecan (327), however, any such mechanism remains to be determined.  
It is important however, to note that ADAMTS versicanases produce versikine, 
they are not the only ECM protease that can cleave versican. Other proteases, 
such as the MMPs, specifically MMP-1, -2, -3, -7 and -9, are also able to cleave 
versican (328-330). However, the main versican protease remains the ADAMTS 
versicanases, particularly ADAMTS5. The ADAMTS proteases are complex, being 
shown to exhibit differing expression patterns in different biological contexts 
such as myogenesis  (17) and fibrosis (321). Regardless, the main role of an 
ADAMTS versicanase is to process versican, forming the much smaller bioactive 
fragment, versikine. 
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Figure 1.4. The cleavage of versican by ADAMTS versicanases. 
A) Versican V0 and V1 can be cleaved by ADAMTS versicanases just 
before the first CS chain on the GAGβ. The cleavage site is depicted 
as a dotted black line, and ADAMTS as a pair of scissors. B) The 
cleavage of versican by ADAMTS versicanases produces two 
fragments - the as yet unnamed V0 G1-DPEAAE1428, and the V1 G1-
DPEAAE441, which is more commonly known as versikine. 
Figure 4 has been modified from (289), using (302, 321). 
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1.7 Versican in skeletal muscle development, repair and 
DMD pathology  
1.7.1 Versican and its remodelling during development  
During development, many meticulously timed processes occur that are integral 
to the developing muscle. Such processes include proliferation, cell adhesion, 
migration, differentiation and apoptosis of cells, along with extensive matrix 
remodelling during these processes (Figure 1.5). As such, many extracellular 
proteins, such as versican, play a large role in developmental processes. Indeed, 
a complete absence of versican is fatal in the heart defect mouse, with embryos 
dying in-utero due to malformed hearts (331). Therefore, versican and its 
proteolytic cleavage are especially important during development. This has been 
recently reviewed (289, 311) and will not be described here in great detail. 
Briefly, versican is important for the heart (331), as well as being present 
elsewhere within the mouse embryo (307), particularly in the embryonic 
hindlimb skeletal muscles (17).  
Versican has been linked to myogenic processes, such as satellite cell 
proliferation, and is upregulated during proliferation of myoblast cultures 
obtained from turkey skeletal muscle (20). Furthermore, the cleavage of versican 
is required for the differentiation of C2C12 myoblasts in culture (17), and is 
thought to be involved in the even spacing of myotubes during development 
(20). Additionally, in another biological context, versican has also been found to 
direct migration, acting as a barrier to ensure the correct migration route of 
neural crest cells (18). Therefore, these processes may all help facilitate the 
expansion of skeletal muscle growth during the developmental phase. 
Furthermore, the remodelling of V1 versican, through the proteolytic activity of 
ADAMTS versicanases, to produce versikine, is also instrumental during 
developmental processes. The remodelling processes occurring during 
development are widely exhibited around the body, and can include processes 
such as synovial joint formation (332), the formation of the cardiac outflow tract 
and endocardial cushions (308, 333), and provides a link between apoptosis and 
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digit formation (334). Furthermore, versican cleavage also aids myogenesis (17). 
Another study linked rounded, densely packed cells within the embryonic 
endocardium with co-localised versikine staining (333). A rounded cell is 
indicative of the mitotic phase of proliferation, the rounded shape providing 
strength and structure for the mitotic spindle (335), for which versikine has been 
shown to be a crucial component (336), proving that versikine is itself an 
important protein. 
1.7.2 The role of versican during regenerative myogenesis 
Versican is highly upregulated during skeletal muscle development, whilst being 
very scarce in the ECM of healthy adult muscles (17, 337). However, versican can 
be studied in cell cultures where stress can be implemented through mechanical 
strain or wounding, with results being suggestive that versican increases after 
injury (338, 339). Indeed, after injury a special transitional matrix, very similar to 
that seen in development, is synthesized (73) (see Figure 1.5 and section 1.2.5). 
This transitional matrix supports the reconstruction of a new mature matrix after 
injury. As versican is increased after injury, it may be a component of the 
transitional matrix in response to the normal regenerative processes (77, 338), 
where it may influence many cellular processes, such as those seen during 
development (see section 1.7.1) to facilitate the reparation of damaged muscle 
tissue. 
1.7.3 Versican as a novel mediator of fibrosis and inflammation in 
DMD pathology 
Versican is upregulated in inflammatory diseases, such as asthma (340) and 
chronic obstructive pulmonary disease (COPD) (341), where inflammation is 
chronic and fibroblast matrix remodelling is abnormal. The uncontrolled 
expansion of the extracellular matrix is also seen within DMD pathology. Indeed, 
in dystrophy, fibrotic endomysial expansion and inflammation is observed 
shortly after birth (94, 281), with versican and CS GAGs found overexpressed 
within endomysial areas of dystrophic skeletal muscle (90, 116), Figure 1.5.  
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Figure 1.5. Known and potential roles of versican in development, 
muscle regeneration and disease. 
It is well known that versican directs the migration of cells during 
development, and is involved in the proliferation of satellite cells. 
Furthermore, the remodelling of versican by ADAMTS versicanases 
produces the fragment called versikine, which has previously been 
linked to apoptosis. This remodelling event is required for the fusion 
of myoblasts to form multinucleated myotubes, an essential step in 
muscle regeneration. Another aspect of regeneration is the increase 
of versican, as part of the transitional matrix, in response to injury. 
This specialised matrix both nurtures and directs cells important to 
the repair process, such as myoblasts and inflammatory cells. 
Versican is known to influence inflammatory cells, and is thought to 
be involved in the transition of monocytes to macrophages, and 
even in the transition of fibroblasts to myofibroblasts. Versikine is 
also associated with inflammation, being able to act as a DAMP and 
could potentially could instigate the inflammatory process. Versican 
may also be one of the factors causing the exacerbation of 
inflammation in DMD. Indeed, DMD is characterised by a vicious 
cycle of inflammation, degeneration and regeneration, ultimately 
resulting in the inefficient repair of muscles and the formation of 
fibrosis, which can also impair regeneration. As myofibroblasts are 
thought to be persistently activated in DMD, depositing copious 
amount of ECM, they could increase the amount of fibrosis in the 
endomysium. This is particularly interesting given that dystrophic 
muscles contain an upregulation of versican in the endomysium, 
and may therefore be implicated in fibrosis. Hence, versican has 
many known and potential roles in muscle processes and DMD 
pathology. Red arrows and text indicate the dysregulation in DMD. 
Figure has been created using (17, 18, 20, 90, 107, 116, 265, 285, 
288, 290, 334, 338, 339, 342-344)  
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1.7.3.1 Potential interaction between TGFβ and versican in skeletal muscle 
fibrosis 
In muscular dystrophy, fibrosis is driven through the increased production of 
TGFβ (345), of which TGFβ1 is the predominant form (119). TGFβ stimulates 
fibroblasts to synthesise and deposit matrix components. Based on in-vitro data 
from fibroblasts, this increase in matrix protein synthesis includes versican (346). 
Versican is upregulated in dystrophic muscles at the gene (347) and protein level 
(90). Given that the core protein of versican can bind TGFβ (52), it may therefore 
have an important role in fibrosis and dysregulated muscle repair.  
Indeed, an excess of versican appears to stimulate the transition of fibroblasts 
into myofibroblasts (348). Myofibroblasts have been described as being 
persistently activated in DMD (107), expanding areas of fibrosis by secreting 
proteins such as collagens I, III and IV (271). As the myofibroblast deposition of 
collagen increases, the amount of versican is decreased, suggesting that the 
versican is being degraded and replaced by a collagen rich mature matrix (41). It 
currently remains unknown what effect versikine has on the myofibroblast, and 
hence should be investigated in future studies. 
1.7.3.2 The potential for versican and versikine to mediate inflammatory 
processes in DMD 
There is emerging support throughout the literature that versican can influence 
and mediate inflammatory responses (288). For instance, versican can bind 
specific chemokines that attract leukocytes (51), or may directly interact with 
adhesion molecules on leukocytes themselves (49), thereby promoting 
inflammatory responses. Versican can also bind macrophages, either though the 
G3 domain, or via the CS GAG chains found on the G2 domain (see sections 
1.6.1.2 and 1.6.1.3). Furthermore, versican is also known to modulate T cell 
activation (343). Hence, versican can be linked to many inflammatory processes, 
and can be thought as being an important mediator for many inflammatory cells.  
Furthermore, the cleavage of V1 versican to form versikine (see section 1.6.2.1) 
is also becoming an important factor for inflammation. Indeed, the signalling 
pathways regulated by versikine are attracting increasing research interest, 
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though little is known about versikine in skeletal muscle or within DMD. 
Versikine has recently been revealed as a damage-associated molecular pattern 
(DAMP) (342, 343), which are produced upon tissue injury and help instigate the 
inflammatory process. It can also act as a pro-inflammatory protein, being able 
to induce expression of IL-1β and IL-6 in myeloma-associated macrophages, 
while both versican and versikine differentially mediated T cell activation (342, 
343). Perhaps versican and versikine might also exhibit similar effects on other 
inflammatory cells, such as neutrophils, monocytes, and the pro-inflammatory 
M1 and anti-inflammatory M2 macrophage subsets, however this remains to be 
seen, as do any studies involving dystrophy in this cellular model. 
Hence the interactions of versican and versikine, although extremely complex in 
regards to dystrophic pathology, are both important to consider and understand, 
as they exert very different effects. As of yet, the relevance of versican within 
dystrophy is largely unstudied, and as increased gene expression of versican is 
observed in human dystrophic muscle (90), it only further highlights versican as 
being an important transitional and mediating protein. An overview of versican 
and its possible interactions and roles is summarised in Figure 1.5. 
1.8 The function of ADAMTS versicanases in healthy and 
dystrophic muscle 
1.8.1 Relevance of ADAMTS versicanases to muscle  
As ADAMTS versicanases are part of an emerging field, little is known about their 
specific roles within skeletal muscle. However ADAMTS1, -4, -5, -9, -15 and 20 
mRNA transcripts are expressed in developing wild type mouse hindlimb muscles 
at E12.5 – E15.5 (17, 334). Furthermore, ADAMTS5 is the most highly expressed 
versicanase in developing embryonic muscle, and has also been associated with 
dystrophic pathology, being highly expressed in serum from both DMD patients 
and dystrophic mdx mice (349). However a well characterised expression 
timeline is still needed for the ADAMTS versicanases, not only during 
development and growth to adulthood, but also in diseased states, such as DMD, 
to better understand the role these proteases have in growth and disease 
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pathology. What is well known though, is the proteolytic interaction between 
ADAMTS versicanases and V1 versican results in the formation of the bioactive 
fragment versikine (see section 1.6.2.1). Both versican and versikine have been 
shown as being integral proteins within cellular processes and regulation of the 
matrix, as documented throughout this review. 
It is important to remember that versican and versikine are also important 
developmental proteins. In some instances, the degradation of versican is 
required for proper development to occur (see section 1.7.1). For instance, 
ADAMTS cleavage of versican, forming versikine and providing a link to 
apoptosis, is integral for web regression and the formation of digits in the 
embryo (334). Furthermore, similar roles involving the cleavage of versican are 
the development and maturation of embryonic synovial joints (332). 
In other contexts, ADAMTS5 and -15 play a prominent role in skeletal muscle 
myogenesis, being observed in culture to proteolytically clear a versican-rich 
matrix during myoblast fusion, enabling the differentiation of the cells into 
multinucleated myotubes (17). This is a crucial process, not only for normal 
muscle growth, but also for muscle repair after injury. 
1.8.2 Relevance of ADAMTS to DMD pathology 
The expression and function of ADAMTS versicanases have not yet been well 
characterised in dystrophic muscle. However, ADAMTS5 is upregulated in serum 
from both the dystrophic mdx mouse and DMD patients (349), hinting at an 
upregulation in DMD. However the expression of ADAMTS seems to be context 
dependent, as when 8 week mdx mice were treated with batimastat, an inhibitor 
of MMPs, the mRNA expression of Adamts1, -5 and -8 was observed to be 
decreased compared to wild type mice (350). It may be that at this age, because 
no fibrosis has yet occurred in the mdx mice, the dysregulation of ADAMTS 
versicanases has yet to begin.  
Hints about ADAMTS versicanases can be obtained through other disease types. 
For instance, the inflammatory cytokines, IL-1β, TNFα, and IL-6 appear to play a 
role in the upregulation of ADAMTS versicanases (351). As these same cytokines 
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are also upregulated in dystrophy (344), perhaps these may also upregulate 
ADAMTS in this context. However in differing cell types that are not dystrophic, 
the expression of ADAMTS versicanases appears to be quite conflicting. For 
example, even though Adamts5 mRNA expression was found to be increased by 
IL-1α treatments in cultured mouse chondrocytes, with no change observed in 
ADAMTS4 expression (352, 353), the opposite occurred in cultured mouse 
synovial fibroblasts treated with IL-1α, where no changes were observed in 
Adamts5 expression (354). Furthermore, in human synovial fibroblasts, no 
change in mRNA expression was seen with treatments of IL-1β, TNFα, or TGFβ, 
whereas Adamts4 mRNA was seen to increase upon addition of TGFβ (355). 
These studies appear to suggest that in different cells, tissue types, and perhaps 
contexts, the ADAMTS versicanases are stimulated differently, potentially due to 
their different structures and roles, by inflammatory mediators. This is further 
supported by studies in myogenesis, hepatic fibrosis and macrophages, which 
show that the versicanases are differentially upregulated (17, 321, 356). 
It may be that the ADAMTS versicanases have these differences in regulation as 
a natural safeguard. If all were to have similar expression and activity, then the 
chance of a dysregulated matrix would be high. The ADAMTS are known to be 
compensatory, such as ADAMTS15 being able to cleave versican in the absence 
of ADAMTS5 (17). It is most likely however, that the differences in expression 
observed are due to the requirement of processing before they become 
catalytically active (see section 1.6.2), or through the regulation of ADAMTS 
inhibitors, such as the TIMPs.  
After injury, TIMP mRNA levels rapidly rise, but decrease quickly 48 h after 
injury, whereas TIMP protein, initially present before injury, was decreased from 
3-24 h, before expression increased from 48 h onwards (357). This suggests that 
not only are ADAMTS proteases carefully regulated, but that also TIMP itself 
could be regulated as another measure of careful control of matrix remodelling. 
Furthermore, in mdx mice, regardless of utrophin expression, all dystrophic 
hearts were observed to have dysregulated TIMP (358). This suggests that the 
regulation of ADAMTS versicanases may be dysregulated in DMD, which would 
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have significant impact on their substrates. Indeed, versican is seen to be greatly 
increased in DMD, particular in endomysial areas (90) indicating a potential 
dysregulation of proteases and their inhibitors in dystrophic fibrosis. 
Other potential roles for ADAMTS in DMD are also coming to light. Fibrosis for 
instance, gains a major contribution of ECM components from fibroblast and 
myofibroblast dysregulation. Fibroblasts are known to express ADAMTS-5 (265) 
and after differentiating into myofibroblasts, they appear to continue expressing 
ADAMTS5, as versican expression appears to be degraded and replaced by 
collagen (41). Furthermore, cultured human macrophages stimulated with IFN-γ, 
TNF-α or IL-1β were observed to regulate Adamts1, -4, -5, -8 and -9 mRNA in 
differing ways (228, 356), suggesting that the ADAMTS versicanases may still be 
differentially expressed. These indicate that ADAMTS regulation is also 
important during inflammatory processes, and may implicate ADAMTS protease 
dysregulation in the inflammatory and degenerative processes in DMD. 
1.9 Current strategies and future directions for DMD 
treatments: The importance of targeting the ECM 
1.9.1 Current therapies used for DMD treatments 
The loss of dystrophin in DMD leads to a multitude of persistent muscle 
degenerative, inflammatory and fibrotic processes (90). There is no cure for 
DMD and the most obvious, but also most complex treatment would be to 
correct the genetic defect. Current methods, extensively reviewed, include exon 
skipping, nonsense stop codon read-through, and viral mediated gene therapies 
(359, 360). However, the DMD gene is the largest known human gene (361). This 
restricts the use of some gene therapies, as the DMD gene is too large to insert 
in viral cassettes (362). Furthermore, there are currently 7,149 different types of 
DMD gene mutations that can cause DMD (359). As there are so many 
mutations, major drug companies would presumably only focus on the most 
common mutations. Therefore, any treatments mentioned above would be 
targeted towards specific mutations and would only benefit patients with the 
corresponding mutation. This is the case with a drug called eteplirsen (Exondys 
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51), recently approved for the treatment of DMD (363). This drug allows the 
skipping of exon 51 on the DMD gene, restricting it for use in approximately 15 % 
of all DMD patients (363, 364). 
Other therapies are compensatory, aiming to help relieve the pathology of 
dystrophy rather than attempting to fix the mutations. These include the 
upregulation of utrophin to counter the loss of dystrophin, increasing muscle 
mass by delivery of IGF-1, or inhibiting myostatin (360). 
Despite much research effort, there is no cure for DMD. At the present, despite 
significant side-effects, glucocorticoids remain the only effective treatment in 
clinical use for all DMD patients. Glucocorticoids work by reducing inflammation 
and facilitating muscle repair (365). To date, the cell signalling pathways 
regulated by glucocorticoids such as the downstream consequences on 
inflammation, fibrosis and muscle function in DMD are not fully understood. A 
better understanding of these pathways will allow for a better understanding of 
the process involved in muscle repair, and therefore to identify potential new 
targets. For gene and cell therapies to work and to get the best out of 
compensatory strategies, the abnormal matrix therefore must be targeted.  
1.9.2 Glucocorticoids in the treatment of DMD 
Glucocorticoids influence many physiological processes within the body and 
have the ability to regulate glucose, protein and fat metabolism (307). They are 
anti-inflammatory and are able to supress inflammatory processes (366). For this 
reason, synthetic glucocorticoids such as prednisone and prednisolone are 
commonly used for the treatment and alleviation of inflammatory disorders such 
as asthma and allergies (285), and also autoimmune diseases such as rheumatoid 
arthritis, multiple sclerosis, and type 1 diabetes (367). Glucocorticoids are 
predominantly used to treat inflammation. Because of this, they can be used to 
alleviate symptoms in other diseases that are not predominately mediated by 
the immune system, but are associated with significant inflammation due to 
tissue damage, such as DMD. 
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There are many review articles that compile the extensive clinical trials using 
glucocorticoids in DMD patients (368-370), and hence will not be reviewed in 
great detail here. Briefly, in patients with muscular dystrophy the benefits of 
glucocorticoids outweigh the side effects, such as weight gain and osteoporosis. 
Glucocorticoids improve respiratory function and muscle strength, reduce 
scoliosis, prolong ambulation (368-370) and potentially reduce fibrosis, all which 
indicate a delay in the progression of the disease.  
Although clinical trials utilize different corticosteroids and a range in dosages, 
the recommended treatments are 0.75 mg/kg of prednisone or 0.90 mg/kg of 
deflazacort (368, 371). The treatments vary from consistent daily dosages to 
intermittent dosages such as alternate days or 10 days on/10 days off (368). To 
date there is no optimal standardised glucocorticoid treatment for patients with 
DMD. Indeed, a study in 2013 found clinicians had high variations between their 
methods of treating DMD patients, and proposed that a high level of uncertainty 
was present towards the benefits and side effects of glucocorticoids treatments 
(372). As such, there is still an urgent need for an optimal treatment regime. 
However this may soon be rectified as a clinical trial, Finding the Optimum 
Regimen for Duchenne Muscular Dystrophy (ClinicalTrials.gov Identifier: 
NCT01603407), is currently underway. This trial aims to identify which is the best 
treatment (daily or intermittent (10 days on/off) 0.75mg/kg of prednisone, or 
daily 0.90 mg/kg of deflazacort) for increasing muscle strength with the least 
side effects.  
However, these human clinical trials are predominantly aimed at finding the best 
treatment regime, and so the mechanism as to how glucocorticoids work or 
affect the extracellular matrix are still relatively unclear. However, studies into 
the effects of glucocorticoids on arthritis found that they inhibit the destruction 
of the matrix surrounding the cartilage, by inhibiting protease (ADAMTS4 and 
ADAMTS5) expression and activity in the inflamed area (373). Furthermore, in a 
study investigating cartilage proteoglycan degradation, short term treatment 
with a glucocorticoid (dexamethasone) was found to inhibit matrix degradation 
by inhibiting the GAG cleavage of aggrecan (374). These studies show that 
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glucocorticoids are beneficial in other pro-inflammatory states other than DMD. 
In addition to this, glucocorticoid treatment during allergen exposure in asthma 
resulted in an increase of versican (375). Therefore the biological context is 
important, especially in inflammatory diseases. 
Glucocorticoids are currently used to treat inflammation within DMD, but it 
currently remains unknown as to how glucocorticoids affect the ADAMTS-
versican axis within muscle. Although glucocorticoids are beneficial for 
alleviating inflammation and can help prolong the lifespan of boys with DMD, 
their use comes at a cost. Long term glucocorticoid use has numerous side 
effects ranging from osteoporosis, skin atrophy, gastrointestinal ulcers, cataract 
formation, increased adipose tissue, excessive hair growth, psychosis, insomnia 
and increased appetite (365, 376). Therefore clinicians typically tend to prescribe 
low dose treatments, or treatments that are staggered, with dosage being 
dependent upon the condition being treated (365). The future directions for 
glucocorticoids however, lie in the creation of new synthetic glucocorticoids, 
such as VBP15 (377), that have all the benefits of reducing inflammation, but 
with minimal side effects.  
1.9.3 Alternate therapeutic strategies to target fibrosis 
Currently, other anti-fibrotic therapies are available. Dystrophic hearts can be 
treated with ACE inhibitors and angiotensin receptor blockers, currently used for 
treating cardiomyopathies (378). An ACE inhibitor called perindopril was able to 
maintain cardiac output by delaying left ventricle dysfunction in DMD patients 
(379). Therefore, these treatments may improve heart complications observed in 
DMD and help prolong the longevity of the patient.  
A complication in DMD is the beginning of pathology and the accumulation of 
fibrosis, mediated in part by MMPs. MMP expression is dysregulated in DMD and 
may lead to the progression of fibrosis, therefore MMP modulators may be a 
useful treatment in this regard (36). Additionally, other anti-fibrotic treatments 
are available that inhibit signalling pathways before disease pathologies become 
complicated. An example is the NFκB pathway. NFκB has been elucidated as 
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being expressed by activated macrophages to stimulate inflammation and 
necrosis in muscle (380). In addition, NFκB can also impair muscle regeneration 
by inhibiting satellite cell activation. 
Another target for inhibition is TGFβ, being upregulated in dystrophic muscles 
(280-282). TGFβ upregulates fibrosis by stimulating myofibroblasts (271) and is 
linked to inflammatory cells, such as M2c macrophages which also secrete TGFβ, 
and which further influences dystrophic pathology (215, 216). Suramin is a TGFβ 
inhibitor, and when mdx mice were treated with the drug, it was found to have a 
protective role where it lessened fibrosis and necrosis in muscle, and improved 
muscle repair (381). 
From the treatment strategies reviewed in this section, it is clear that there is an 
urgent need for therapeutic strategies which target fibrosis, and are safe for long 
term use and have minimal side effects; in particular cardiac side effects. It 
would be best if any strategy to target fibrosis could be administered when 
satellite cells still have a good regenerative potential. This would be so the ECM 
can be regulated from the beginning and hence the fibrosis could be controlled - 
it should not expand, nor should it worsen any pathological outcomes. 
Regardless of the treatment, it is integral that it keeps ECM synthesis and 
remodelling balanced to minimise degeneration and excessive inflammation. 
1.10 Overview and rationale of thesis 
The ECM is a diverse, complex and dynamic scaffold that surrounds all cells and 
tissues (231). It is comprised of a variety of proteins including collagens, 
glycoproteins including laminin and fibronectin, and proteoglycans such as 
versican (382). Key to the structure and function of the ECM are the integrins 
and syndecans, transmembrane proteins that mediate matrix and cell adhesion. 
All matrix proteins can be remodelled by ECM proteinases, such as MMPs and 
ADAMTS proteoglycanases. 
Beyond structural support, the ECM can regulate cell fate and behaviour, 
through the synthesis and remodelling of specific ECM proteins, integrin and 
51 
 
syndecan mediated signalling (14), and through the regulation of growth factor, 
cytokine and chemokine bioavailability (231, 383, 384). For optimal cell health 
and function, the integrity of the ECM must be maintained and its composition 
and remodelling need to be tightly regulated. If the ECM is damaged, or if 
synthesis and remodelling is dysregulated, then the health and function of the 
cell will be compromised. 
The ECM is an important component of skeletal muscle, and aberrant ECM 
synthesis and remodelling is associated with muscle pathology. This can lead to 
degeneration, weakness and muscle loss, as is seen in DMD (141). DMD is also 
characterised by aberrant ECM synthesis and remodelling, resulting in fibrosis, 
which is both a cause and consequence of the disease (87, 94).  
Anti-fibrotic treatments, such as those reviewed in section 1.9.3, are generally 
aimed at reducing fibrosis. Indeed, anti-fibrotic treatments, drugs such as 
Losartan and Suramin, or injections of decorin, administered to rats or mice with 
muscular injuries or diseases, were found to have reduced fibrosis and overall 
improved muscle regeneration and function (385, 386). There is evidence in the 
literature that perhaps a reduction in fibrosis improves regeneration (381, 386) 
and also lessons degeneration. For instance, mdx mice were treated with a TGFβ 
inhibitor called Suramin, which was found to reduce fibrosis and necrosis in 
dystrophic muscles (381). Therefore, it can be theorised that anti-fibrotic 
therapeutics not only lessen fibrosis, but may also be beneficial in reducing 
inflammation and degradation in healthy and diseased muscles alike. 
Skeletal muscle comprises approximately 40 % of the human body and is 
essential for locomotion, respiration, posture and metabolism (387). Muscle is a 
highly adaptive tissue and when damaged has the capacity to undergo repair. 
The carefully regulated remodelling and synthesis of muscle ECM is important 
for successful repair following injury, because of its effects on inflammation, and 
satellite cell function (86).  
Whilst there are numerous ECM proteins involved in effective muscle 
regeneration, it can be hypothesised that the carefully regulated synthesis and 
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remodelling of the ECM proteoglycan versican is essential. Versican is a 
chondroitin sulphate proteoglycan and is synthesised as part of a transitional 
matrix (49, 74, 388). In skeletal muscle, versican expression is upregulated during 
early myogenesis and its subsequent cleavage by ADAMTS versicanases facilitate 
the fusion of myoblasts into muscle fibres (17), a process critical for successful 
repair. A versican-rich matrix also has an emerging role in regulating 
inflammation (48). Versican is able to bind and store inflammatory cytokines and 
chemokines, thus attracting monocytes (389). These bind to versican, become 
activated and transition into macrophages. Both monocytes and macrophages 
can synthesize and secrete versican, and add to the already versican-rich area 
(290, 390, 391).  
In healthy skeletal muscle versican expression is low. Whereas, in DMD, high 
levels of versican expression are observed, particularly in areas of damage, 
inflammation and fibrosis (90). To date, glucocorticoids are the only treatment 
with clinical efficacy in DMD, however the exact mechanisms as to how they 
work remain unclear. Furthermore, it remains unknown as to how aberrant 
versican synthesis and remodelling may affect the pathology and function of 
dystrophic muscle fibre types during growth. 
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Therefore, the aims of this thesis were to investigate the hypotheses that:  
(1) Whether the expression of versican and versikine in dystrophic mdx mice 
was similar to that observed in wild type mice. 
 
(2) Whether dexamethasone decreases versican expression in cultured 
muscle cells and thus enhances myogenesis, potentially leading to the 
identification of a potential mechanism of action for glucocorticoids. 
 
(3) Whether the genetic reduction of versican in dystrophic mdx mice could 
improve the pathology and muscle function of the diaphragm, the muscle 
most representative of the human form, through an attenuation in 
inflammation and fibrosis, as well as improve regenerative myogenesis. 
 
(4) Whether the genetic reduction of versican in dystrophic 6 and 26 week 
old mdx mice could improve the pathology and muscle function of fast 
and slow twitch muscles of the hindlimb, through an attenuation in 
inflammation and fibrosis, as well as improved regenerative myogenesis. 
  
54 
 
Chapter 2:  Methods  
2.1 Cell maintenance and experiments 
2.1.1 Overview of C2C12 myoblasts  
C2C12 myoblasts are a well characterised model of mouse satellite cells capable 
of differentiating into multinucleated myotubes. C2C12 myoblasts were 
originally extracted and isolated by Helen Blau in 1981 (392). These cells produce 
an extracellular matrix which includes proteins such as collagen (393), 
fibronectin, hyaluronan (394) and versican (17). In DMD, an increase in collagen, 
fibronectin and versican is seen and is associated with increased fibrosis (119). 
Furthermore, versican is thought to affect myoblast migration, proliferation and 
differentiation (17, 395, 396). Therefore, C2C12 cells may be a useful tool for 
investigating ECM remodelling during myogenesis in-vitro. 
2.1.2 C2C12 myoblast maintenance 
In order to effectively culture C2C12 myoblasts, they need to be maintained, 
with optimum parameters, to ensure good growth or differentiation. Below 
describes the general requirements for growing or differentiating C2C12 
myoblasts into multinucleated muscle fibres. C2C12 myoblasts were grown in a 
HERAcell I50 CO2 incubator (ThermoFisher Scientific), at a temperature of 37 oC 
with 5 % CO2 levels. C2C12 myoblasts were proliferated up to 70 % confluency in 
75 cm2  flasks with Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) with 10 
% FBS (Invitrogen) (hereby referred to as growth media). When passaging, cells 
were loosened by the addition of 1 ml of trypsin (Gibco), then resuspended in 
growth media. Cells were passaged at a 1:30 dilution to maintain the cell line. To 
differentiate C2C12 myoblasts, the growth media was replaced with 
differentiation media (DMEM supplemented with 2 % horse serum). 
Differentiation media was refreshed daily for up to 4 d.  
2.1.3 Cell Counting 
For all in-vitro experiments, cells were trypsinised and resuspended in media. A 1 
mL volume was transferred to an eppendorf tube, and were stained with trypan 
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blue (Amresco) before being manually counted using a haemocytometer and a 
handheld counter. This was done to get the number of cells per mL, which was 
needed to calculate the appropriate volume of resuspended cells required for 
seeding into a 6, 12 or 96 well plate for experiments. 
2.1.4 C2C12 culture with dexamethasone treatments 
Differentiating C2C12 myoblasts were treated with 25 and 100 nM 
dexamethasone, which is considered to be a low dose treatment and has 
previously been shown to increase myoblast fusion (397). 
To assess the effect of dexamethasone on myoblast proliferation, C2C12 
myoblasts were seeded in a 96 well plate (Corning) at a density of 10,000 
cells/cm2 per well, and were left to proliferate for 24 h or 48 h in growth media 
supplemented with 0 nM, 25 nM or 100 nM dexamethasone. Media and 
treatments were refreshed daily. After 24 h or 48 h, the WST-1 assay was 
performed (see section 2.1.6). 
To assess the effect of dexamethasone on myoblast differentiation, C2C12 
myoblasts were seeded in a 12 well plate (Corning, USA) at a density of 25,000 
cells/cm2 per well, and were left to proliferate for 48 h. Myoblasts were then 
treated with 0 nM, 25 nM or 100 nM dexamethasone in differentiation media for 
72 h. The media and treatments were replaced daily. After 3 or 4 days, the cells 
were either fixed in 4 % PFA for the determination of the fusion index (see 
section 2.1.9) or were stored at -80 oC for RNA extraction and subsequent gene 
expression analysis (see sections 2.2.1, 2.2.3 and 2.2.5). 
2.1.5 Conditioned Media Preparation 
2.1.5.1 Preparation of constructs  
To create conditioned media which was to treat differentiating C2C12 myoblasts 
with excess versican or versikine, it is first necessary to insert the relevant 
constructs of required proteins into Escherichia coli (E.coli). As E.coli replicates 
quickly over a few hours duration, it becomes an easy and economical way to 
produce a large quantity of plasmid DNA, specific for each protein construct 
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needed. Constructs listed in Table 2.1 were diluted using nuclease free water 
(Ambion) before being added to DH5α E.coli (Invitrogen) and placed upon ice for 
a period of 20 min. Afterwards, the E.coli and DNA constructs were heat-shocked 
for 50 s using a heat block at 42 °C and placed onto ice for 2 min. Using aseptic 
technique, Luria Broth (LB) (Amresco) was added to each tube, which was then 
placed into an orbital shaker set to a speed of 250 rpm, at 37 °C for 1 h. Aliquots 
of each sample and ampicillin were spread upon LB agar plates (Amresco) 
allowing for the easy selection of E.coli colonies. Any bacterial colonies that grow 
will have ampicillin resistance, gained through the successful incorporation of 
the DNA construct. The plates were allowed to dry slightly, then were inverted 
and placed within an incubator for 16 h at 37 °C. Afterwards, single colonies 
were collected, dropped into a 14 mL Falcon tube of LB broth. Tubes were then 
placed into an orbital shaker at a speed of 250 rpm, at 37 °C for 16 h to allow E. 
coli to replicate. 
 
Table 2.1 Overview of constructs and purpose of conditioned media 
Construct name Purpose of conditioned media 
Empty vector (EV) 
The empty vector is used as a control for every cell 
culture experiment utilising conditioned media. 
V1 versican 
Most published research does not distinguish between 
versican and versikine. C2C12 cell culture experiments 
are a useful tool to begin to dissect these differences. 
Therefore, C2C12 myoblasts were treated with 
conditioned medias and observed for changes in 
proliferation, migration and fusion of myoblasts.  
G1-DPEAAE 
(Versikine) 
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2.1.5.2 Purification of the plasmid DNA using mini prep extractions 
To purify the plasmid DNA for transfection into mammalian cells, overnight E. 
coli cultures (see section 2.1.5.1) were centrifuged to obtain bacterial cell pellets. 
The PureLink Quick Plasmid Miniprep Kit (Invitrogen) was then used to isolate 
plasmid DNA as per the manufacturer’s instructions, and allowed the removal of 
bacteria and waste. The purified plasmid DNA was eluted into 1.5 mL microtubes 
with TE buffer, and the concentration (ng/μl) was quantitated using the 
NanoVue spectrophotometer (GE Healthcare), with A260/280 rations of >8 being 
acceptable for use. Plasmid DNA was stored at -20 °C for future use. 
2.1.5.3 Lipofectamine transfection of Hek293T cells for conditioned media 
synthesis 
Lipofectamine disrupts the cell membrane allowed the purified plasmid DNA to 
be incorporated into Hek293T cells. Following transfection, Hek293T cells were 
cultured in serum free media to ensure that the resulting secreted protein would 
not be drowned out by other serum proteins, such as albumin. Conditioned 
media containing versican, active or inactive ADAMTS5 and ADAMTS15 has been 
successfully used as treatment for C2C12 myoblasts in a similar study 
investigating matrix clearance in myogenic regeneration (17). Hek293T cells 
were used to make the conditioned media, because they are readily transfected 
and secrete a high yield of versican, versikine, and both the active and inactive 
forms of ADAMTS5 and -15 with good efficiency (17).  
Hek293T cells were grown in a 75 cm2 flask (Corning) using DMEM (Gibco) plus 
10 % FBS in a HERAcell I50 CO2 incubator (ThermoFisher Scientific) at 37 oC with 
5 % CO2. Once 70 % confluent, they were transfected with 8 μg of plasmid DNA, 
Lipofectamine-2000 reagent (Invitrogen, USA) and serum free DMEM (Gibco). 
Cells were placed back in the incubator to grow for 5 h, upon which the flasks 
were aspirated and serum free DMEM was added. Cells were left to grow for an 
additional 48 h, after which all media was collected and centrifuged to remove 
cell debris. The conditioned media was immediately placed upon ice and stored 
at -80 °C. 
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2.1.6 WST-1 assay 
The WST-1 assay was used to assess C2C12 myoblast numbers after being 
treated with dexamethasone or conditioned media containing empty vector 
(EV), versican or versikine. The WST-1 reagent contains tetrazolium salts that are 
cleaved on the cell surface through the trans-plasma membrane electron 
transport chain by electron carrier (1-methoxyPMS) that is driven by a reduction 
in NAD(P)H from mitochondria (398, 399). The cleavage of the tetrazolium salts 
forms a coloured formazan which is an indication of viable cells. This colour 
change can be measured by a plate reader, with a stronger colour having more 
viable cells. This means that the WST-1 assay is a relatively easy and simple way 
to generate an approximate cell number. However, a limitation to this is that if 
mitochondrial function is impaired or increased within individual cells, then the 
assay may not accurately reflect cell number. 
 
 
 
Figure 2.1 Example of a WST-1 standard curve.  
A known amount of cells are plated and the absorbance is read to enable 
the creation of a standard curve. A trendline with a high R2 value, such as 
0.983, is considered to be very good, and allows for the determination of 
the slope equation, which is used to calculate the cellular concentration of 
unknown experimental samples. 
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2.1.6.1 WST-1 Standard Curve 
A standard curve of known cellular concentrations is produced for the WST-1 
assay so that it can be used to calculate the amount of cells in the samples with 
unknown concentrations. An example of a WST-1 standard curve can be viewed 
in Figure 2.1. In order to produce a standard curve, C2C12 myoblasts were 
serially diluted using densities ranging from 0 to 100,000 cells/cm2. Myoblasts 
were seeded into a 96 well plate (Corning) and left to adhere for 7 h in growth 
media. Following the supplier’s protocol, WST-1 reagent (Roche) was added to 
each well and incubated at 37 oC for a further 2 h. An Alpha Fusion plate reader 
was used to read the plate at 450 nm, the results enabling the creation of a 
standard curve with known concentrations. 
2.1.6.2 WST-1 experiment 
Following 24 h or 48 h of proliferation, WST-1 reagent (Roche) was added to 
each well and the plate was placed back into the incubator for an additional 2 h. 
An Alpha Fusion plate reader was used to read the plate at 450 nm. The results 
were used to calculate cell number based on the standard curve produced above 
(see section 2.1.6.1). Three biological experiments were performed, with 8 
experimental replicates per treatment.  
2.1.7 Wound migration assay 
In-vivo, myoblasts are required to migrate to the site of injury to repair it. A 
wound migration assay is a simple method to assess the effects of the 
treatments on cell migration in-vitro. For experimental consistency, care was 
taken to make scratches of a consistent width. 
2.1.7.1 Cell maintenance for the wound migration  
C2C12 myoblasts were seeded at a density of 8,500 cells/cm2 in 6 well plates 
(Corning), and left to proliferate for 3 days. The growth media (Gibco, USA) was 
refreshed once after 48 h. After 3 days, the wound migration assay was 
performed. 
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2.1.7.2 Wound migration experiment 
After 72 h, a wound was made through the confluent monolayer, down the 
length of each well. PBS was added so wounds could be viewed under a 
microscope, allowing for a digital image of the 0 h time point to be captured. 
Each well was marked in 3 places along the wound, to be used as a guide when 
taking digital images at 6 h and 10.5 - 11 h post wounding. Once the initial image 
was captured, the PBS was aspirated and the relevant treatment was added to 
each well (N = 2-3 wells per treatment). For the three control wells, only growth 
media was added. For the treatment wells, the relevant conditioned media (EV, 
versican or versikine) was diluted 1:4 with growth media and added to the 
appropriate wells. The plates were returned to the incubator for 6 h. Photos 
were again captured at the 6 hour timepoint, with the final sets of photos taken 
at the 10.5 - 11 h time point. An example of the progression of cellular migration 
can be viewed in Figure 2.2. Digital images were captured using a IX71 Olympus 
inverted fluorescence microscope and a XM10 camera. Using the digital images, 
the distance between the edges of the scratches over the three time points was 
measured using the program ImageJ 1.47v, a program freely available on the 
internet (https://imagej.nih.gov/ij/). 
 
 
Figure 2.2 Example of the progression of a migration assay.  
A) Named time point 0 h, this is an image taken straight after the scratch 
was performed. B) An image taken 6 h, and C) 10.5-11 h after the start of 
experiment to view the rate of wound closure by measuring distance of 
cellular migration over a set time period. 
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2.1.8 Dexamethasone and conditioned media treatments 
To assess the effects of dexamethasone on myotube formation in the presence 
of excess versican or versikine, C2C12 myoblasts were seeded in a 6 well plate at 
a density of 20,000 cells/cm2 per well and were left to proliferate for 24 h or 48 h 
in growth media. After 24 h or 48 h, differentiation media was added and, 
depending upon the treatment required, was supplemented with either 0nM, 25 
nM or 100 nM dexamethasone, and/or EV, versican or versikine conditioned 
media (diluted 1:4). Differentiation media and all treatments were refreshed and 
applied daily. After 3 or 4 days, cells were fixed in 4 % PFA for determination of 
the fusion index (section 2.1.9). Additional experiments using the same 
parameters, but in a 6 well plate, were used for the creatine kinase and BCA 
assays (see section 2.1.10), with cell lysates used for western blots (see section 
2.2.6). 
2.1.9 Fusion index 
The fusion index, a marker of myoblast differentiation efficacy, is the proportion 
of fused compared to total myonuclei (17). Myotube fusion has two distinct 
stages. Individual myoblasts must fuse together to form a nascent myotube, 
which contains less than 3-4 nuclei. Subsequent myotube growth and secondary 
fusion require individual myoblasts to further fuse with the nascent myotube 
forming mature myotubes (17, 400-402). Myotube maturity can be assessed by 
counting how many fused nuclei each myotube contains. 
Following the fixation of C2C12 myotubes in 4 % in PBS, cells were stained with 
AlexaFluor 568 phalloiden (Invitrogen, diluted 1:50), which stains cytoskeletal 
actin. The plate was kept in the dark, on a rocker for 20 min at room 
temperature. Nuclei were counterstained using DAPI blue fluorescent nuclear 
stain (Invitrogen; diluted 1:20), the plate was again kept in the dark, placed on 
the rocker for 20 min at room temperature. Images were captured on an 
Olympus 1X71 Inverted Fluorescence Microscope with an XM10 camera. A view 
with well differentiated myotubes was located and an image was captured, 
followed by two random images within 1 field of view of this initial image (17). 
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This process was repeated for a total of three times, yielding a total of 9 images 
per well for each experimental condition, performed in duplicate for each of the 
3 biological replicates. To determine the fusion index, individual nuclei were 
counted and designated as either fused or unfused, with myotubes also being 
counted and classified using the program ImageJ 1.47v, as either a nascent (3-4 
fused nuclei), mature (5 - 10 fused nuclei) or super mature (10 + fused nuclei) 
myotubes.  
The fusion index was used to assess the myotube maturation. For differentiating 
myoblasts treated with 25 nM or 100 nM dexamethasone, 3 biological replicates 
in duplicate were performed, with 8897 ± 222 nuclei and 270 ± 23 myotubes 
counted per experimental condition for each biological replicate. For 
differentiating myoblasts treated with dexamethasone, and/or conditioned 
media, a total of 5 biological replicates in duplicate were performed, with 3156 ± 
96 nuclei and 110 ± 3 myotubes counted per experimental condition for each 
biological replicate. 
2.1.10 Creatine kinase and BCA assays – C2C12 lysates 
The creatine kinase (CK) assay was used as a measure of C2C12 myoblast 
differentiation. C2C12 cells (section 2.1.8) were lysed, one aliquot was used in a 
CK activity assay (Abcam) to company specifications, and another aliquot of 
lysate was used in a BCA assay (ThermoFisher Scientific) to measure protein 
levels within the samples, also to company specifications. The BCA assay was 
used to normalise the CK assay results to protein levels.  
2.2 Molecular biology  
2.2.1 Total RNA isolation from cell culture 
TRIzol breaks down cells within moments of adding to the samples and therefore 
is used to ensure high quality yields of RNA are extracted. TRIzol (Ambion) was 
added to each sample and cells were lysed by pipetting up and down before 
being collected into an eppendorf tube and stored at -80 °C. The RNA was 
extracted by following the manufacturer’s protocol. Briefly, chloroform was 
added to each sample and were centrifuged at 12,000 g for 15 min at 4 oC. After 
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centrifugation, the samples separated into three distinct layers. The top aqueous 
phase contains RNA, which was carefully transferred into a sterile eppendorf 
tube to avoid contaminating with the white organic phase which contains DNA. 
Then isopropanol was added to each sample and spun down 12,000 g for 15 min 
at 4 oC to form a pellet at the bottom of the tube. The isopropanol was removed 
and samples were washed with 75 % ethanol before being centrifuged again. As 
much ethanol as possible was removed before the RNA pellets were dried by 
incubating on a heat block at 65 °C, then resuspended in nuclease free water 
(Ambion) by gentle pipetting. The samples were further incubated on the 65 °C 
heat block for 5 min to ensure that RNA was thoroughly dissolved and 
resuspended. The RNA concentration and purity was determined using the 
NanoVue spectrophotometer (GE Healthcare) with an A260/A280 nm ratio of ≥ 
1.8 deemed acceptable for downstream analysis. The extracted RNA samples 
were then stored at -80 °C.  
2.2.2 Total RNA isolation from skeletal muscle tissue 
EDL, soleus and diaphragm muscles (see Section 2.3.7) were homogenised in 1 
mL of TRIzol using a handheld homogeniser. Chloroform was added to each 
sample and centrifuged at 12,000 g for 15 min at 4 oC to allow the formation of 3 
distinct layers. The top aqueous phase containing RNA was carefully transferred 
into an eppendorf tube with the addition of isopropanol. The samples were then 
transferred into RNeasy spin columns (Qiagen) and the manufacturer’s protocol 
was followed. Samples were eluted in 30 µL or nuclease free water. RNA 
concentration and purity was determined using the NanoVue 
spectrophotometer (GE Healthcare) with an A260/A280 nm ratio of ≥ 1.8 
deemed acceptable for downstream analysis. The extracted RNA samples were 
then stored at -80 °C.  
2.2.3 Reverse transcription  
Reverse transcription was used to synthesize cDNA from extracted RNA. The 
defrosted RNA (up to 1μg) was reverse transcribed to cDNA using the 
manufacturer’s protocol from the iScript CDNA Synthesis Kit (BioRad). For one 
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sample, the following master mix was made; 5x iScript reaction mix (4 µl), iScript 
reverse transcriptase (1 µl), 1 µg of RNA template, with nuclease free water 
(Ambion) being used to make up a total of 20 µl. For multiple samples, each 
volume was multiplied according to the number of samples to be used. The 
reactions were incubated on the Bio-Rad T100 ThermoCycler at 25 °C for 5 min, 
42 °C for 30 min and 85 °C for 5 min before being held at 4 °C. The cDNA samples 
were stored at -20 °C until required.  
2.2.4 cDNA quantitation via OliGreen assay 
All gene expression data were normalised to cDNA concentration. The cDNA 
concentration was quantified using the Quant-iT OliGreen ssDNA reagent kit 
(Invitrogen) as per the manufacturer’s protocol. Briefly, a black well, clear 
bottom 96 well plate (Thermofisher) was set up so that the oligonucleotide 
standards and cDNA samples could be added in triplicate. Tris-EDTA (TE) buffer 
(95 μl) was added per well, followed by 100 µl Quant-iT Oligreen ssDNA reagent. 
The plate was wrapped in aluminium foil and incubated for 5 min in the dark at 
room temperature. The fluorescence was measured using a microplate reader 
with the following fluorescent wavelengths: excitation 485 nm and emission 535 
nm. The cDNA concentration was determined by firstly constructing a standard 
curve from the absorbance values of the oligonucleotide standards, and then 
using the slope equation on the standard curve to determine the cDNA 
concentrations of the unknown samples. A CV value of 5 % or less was used to 
screen out any outliers. 
2.2.5 Real time PCR 
RT-PCR is a semi-quantitative way to assess gene expression in cells, however 
the results need to be normalised to OliGreen for cDNA content. The primers 
used (Table 2.2) have all been previously tested and found to work efficiently at 
55 oC. Additionally, any peaks other than the dissociation curve graph (or 
background noise near baseline) produced at the end of the program run will 
indicate the presence of any contamination or primer-dimers. As a further 
control measure, non-template controls (NTC’s) that contain everything but 
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cDNA, are run alongside the samples to act as a safeguard against 
contamination. 
Samples were added in duplicate to clear 96 well plates (4titude). Following 
manufacturer protocol, iTaq Universal SYBR Green Supermix (BioRad), forward 
and reverse primers of interest, nuclease free water (Ambion) and the relevant 
cDNA template was added to each well. The plate was sealed using 8-strip flat 
caps (4titude) and loaded into a Stratagene Mx3000P QPCR System (Agilent 
Technologies). The following conditions were used: 10 min at 95 °C, followed by 
40x (30 s at 95 °C, 30 s at 55 °C and 30 s at 72 °C), followed by 1x (1 min at 95 °C, 
30 s at 60 °C, 30 s at 95 °C). Relative changes in mRNA levels were calculated 
using the 2ΔCt method normalised for cDNA concentration using an OliGreen 
assay (section 2.2.4). 
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Table 2.2 Primer sets used for RT-PCR 
Accession Number Primer name 5’ Forward 3’ Reverse 
NM_007392.3 Acta2 CAGGCATGGATGCGATCAATCAC ACTCTAGCTGTGAAGTCAGTGTCG 
NM_009621.5 ADAMTS-1 CCTGTGAAGCCAAAGGCATTG TGCACACAGACAGAGGTAGAGT 
NM_011782.2 ADAMTS-5 GCTACTGCACAGGGAAGAGG GCCAGGACACCTGCATATTT 
NM_001329420.1 ADAMTS-15 GCTCATCTGCCGAGCCAAT CAGCCAGCCTTGATGCACTT 
NM_007542.5 Biglycan GAGATTCCTCCCAACCTGCC GGATTCCCGCCCATCTCAAT 
NM_007710.2 
Creatine Kinase muscle 
(CKm) 
CCGTGTCACCTCTGCTGCTG TCCTTCATATTGCCTCCCTTCTCC 
NM_007742.4 Collagen 1a1 (Col1a1) TCATCGTGGCTTCTCTGGTC GACCGTTGAGTCCGTCTTTG 
NM_009930.2 Collagen 3a1 (Col3a1) GCCCACAGCCTTCTACAC CCAGGGTCACCATTTCTC 
NM_009931.2 Collagen 4a1 (Col4a1) TGTGGATCGGCTATTCCTTC ATGGGGCGCTTCTAAACTCT 
NM_008907.2 Cyclophillin CCCACCGTGTTCTTCGACA CCAGTGCTCAGAGCTCGAAA 
NM_001190451.2 Decorin TCATAGAACTGGGCGGCAAC AGTAGGCAGACCTTGAGGGAT 
NM_010043.2 Desmin AACTTCGAAACCAGCCC CTGTGTAGCCTCGCTGACAA 
NM_008216.3 
Hyaluronan synthase 2 
(Has2) 
GGGACCTGGTGAGACAGAAG ATGAGGCAGGGTCAAGCATA 
XM_006511645.3 Hyaluronidase 2 (Hyal2) AGCCGCAACTTTGTCAGTTT GAGTCCTCGGGTGTATGTGG 
NM_001355722.1 F4/80 AAGCATCCGAGACACACACA GGCAAGACATACCAGGGAGA 
XM_011250822.2 Furin (Pcsk3) CAGCGAGACCTGAATGTGAA CAGGGTCATAATTGCCTGCT 
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NM_011333.3 
Macrophage 
Chemoattractant  
Protein  1 (MCP1) 
CCCAATGAGTAGGCTGGAGA TCTGGACCCATTCCTTCTTG 
XM_017314318.1 Myosin Heavy Chain 
(MyHC) 
GCTCAAAGCCCTGTGTTACC CATAGACGGCTTTGGCTAGG 
NM_010866.2 MyoD ACAGTGGCGACTCAGACGC CGCTGTAATCCATCATGCCAT 
NM_031189.2 Myogenin TCGGTCCCAACCCAGGA GCAGATTGTGGGCGTCTGTA 
NM_011039.2 Pax7 GCTACCAGTACAGCCAGTATG GTCACTAAGCATGGGTTAGATG 
NM_001291184.1 PACE4  (Pcsk6) ATTTCCCCAACCTCGTCTCT AGCTGAGTCCTTGCCACCTA 
NM_011577.2 TGFβ1 GCCTGAGTGGCTGTCTTTTGA CACAAGAGCAGTGAGCGCTGAA 
NM_001081249.1 (V0) 
NM_019389.2 (V1) 
Versican (V0/V1) ACCAAGGAGAAGTTCGAGCA  CTTCCCAGGTAGCCAAATCA 
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2.2.6 Western blotting  
Western blotting was used to confirm that the transfected Hek293T cells had 
successfully incorporated the plasmid DNA of interest and were secreting the 
relevant protein. Versican conditioned media and cell lysates first underwent a 1 
μl addition of chondroitinase ABC (Seikagaku, Tokyo, Japan) and a 2 h incubation 
at 37 oC to remove GAG chains as described (319). All samples were then 
combined with 1x loading dye (BioRad).  
Conditioned media samples were loaded onto 1.5 mm 7.5 % acrylamide gels and 
subjected to reducing sodium dodecyl sulphate – polyacrylamide gel 
electrophoresis (SDS-PAGE) (30 mAmps per gel, for 1 hour) before being 
transferred (150 mAmps per gel, for 1 hour) onto a polyvinylidene difluoride 
(PVDF) membrane. Membranes were blocked in 5 % skim milk powder / Tris 
Buffered Saline containing 0.1 % Tween-20, then incubated with primary and 
secondary antibodies (Table 2.3).  
The dexamethasone treated C2C12 cell lysates underwent SDS-PAGE using pre-
cast Mini-PROTEAN TGX Stain-Free Protein Gels (BioRad) to allow imaging of 
protein in lanes using stain-free technology on benchtop Chemidoc XRS+ 
(BioRad), followed by electrophoresis using pre-cut Trans-Blot Turbo Mini PVDF 
Transfer Packs (BioRad) utilizing a Trans-Blot Turbo Transfer System (BioRad).  
Visualisation of conditioned media was facilitated by an anti-rabbit or anti-
mouse horseradish peroxidase (HRP)-labelled secondary antibody (Table 2.3). 
Bands were exposed manually by covering PVDF membranes with 750 ul of ECL 
prime western blotting detection reagent (GE Healthcare) for 1 min, then 
drained and added to a cassette for manual exposure, or placed on the quartz 
surface within the chemidoc system. The film was exposed in the dark for 30 s to 
10 min, with developed films being scanned to obtain a digital image. The 
exposure time used with the Chemidoc was calculated automatically by the 
software.  
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Table 2.3  Antibodies used for Western blotting 
 Primary antibody Dilution Secondary antibody Dilution 
G1-DPEAAE (Versikine) 
Versican V0, V1 Neo Antibody 
(ThermoFisher Scientific; PA1-
1748A) 
1:1000 Peroxidase AffiniPure Goat Anti-Rabbit IgG (H+L) 1:5,000 
Empty vector and Versican 
Anti-Versican Antibody, a.a. 
1360-1439 of mouse versican 
(Merck; AB1033) 
1:200 Peroxidase AffiniPure Goat Anti-Rabbit IgG (H+L) 1:5,000 
GAPDH 
Anti-Glyceraldehyde-3-
Phosphate Dehydrogenase 
Antibody, clone 6C5 (Merck;  
MAB374) 
1:10,000 Anti-mouse IR680, (Sigma Aldrich) 1:10,000 
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For cell lysate visualisation, an anti-rabbit horseradish peroxidase (HRP)-labelled 
secondary antibody (Table 2.3) was used. An equal volume (750 μl) of part A and 
B chemoluminescent (BioRad) was used to cover the membrane, before being 
drained and placed into the Chemidoc, with the computerized system 
automatically calculating exposure times. Downstream analysis of the cell lysate 
bands was undertaken through the use of the accompanying ImageLab software.   
2.3 Animal studies  
2.3.1 Mouse rationale and husbandry 
All animals and experiments used in Chapters 4 and 5 were approved by the 
Deakin University Animal Ethics Committee. (Applications A79-2011 and 
G06/2015). Female C57BL/6 and C57BL/10 wild type mice and C57BL/10ScSn-
Dmdmdx/Arc mice, hereafter referred to as mdx mice, were obtained from the 
Animal Resource Centre (Canning Vale, Western Australia). Male versicanheart 
defect/+ (Vcanhdf/+) were obtained from Hoffman-La Roche Pharmaceuticals. All 
mice were maintained on a 12 hour light-dark cycle, with standard mouse chow 
and water provided ad libitum. 
The Vcanhdf-/- strain, homozygous for the deletion of versican, is embryonically 
lethal at E10.5. Therefore, as the heterozygous Vcanhdf/+ mouse has one 
functional versican allele, they are a viable strain (331) and were therefore used 
in this thesis as a source of genetically reduced versican. The Vcanhdf/+ mice, 
hereafter known as hdf mice, were maintained on a C57BL/6 background. 
Female C57BL/6 mice were bred with male hdf mice in order to produce more 
hdf males. The hdf males on a C57BL/6 background were bred with female mdx 
mice on a C57BL/10 background to generate male pups that were mdx 
(dystrophic with normal versican) or mdx-hdf (dystrophic with reduced versican) 
and on a mixed C57BL/6 and C57BL/10 background. Mice were bred as required, 
with pups being weaned at 3-4 weeks of age. At 5 weeks of age, female pups 
were humanely, culled, while males were housed until reaching 6 or 21-26 
weeks of age for experiments.  
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The mouse ages were chosen specifically, as at 6 weeks of age, mdx mice are 
past their period of spontaneous degeneration and are still in a period of 
postnatal growth (403), which is thought to be an additional stress on dystrophic 
muscles (404). The 6 week mice also approximately equate to 14-18 human 
years of age (129), a period where patients with DMD lose ambulation. Adult 
mdx mice between 21-26 weeks of age were also chosen as an age point, as 
although mice have stopped growing, at this point the dystrophic pathology 
steadily progresses, especially in the diaphragm, and muscles fibres have 
undergone numerous cycles of degeneration and regeneration (403). These 
adult mice equate to approximately 35 years in humans (129), an age that has 
severe complications from pathology and is towards the end of lifespan in DMD 
patients. 
2.3.2 Mouse genotyping 
As there were no obvious phenotypical differences between the mice, the male 
pups therefore required genotyping to be able to know which mice were mdx 
and which were mdx-hdf (133, 405, 406). From 5 weeks of age, male pups had an 
ear punch biopsy taken for genotyping. A 3-4 mm sized ear punch biopsy was 
placed into an eppendorf tube containing 75 µl of ice-cold extraction buffer (25 
mM NaOH, 0.25 mM EDTA, distilled water), and immediately placed on ice. 
Samples were placed on a heat block at 100 oC for 30 min, after which they were 
placed on ice to cool down before the addition of 75 µl of neutralisation buffer 
(40 mM Tris-HCl, pH 5) to each tube. Samples can be stored at -20 oC if required 
for further use. Samples were run alongside a 1000 kDa EZ load molecular ruler 
(BioRad), on a 1 % agarose gel at 100 amps for 45 min, and visualised bands of 
interest were imaged on the Chemidoc XRS+. If mice are mdx-hdf, there will be a 
band at 400 kDa due to the LacZ promoter insertion, which causes the partial 
knockdown of versican (Figure 2.3). If the male is mdx, then there will be no 
band present at this location.  
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Figure 2.3 Example of a genotyping gel.  
Two ladders are situated on either side of the image to match up 
sample bands. Lanes 1 to 6 show unknown mice genotypes, and 
lanes 7 to 9 are controls: known mdx and mdx-hdf samples along 
with a negative control (neg; no DNA). 
 
2.3.3 Assessment of body composition - EchoMRI 
Directly prior to function testing, all mice were weighed and placed into an 
EchoMRI for rodents (Body Composition Analyser ESF-005, EchoMRI). The 
EchoMRI tests for body composition of each individual mouse at the time of 
testing, relevant to its own bodyweight. Specifically it measures the following: 
total body fat content measures fat within the body; lean content measures the 
tissues (muscle) containing water within the body excluding fat and bones; total 
water content measures all water within the body; and free water content 
measures the water in the bladder. 
2.3.4 Ambulation and respiratory measures using calorimetric cages 
The results obtained from calorimetric cages allowed for investigations into 
respiratory and metabolic functions, and also detailed analysis for spontaneous 
physical activity during the duration the experiment. The calorimetric cages are 
kept in a room that has the exact same parameters as the mice re normally 
exposed to, they were kept at the same temperatures and light/dark periods as 
normal. Mice were acclimatised to the metabolic cages (Accuscan Fusion v3.6; 
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Columbus Instruments International, OH, USA) for a 3 h period, 48 h prior to 
contractile function testing. The day before function testing, mice were placed 
into metabolic cages (Columbus instruments, USA) for 24 h in order to measure 
the volumes of oxygen (VO2) consumed, carbon dioxide (VCO2) released and 
respiratory exchange rate (RER) per mouse. As the respiratory data is recorded 
every minute during the 24 h experiment, it was therefore possible to 
breakdown the data into the 12 h light and dark periods that the mice undergo 
normally. Additionally, infrared sensors lining the cages allowed for the 
measurement of spontaneous activity by recording the total (crossing 2 or more 
infrared beams, ie: walking) and ambulatory (crossing only 1 infrared beam, ie: 
twitching) movement of each mouse. As the counter connected to the infrared 
sensors was only basic and could only tally the movements, only total data for 
the 24 h period could be obtained. Afterwards, mice immediately underwent 
contractile function testing (section 2.3.6). 
2.3.5 Echocardiography 
The results obtained through echocardiography allowed for more detailed 
investigations into heart function. Both DMD patients and mdx mice have a 
dilated cardiac myopathy and myocardial fibrosis as a consequence of the 
disease. More importantly, however, is that versican is very important for heart 
development, a complete absence being embryonically lethal at E10.5 due to a 
malformed heart, whereas heterozygous hdf mice are viable (331).  Therefore it 
was necessary to investigate the interaction between reduced versican and heart 
function. A veterinarian (Dr Richard Wooley) performed echocardiography on 25 
week old mice using a HD15 purewave ultrasound system (Phillips), as previously 
described (407). By placing the mouse nose into a nosecone, mice were lightly 
anaesthetised by inhalation of a maintained gas flow of 1.5 % isoflurane in 
oxygen. The parameters acquired were measured in M-mode and included 
interventricular septal dimension (IVSd, IVSs), left ventricular internal diameter 
(LVIDd, LVIDs), left ventricular posterior wall dimensions (LVPWd, LVPWs); where 
d = diastole and s = systole. Other important parameters acquired included the 
stroke volume, ejection fraction and fractional shortening for each heart.  
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2.3.6 Muscle function testing 
After removal from metabolic cages (section 2.3.4), mice were anaesthetised 
using medetomidine (0.5mg/kg), midazolam (5mg/kg) and fentanyl (0.05mg/kg), 
administered via an IP injection in ~1 ml sterile saline. Once mice were 
unresponsive to tactile stimuli, the hind limb was shaved to remove fur and an 
incision was made between the knee and ankle. The extensor digitorum longus 
(EDL) was carefully excise by firstly locating the proximal tendon, which was then 
tied with a surgical silk suture. The surrounding membrane, nerve and blood 
vessels were very carefully removed from the muscle surface so as not to 
damage the muscle during this process. Another suture was tied around the 
distal tendon, and the EDL muscle was then dissected free. The EDL muscle was 
then tied to a dual mode force transducer/servomotor for muscle function 
testing and assessment. 
Then, the 6 and 26 week mouse hind limbs were rotated to allow for the 
dissection of the soleus by firstly tying the proximal aponeuroses, a type of 
connective tissue that connects the soleus to the tibia and fibula bones near the 
knee, and the distal tendon (Achilles tendon) at the back of the foot. Once both 
ends of the soleus were tied, it was carefully excised starting at the proximal 
tendon and tied to a dual mode force transducer/servomotor for muscle 
function testing and assessment. 
The 21 week old mice were dissected to obtain access to the diaphragm. Once 
dissected free, the diaphragm and surrounding ribcage was placed into a glass 
dissecting dish full of ringers and bubbled carbogen whilst finer dissections were 
undertaken. The diaphragm was pinned down and the ribs removed. Then the 
diaphragm was cut in half again pinned carefully. From this, a small ~1 cm strip 
was carefully cut, leaving the rib and central tendon on the muscle strip which 
were then tied with sutures. The small strip of diaphragm was then tied to a dual 
mode force transducer/servomotor for muscle function testing and assessment. 
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Figure 2.4 Examples of muscle tracings at different frequencies.  
A) The tracing of a single twitch at 1 Hz. B) A tracing of 4 twitches 
after a stimulation of 10 Hz, and C) after 30Hz, a series of twitches 
can be seen, which leads to D) complete tetanus is was achieved 
after stimulation at 100 Hz. 
 
To assess muscle function, the muscles were transferred to the muscle function 
bath, which was filled with Kreb’s ringer buffer (NaCl 137 mM, NaHCO3 24 mM, 
D-glucose 11 mM, KCl 5 mM, NaH2PO4·H2O 1mM, MgSO4 1 mM, CaCl2 2 mM, d-
tubocurarine chloride 0.025 mM), continuously bubbled with Carbogen (medical 
grade 95 % CO2 and 5 % O2; BOC gases) and thermostatically maintained at a 
temperature of 25 oC. Each muscle was attached to the muscle function machine 
by firstly tying the distal tendon end to an immovable pin, while the proximal 
tendon was tied onto the lever arm of the transducer, as recommended in the 
standard operating procedure (SOP), entitled: Measuring isometric force of 
isolated mouse muscles in vitro (SOP ID number:  DMD_M.1.2.002). This is SOP is 
freely available on the TREAT-NMD website (http://www.treat-
nmd.eu/research/preclinical/dmd-sops). All muscles were stimulated using a 
voltage of 40 mV, and supramaximal square wave pulses of 350 ms in duration 
used for the EDL and diaphragm, with 1200 ms duration used for the soleus. All 
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stimulation parameters and contractile responses were controlled, measured 
and recorded on a desktop computer, using Dynamic Muscle Control Software 
(DMCv5.415) along with transducer control/feedback hardware (Aurora 
Scientific). The optimal muscle length was obtained from a series of twitches 
until a force plateau was reached. Then muscle length was measured using a set 
of digital callipers. The maximal isotonic force (Po) was determined from a  force-
frequency curve; a series of stimulations comprising of 1, 10, 30, 50, 60, 80, 100, 
and 120 Hz for diaphragm and EDL, with 1, 10, 20, 30, 50, 60, 80, 100 and 120 Hz 
for the soleus. Some examples of the muscle tracings can be found in Figure 2.4.  
To assess muscle fatigue, each muscle was stimulated once every 5 s for a total 
of 4 min at the optimal length and a submaximal stimulation frequency of 60 Hz 
(408-411). The recovery of Po was determined by stimulating the muscles at 60 
Hz at 2, 5 and 10 min after the fatigue protocol was run.  
As Po is highly dependent on the size of each muscle, Po values were 
subsequently normalized to muscle cross-sectional area and were expressed as 
specific force (sPo;kN.m-2). Muscle cross-sectional area was calculated by dividing 
the muscle weight by the optimum fibre length (Lf) and 1.06 mg/mm3, which is 
the density of mammalian muscle. The Lf is calculated by multiplying Lo with 
previously determined Lo.Lf ratios of 0.44 for the EDL, and 0.71 for the soleus 
(127, 412). 
2.3.7 Sample collection and storage 
Following muscle function testing the EDL, soleus and diaphragm muscles were 
dissected free of any tendons and connective tissue, then weighed on an 
analytical balance. The muscles were then snap frozen in liquid nitrogen and 
stored in the -80oC freezer for analysis of gene expression. 
Muscles from the contralateral hindlimb and diaphragm, not used for function 
testing, were used for histological and immunohistochemical analysis. They were 
stretched out to Lo and covered with a layer of OCT medium (VWR International), 
and frozen in thawing isopentane.  
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Blood was obtained by cardiac puncture and stored at 4 oC for 24 h to allow clot 
formation. Blood was centrifuged at 13,400 rpm for 2 min to separate the red 
blood cells from the serum, in the form of a pellet. Serum was carefully extracted 
and stored at -80 oC. 
Hearts were weighed and subsequently stored in 4 % PFA for 24 h, before being 
stored in PBS in a fridge, until they were embedded in paraffin. Embedded hearts 
were stored at -20 oC. 
2.3.8 Creatine kinase assay - mouse serum  
The creatine kinase assay was used as an unspecific, whole body measure of 
muscular damage in the mdx mice. Serum obtained from mice (section 2.3.7) 
was used in a creatine kinase (CK) activity assay (Abcam), to company 
specifications. Note that the assay measures brain, heart and muscle isoforms of 
creatine kinase within the serum, and is not specific for the muscle isoform. 
2.3.9 Histology  
2.3.9.1 Haematoxylin and Eosin staining 
In order to view the muscle morphology, each muscle was sectioned and stained 
with haematoxylin and eosin (H&E). Eosin stains muscle fibres and cytoplasm 
bright pink and haematoxylin stains nuclei purple, so the muscular structures 
become very easy to differentiate. Frozen muscle sections of 8 µM thickness 
were fixed in 70 % ethanol for 3 min and rinsed in running tap water, then 
washed with distilled water. Sections were stained in Mayer’s haematoxylin 
(Sigma) for 1 min, rinsed under running tap water for 30 s and placed in 0.05M 
Tris Buffered Saline (TBS) for 1 min to allow the colour to develop. Sections were 
rinsed underrunning tap water for 30 s, following by distilled water. The slides 
were stained with aqueous Eosin (Sigma) for 15 s and immediately rinsed in tap 
water. Slides were dehydrated by dipping 10 times in 70 % ethanol, 10 times in 
95 % ethanol (repeated twice), 10 time in 100 % ethanol (repeated twice) and 10 
dips in xylene (repeated twice). Muscle sections were mounted using DPX 
(Sigma) and glass coverslips. 
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2.3.9.2 Muscle morphology analysis 
As H&E staining allows for the easy viewing of muscle structures, it is possible to 
then analyse the muscle fibres and areas of damage. An example of the 
dystrophic pathology found in mdx mice can be found in Figure 2.5. Two images 
of muscle H&E stained muscles were captured at 100x magnification on a 
camera mounted Leica microscope. The program Image-Pro Plus (version 7) was 
used to assess the mean cross surface area (CSA) and centrally nucleated 
myofibres were counted to assess recently damaged and repaired myotubes. 
Cells located in the ECM surrounding the muscle fibres were assumed to be 
inflammatory cells and fibroblasts, while areas of thick connective tissue 
deposits (clear or very pale pink in colour) were assumed to be fibrosis. Muscle 
damage was analysed by identifying and circling areas of mononuclear 
infiltration and degeneration (413, 414), which includes inflammatory cells, 
adipose and connective tissues, and expressing the circled area as percentage of 
the total muscle area. Furthermore, additional images were also taken on the 
same microscope at 200x magnification in order to produce a representative 
figure panel. 
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Figure 2.5 Example of mdx muscle stained with H&E.  
This mdx muscle section gives a good overview of dystrophic 
pathology. Given the varying size of muscle fibres in the muscle, 
both small and large fibres are highlighted. Undamaged muscles and 
recently regenerated fibres, those with central nuclei, are also 
present. Areas of inflammation and necrosis can also be seen, as 
well as the infiltration of fibrosis and adipose tissue. 
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2.3.10 Immunohistochemistry 
2.3.10.1 Versican and versikine 
Immunohistochemistry was undertaken in order to investigate the cellular 
localisation of versican and versikine within muscle sections, and also to assess 
their expression level by analysing the proportion of the muscle section 
immunoreactive for versican and versikine. Frozen muscle sections were left to 
defrost at room temperature for 15 min, after which they were fixed in 4 % PFA 
for 10 min at 4 oC. Sections were rinsed in PBS twice. Muscles were 
permeabilized using 1 % Triton X-100 in PBS for 10 min. Sections were placed in a 
small container with wet tissues at the bottom for humidity, and were blocked at 
room temperature with 200 µl of protein block (Dako) for 30 min. This was 
followed by the addition of 100 µl of primary antibody for versican (Millipore, 
AB1033), or versikine (Pierce, PA1-1748A) per slide, added at a dilution of 1:200 
in antibody diluent (Dako), kept in the dark, at room temperature for a period of 
1 hour. The negative control slide was not treated with a primary antibody, and 
was instead incubated with antibody diluent. Sections were washed 4x 10 min 
using 1 % NGS in PBS. The fluorescent Alexafluor goat-α-rabbit 594 secondary 
antibody (Life Technologies) was added at a dilution of 1:750 using antibody 
diluent (Dako), and the humid box containing the muscle section was carefully 
placed at 4 oC overnight to incubate. Sections were washed 6x 10 min in PBS and 
were mounted using fluoroshield mounting media with DAPI (Abcam), covered 
with a glass coverslip (ProSciTech) and sealed with nail polish. Slides were kept in 
a foil covered box (away from light) at 4 oC. Two non-overlapping images for 
each slide were imaged at 60x magnification on a confocal microscope (Olympus 
Fluoview FV10i, All in One Confocal Laser Scanning Microscope). Staining was 
quantified by using Image-Pro Plus (version 7), expressing the area of staining as 
a percentage of the total muscle area in the field of view. 
2.3.10.2 Myosin heavy chain (MyHC) IIa 
This experiment and analysis was performed by Alex Addinsall. 
To explain the increase in endurance observed in the mdx-hdf diaphragm, it was 
hypothesised that perhaps they has an increased amount of fast twitch type IIa 
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fibres. Analysis of the proportion of MyHC I is also planned. Diaphragm sections 
from mdx and mdx-hdf mice were stained with anti-MyHCIIa (Developmental 
Studies Hybridoma Bank; SC-71; diluted 1:50), and incubated for 2 h. Sections 
were then reacted with Alexa Fluor 488 goat anti-mouse IgG1 (Thermo Fischer 
Scientific; A21121; diluted 1:500) fluorescent secondary antibody at room 
temperature, with nuclei being counter stained with DAPI containing mounting 
medium (Vectashield). Two non-overlapping images for each slide were imaged 
on a Zoe Fluorescent Imager at 200x (Bio-Rad). To control for non-specific 
staining, negative controls incubated with the secondary antibody were included 
with all analyses. 
2.3.10.3 Wheat germ agglutinin 
As wheat germ agglutinin is a quick and easy stain that has been shown to be an 
effective marker of fibrosis (415), it was used to stain the diaphragm sections. As 
WGA is a fluorescent stain, this allowed for the easy viewing of fibrotic tissue 
and its subsequent morphometric image analysis. The limitations of WGC 
staining are that the sarcolemma of muscle fibres also stains positive for WGA, 
and this limits the sensitivity of the technique. Frozen diaphragm sections from 
mdx and mdx-hdf mice were defrosted at room temperature for 15 min, after 
which they were fixed in 4 % PFA for 10 min at 4 oC. Sections were rinsed 3 times 
in distilled water for 30 s. Muscles were permeabilized using 0.5 % Triton X-100 
in PBS for 10 min, then stained with a fluorescent Wheat Germ Agglutinin 
Conjugate (Invitrogen; 1:50). Sections were rinsed twice in PBS and mounted 
using fluoroshield mounting media with DAPI (Abcam), covered with a glass 
coverslip (ProSciTech) and sealed with nail polish. Two non-overlapping images 
for each slide were imaged on an Olympus 1X71 Inverted Fluorescence 
Microscope with an XM10 camera. Staining was quantified by using Image-Pro 
Plus (version 7), expressing the area of staining as a percentage of the total 
muscle area in the field of view. 
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2.4 Statistical analysis 
Statistical analyses were performed using either 1- or 2-way General Linear 
Model (GLM) ANOVA and Tukey’s post hoc analysis, or an independent sample T-
test, where appropriate. The statistical test used has been indicated within each 
of the relevant figure legends. Minitab 16 statistical software (Version 16.2.1) 
was used to calculate the GLM ANOVA, with Microsoft Excel used for 
independent t-tests. All data were expressed as the mean ± SE, with p < 0.05 
considered statistically significant. 
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Chapter 3: Dexamethasone improves myogenic 
differentiation in-vitro by suppressing the synthesis 
of versican, a transitional matrix protein 
overexpressed in dystrophic skeletal muscle 
 
The majority of results in this Chapter was incorporated into a manuscript which 
was published in December 2017. Details of the publication are as follows: 
MCRAE, N., FORGAN, L., MCNEILL, B., ADDINSALL, A., MCCULLOCH, D., VAN DER 
POEL, C. & STUPKA, N. 2017. Glucocorticoids Improve Myogenic Differentiation 
In Vitro by Suppressing the Synthesis of Versican, a Transitional Matrix Protein 
Overexpressed in Dystrophic Skeletal Muscles. International Journal of Molecular 
Sciences, 18, 2629. doi: 10.3390/ijms18122629.  
N. McRae performed all experiments, analysed the majority of data, and 
prepared all figures. The contributions of the co-authors are stated within the 
methods of this Chapter where appropriate. 
 
3.1 Introduction  
Duchenne muscular dystrophy, is an x-linked muscle degenerative disease, 
characterised by persistent inflammation and repeated bouts of ECM 
remodelling due to muscle degeneration and regeneration occurring in different 
locations within the same muscle (284, 344). This ultimately results in a 
permanent expansion of ECM components, such as collagens, fibronectin and 
versican, and is collectively known as fibrosis. Fibrosis in turn causes further 
damage during dystrophic pathology, being both a cause and consequence, as 
fibrotic tissue creates solitary microenvironments and increases ECM stiffness, 
thereby interfering with normal cellular processes and compromising muscle 
integrity and function (93).  
The accumulation of fibrotic tissue becomes very severe in DMD, eventually 
affecting striated skeletal, respiratory and cardiac muscle in a detrimental 
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manner. Within their limited lifespan, dystrophic patients loose ambulation in 
the limbs, and eventually succumb to respiratory and cardiac failure by 
approximately 30 years of age (109, 111, 416). Fibrosis is usually thought of as an 
endpoint to dystrophic pathology, but it is important to note that the 
accumulation of endomysial components precedes the degeneration of muscle 
(417) and may actively contribute to the degeneration of dystrophic muscles 
(119, 207, 418) 
The mature ECM of normal healthy skeletal muscle is composed of proteins such 
as collagens and proteoglycans containing HS and CS/DS GAG side chains (116). 
Endomysial fibrosis in DMD is associated with the increased expression of not 
only these mature ECM proteins (107, 419), like decorin and biglycan (40), but 
also transitional ECM proteins such as versican (90), hyaluronan (420) and 
tenascin C (421). These transitional matrix proteins, through their synthesis and 
remodelling, are able to regulate cell behaviour during normal development and 
regeneration, functioning as a scaffold for the deposition of mature ECM 
components (73, 289). 
The role of the matrix is not well recognised during development and within 
tissue repair processes, and as such, has not been fully elucidated in the context 
of fibrosis. Therefore strategies to understand the formation of fibrosis and its 
inhibition are of great therapeutic interest within DMD. Given the importance of 
a transitional matrix during tissue repair, proteins such as versican should be of 
particular interest as potential therapeutic targets (74). 
However much still remains unknown about versican and its implications upon 
fibrosis. Versican has previously been established as an important protein 
associated with various cellular processes. Versican is associated with the 
proliferation of myoblasts (20), promotes migration in valvular interstitial cells 
(338), and upon cleavage, is able to help facilitate myoblast fusion (17).  
Furthermore, versican also has a role in inflammatory processes (288), being 
able to bind both chemokines and inflammatory cells via its CS GAG chains (51, 
53), as well as being associated with the differentiation of fibroblasts to 
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myofibroblasts (265). Myofibroblasts secrete prolonged and increased levels of 
ECM proteins, including collagens (422), and are a major contributor to fibrotic 
areas, especially in DMD (107) where versican is also known to be highly 
upregulated (90).  Additionally, ADAMTS5, a protease capable of cleaving 
versican, is upregulated in serum from both mdx mice and DMD patients (349), 
and increased Adamts5 mRNA transcripts were observed in mdx hindlimb 
muscles compared to wild type mice (423). These are suggestive that ADAMTS5 
may also be implicated in fibrotic regions of dystrophic tissues. 
There is currently no cure for DMD, or for the debilitating fibrosis. However 
steroids known as glucocorticoids are currently the only treatment of clinical 
beneficence, and offer some comfort for the dystrophic patients. Glucocorticoids 
are known to reduce inflammation and are already used for treating an 
assortment of inflammatory disorders, such as asthma and allergies (285), 
autoimmune diseases such as rheumatoid arthritis (424), multiple sclerosis and 
type 1 diabetes mellitus (367). Because of the wide range of potential beneficial 
effects, they are used to treat DMD patients to help alleviate disease symptoms. 
Glucocorticoids can delay the progression of DMD by improving muscle strength 
and respiratory function, increasing ambulation, and by reducing scoliosis (366, 
425). These beneficial effects may be due to membrane stabilisation and a 
reduction in inflammation, along with decreases in muscle necrosis and fibrosis, 
and improved regeneration of muscle (285, 426). 
Although patients are treated with glucocorticoids, it still remains largely 
unknown how the treatment affects the genes able to regulate transitional 
matrix synthesis and remodelling, the cellular processes important for 
regenerative myogenesis. It is generally thought that the administration of 
glucocorticoids can dampen the inflammatory response, effectively resetting the 
process, and thereby allowing muscle repair processes to occur normally (365). 
Indeed, glucocorticoids have been previously shown to modulate ECM proteins 
in other pro-inflammatory diseases. In cultured rat mesangial cells, 
glucocorticoids were shown to decrease versican and decorin gene expression 
(427). Another glucocorticoid, budesonide, was also observed to decrease 
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versican, along with perlecan and decorin protein levels in human lung 
fibroblasts stimulated with serum, but whereas versican gene expression was 
decreased, no effect was observed for perlecan or decorin (428). Studies into the 
effects of glucocorticoids on arthritis found that they inhibit the destruction of 
the matrix surrounding the cartilage, by inhibiting protease (ADAMTS4 and 
ADAMTS5) expression and activity in the inflamed area (373). These studies 
suggest that the observed effects of glucocorticoids are quite complex, being 
tissue and context dependent. 
Glucocorticoids can also improve muscle repair, as shown in both in-vivo and in-
vitro studies. In dystrophic mdx mice, high dose treatment with the 
glucocorticoid deflazacort suggested an increase in satellite cells during myofibre 
formation following crush injury in the TA (429). Additionally an increase in 
muscle fibre diameters in the uninjured TA and diaphragm, suggested that the 
treatment may have an effect on muscle growth (429). Another study observed 
that when mdx mice were treated with prednisone or VBP15, a dissociative 
glucocorticoid, they suppressed TGFβ and fibrotic networks, which included a 
reduction in collagen 1A1, 3A1 and 6A1 gene expression, leading to improved 
muscle repair (285). Glucocorticoids have also been shown to enhance myofibre 
formation in primary wild type and dystrophic mdx myoblasts, as well as in 
C2C12 cells in-vitro (397, 430). 
However, the downstream effects of glucocorticoids on important processes, 
such as the regulation of genes and ECM components, cellular migration and 
muscle regeneration, remain largely unstudied. However, being steroids, they 
also come with a wide range of undesirable side effects, and therefore are only 
administered for a brief period or at low dosages (365, 376). Thus, 
understanding how glucocorticoids work can lead to the development of better 
therapeutic strategies, especially those targeting aberrant matrix synthesis and 
remodelling. 
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3.2 Methods 
3.2.1.Versican and versikine expression in mdx and WT mouse 
skeletal muscles 
Transverse frozen sections from 12 week old C57/BL10 and mdx mice were 
already prepared and kindly provided by Chris Van der Poel (LaTrobe University), 
and Nicole Stupka. Slides were mounted with 8 µm thick sections from the mid-
belly of the TA, or strips from the diaphragm, stored at −80 °C until analysis. The 
muscles were stained with versican or versikine. Four representative digital 
images were captured on a confocal microscope of each muscle section at 600× 
magnification and analysed for area of immunoreactivity using Image-Pro Plus 
software (version 7). While N.McRae quantified the area of staining in the 
majority of images, both L. Forgan and B. McNeill quantified some images and 
thereby contributed to the analysis in this experiment. Resultant data were 
expressed as % immunoreactivity. A more detailed version of this protocol is 
found in section 2.3.10.1. 
3.2.2 C2C12 cell culture experiments 
3.2.2.1 C2C12 cell culture conditions  
C2C12 myoblasts were maintained in growth media (DMEM plus 10 % FBS) in 
atmospheric O2 and 5 % CO2 at 37 °C. A different passage number was used for 
each replicate to ensure individuality and to avoid duplicating results. When 
differentiation of myoblasts was required, growth media was replaced with 
differentiation media (DMEM plus 2 % HS). 
3.2.2.2 The effects of dexamethasone treatments on C2C12 myoblast 
differentiation   
To determine the effects of dexamethasone on myoblast differentiation, 
myoblasts were seeded at 25,000 cells/cm2; in duplicate wells for fusion index 
determination, and in triplicate wells for gene and protein expression and 
creatine kinase activity analyses. Following 48 h of proliferation (and at 90 % 
confluence), myoblasts were treated with 0 nM, 25 nM or 100 nM 
dexamethasone in differentiation medium (DMEM plus 2 % HS) for 72 h, 
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refreshed every 24 h. Following this, the cells were harvested for biochemical 
analyses (as below), or fixed with 4 % paraformaldehyde and stained with 
phalloidin and DAPI for 20 m. 
The fusion index was used to assess myoblast differentiation. Therefore to 
quantify the differentiated myotubes collected from culture, the small nascent 
myofibres were those with 3-4 myonuclei, and mature myofibres containing 5-9 
nuclei or those with 10+ myonuclei, were quantified as previously described (17, 
431). For the fusion index, 3 biological replicates in duplicate were performed, 
with 8897 ± 222 nuclei counted per experimental condition for each biological 
replicate. To assess myofibre maturation, 270 ± 23 myofibres were classified and 
counted per experimental condition for each biological replicate. While N.McRae 
counted myotubes in two experimental replicates, A. Addinsall contributed to 
this experiment by counting myotubes in one experimental replicate. In order to 
support the fusion index data, muscle creatine kinase (Ckm) and myosin heavy 
chain (MyHC), both gene markers of myoblast differentiation, were performed 
along with a creatine kinase enzyme activity assay kit, as per manufacturer’s 
instructions. 
3.2.2.3 RNA extraction, cDNA analysis and RT-PCR of C2C12 cells treated with 
dexamethasone  
To observe the effect of dexamethasone on the synthesis and processing of a 
versican and hyaluronan rich pericellular matrix, C2C12 myoblasts were 
harvested in triplicate wells, collected in TRIzol and stored at −80 °C. Upon 
thawing, RNA was extracted and 1 μg of total RNA was reverse-transcribed using 
an iScript cDNA synthesis kit (Bio-Rad). Quantitative RT-PCR was performed using 
iQ SYBR Green Supermix (Bio-Rad) and oligonucleotide primers for the murine 
genes of interest (Table 2.2). Relative changes in mRNA levels to untreated 
myofibres were calculated using the 2ΔCt method. Real time data was 
normalised to cDNA content, as determined using a Quant-iT Oligreen ssDNA 
reagent kit.  
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3.2.2.4 HEK293 cell culture conditions, and preparation of constructs and 
conditioned media  
HEK293T cells were grown in DMEM (25 mM glucose) containing 10 % FBS in 
atmospheric O2 and 5 % CO2 at 37 °C. Cells were transfected using Lipofectamine 
2000 with constructs encoding 1) V1 versican construct (kindly provided by 
Professor Dieter Zimmermann), 2) the G1-DPEAAE versikine fragment, produced 
by the insertion of a stop codon in the V1 versican construct after the Glu441-
Ala442 peptide bond cleavage site (334), and 3) an empty vector control 
(pcDNA3.1MycHisA+). Serum-free conditioned media was collected from the 
HEK293 cells for use in the myoblast differentiation experiments, as previously 
described (17). The conditioned media underwent western blotting for 
confirmation of V1 versican and versikine protein expression.  
3.2.2.3 Dexamethasone and versican or versikine on differentiating C2C12 
myoblasts 
To assess the effects of dexamethasone treatments on myofibre formation in the 
presence of excess versican or versikine, C2C12 myoblasts were seeded at 
20,000 cells/cm2 in duplicate wells for 24 h or 48 h. Afterwards, differentiation 
media (DMEM plus 2 % horse serum) was added for 3 or 4 days, respectively. 
Depending on the experimental conditions, the differentiation medium was 
supplemented with 0 nM or 100 nM dexamethasone, and serum-free versican, 
versikine or empty vector conditioned media (diluted 1:4; refreshed daily). 
Fusion index and myofibre number were then determined as described above. 
Five biological replicates in duplicate were performed, with a total of 3156 ± 96 
nuclei and 110 ± 3 myofibres counted per experimental condition for each 
biological replicate. 
3.2.2.3 Western blotting and protein quantification  
The versican and versikine conditioned media, and the dexamethasone treated 
C2C12 cell lysates from the creatine kinase enzyme activity assay, were used for 
analysis and quantification of versican and versikine protein expression. The GAG 
chains on versican were removed by adding of 1 μl of chondroitinase ABC 
(Seikagaku) to versican conditioned media and to the cell lysates from the 
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creatine kinase enzyme assay for 2 h at 37 oC. The serum free conditioned media 
containing versikine was subjected to the western blotting as previously 
described (319). The versican conditioned media and C2C12 cell lysates 
underwent SDS-PAGE using pre-cast Mini-PROTEAN TGX Stain-Free Protein Gels 
(BioRad), which were transferred onto PVDF membranes. Primary antibodies 
used were versican, versikine and GAPDH, and secondary antibodies used were 
peroxidase AffiniPure goat anti-rabbit IgG and anti-mouse IR680 (Table 2.3). 
Proteins were visualised either manually by film, or by chemiluminescence on a 
Chemidoc XRS+ and analysed using ImageLab software. Versican and versikine 
protein levels were normalised to total optical density of all protein bands on the 
TGX Stain-Free Protein Gel. A more detailed version of this protocol is found in 
section 2.2.6. 
3.2.2.4 The effect of dexamethasone and versican or versikine upon C2C12 
myoblast migration and proliferation 
C2C12 myoblasts were seeded at 8,500 cells/cm2 in triplicate wells and 72 h later 
(when 100 % confluent) a scratch wound assay was performed (432). Growth 
media was supplemented with serum-free versican, versikine or empty vector 
conditioned media (diluted 1:4) for up to 11 h. To determine migration rate, 
digital images (three per well with duplicate or triplicate wells) were captured at 
0 h, 6 h and 11 h post-wounding with a IX71 Olympus inverted fluorescence 
microscope and a XM10 camera. The distance between the edges of the 
scratches was measured using ImageJ. Migration rate calculated in pixels/m.  
To assess the effects of versican and versikine on myoblast proliferation, 
myoblasts were seeded at 10,000 cells/cm2 in growth media was supplemented 
with serum-free versican, versikine or empty vector conditioned media (diluted 
1:4; refreshed daily) for 48 h. Myoblast number was assessed using the WST-1 
cell proliferation reagent, as per the manufacturer’s directions. 
3.2.3 Statistics 
For the quantitation of immunoreactivity against versican and versikine in TA 
and diaphragm muscles, independent T-tests were used to assess differences in 
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immunoreactivity for each muscle type. For the cell culture, biochemical and 
fusion index analyses, independent T-tests, or 1-way or 2-way general linear 
model ANOVA were performed as indicated and followed by Tukey's post-hoc 
analysis where appropriate. All data are presented as mean ± S.E. and were 
considered statistically significant when p < 0.05. 
3.3 Results 
3.3.1 Versican, but not versikine, protein levels were increased in 
dystrophic muscles and correlate with the severity of pathology 
The pathology of TA muscles from adult mdx mice is moderate compared to that 
of the human disease. Specifically, in hindlimb muscles from mdx mice there is 
minimal fibrosis, lower levels of inflammation and effective regeneration (129), 
although muscle strength is compromised (127). The pathology of mdx 
diaphragm muscles is more representative of DMD, with high levels of 
endomysial fibrosis and greatly impaired contractile function (433, 434).  
Here, versican protein levels were upregulated 6-fold in mdx TA muscles and 21-
fold in mdx diaphragm muscles compared to those of the wild type muscles, as 
quantified in Figure 3.1 I. In particular, the endomysial versican staining was 
more extensive in the mdx diaphragm than the TA muscles. In the mdx 
diaphragm and TA muscles, versican staining was also associated with regions of 
mononuclear infiltrate. This is consistent with the synthesis and secretion of 
versican by various cells such as inflammatory cells (48), satellite cells (20), and 
fibroblasts (348).  
Remodelling of versican by ADAMTS proteoglycanases yields the bioactive 
versikine fragment (289). Versikine protein levels were similar in TA and 
diaphragm muscles from mdx and wild type mice, as quantified in Figure 3.1 J. 
Areas of mononuclear infiltrate within the mdx TA and diaphragm sections were 
also observed to contain versikine staining. This is interesting given the 
association of versikine with inflammation (342). 
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Figure 3.1 Versican and versikine staining in TA and diaphragm 
muscle cross-sections from 12 week old wild type and mdx mice.  
Versican staining is red; versikine staining is red; and nuclei are 
stained blue with DAPI). A-H) Representative images from TA and 
diaphragm muscles from wild type and mdx mice. I) Quantification 
of versican immunoreactivity revealed an upregulation in TA (*p = 
0.001; T-test) and diaphragm muscles (#p = 0.0001; T-test) from mdx 
mice when compared to wild type mice. J) Versikine 
immunoreactivity was similar in mdx and wild type TA or diaphragm 
muscles. White asterisks denote areas of mononuclear infiltration. 
Immunoreactivity analysis was determined from n = 5 wild type 
mice and n = 5 mdx mice.  Scale bar = 100 µm. Error bars = S.E. 
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3.3.2 Dexamethasone enhances myoblast fusion and myotube 
formation  
To characterise dexamethasone mediated effects upon transitional matrix 
synthesis and remodelling, during myogenic differentiation, C2C12 skeletal 
muscle myoblasts were used. Like skeletal muscle development in-vivo, 
myogenic differentiation of C2C12 myoblasts is associated with an upregulation 
of transitional matrix genes, including Vcan (versican), Adamts1, Adamts5, 
Adamts15, Pcsk6 (17), Has2 and Hyal2 (73, 435). Differentiating C2C12 myoblasts 
were treated with 0 nM, 25 nM or 100 nM dexamethasone, see Figure 3.2 for 
representative images. These are low and clinically relevant concentrations, 
which have previously been shown to increase the efficiency of myoblast fusion 
(397).  
Following 72 h of treatment, a two-fold increase in muscle creatine kinase (CKm) 
gene expression (Figure 3.3 A), was observed along with dose dependent 
increases in total CK activity (Figure 3.3 B), suggesting that dexamethasone may 
improve differentiation in C2C12 cells. Indeed, CKm is a known myogenic 
differentiation marker and has been shown to be increased alongside myosin 
heavy chain (MyHC) during myogenic processes (436, 437). However, MyHC 
mRNA transcripts, although tending to increase, were not significant in this study 
(Figure 3.3 C).  
Therefore, the fusion index was used to further assess myoblast differentiation. 
To analyse the differentiated myotubes collected from culture, total myotube 
numbers and nuclei were counted. The fusion index involves counting small 
nascent myofibres containing 3 or 4 myonuclei, and growing myofibres 
undergoing secondary fusion containing 5-9 myonuclei or 10+ myonuclei, 
quantified as previously described (17, 431). The myotubes that formed 
following 25 nM and 100 nM dexamethasone treatments were larger and 
contained a greater number of myonuclei compared to untreated cells (Figure 
3.3 D-F). Specifically, the fusion index, which is the proportion of nuclei fused 
into multinucleated myotubes compared to total nuclei, was increased in a dose 
dependent manner following treatment with 25 nM and 100 nM dexamethasone 
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(Figure 3.3 D). This was associated with a dose dependent increase in myotube 
number following dexamethasone treatment (Figure 3.3 E). Myotube formation 
is a two-step process with differentiating myoblasts initially fusing to form 
nascent myotubes, with further growth achieved through secondary fusion of 
additional myoblasts, which ensures the maturation of the myotube  (438, 439). 
The dexamethasone treatments also appeared to enhance secondary fusion. 
There were more myotubes with 5-9 nuclei and 10+ nuclei in cells treated with 
25 nM and 100 nM dexamethasone versus untreated cells. Specifically, the 
increase in the number of mature myotubes with 5-9 nuclei was dose 
dependent, with more myotubes with 5-9 nuclei observed following 100 nM 
compared to 25 nM dexamethasone treatment (Figure 3.3 F). Interestingly, the 
100 nM dexamethasone treatment also increased the formation of nascent (3-4 
nuclei) myotubes (Figure 3.3 F). This is a significant observation as distinct 
signalling pathways mediate the formation of nascent and mature myotubes 
(400, 440, 441), and the increased formation of nascent myotubes by 
dexamethasone suggests a possible upregulation of these early myogenic 
pathways. 
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Figure 3.2 Representative images for differentiating C2C12 cells 
treated with dexamethasone.  
Representative images of differentiating C2C12 myofibres treated 
with A) and D) 0 nM dexamethasone, B) and E) 25 nM 
dexamethasone, or C) and F) 100 nM dexamethasone. Cells were 
stained with phalloidin for F-actin (red) and DAPI for nuclei (blue).  
Scale bar = 200 µm. 
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Figure 3.3 Low dose dexamethasone treatment for 72 h increased 
myogenic differentiation efficacy in C2C12 myoblasts.  
A) The gene expression of myogenic differentiation marker creatine 
kinase (Ckm) was increased 2-fold in cells treated with 25 nM and 
100 nM dexamethasone treatment (*p < 0.01; T-test). B) CK enzyme 
activity in cell lysates was also increased following treatment with 
25 nM (*p = 0.02; T-test) and 100 nM (#p = 0.01; T-test) 
dexamethasone. C) Dexamethasone (Dex) treatment did not 
significantly increase myosin heavy chain (MyHC) mRNA transcripts. 
D-E) Fusion index (FI; *p < 0.001; 1-way GLM ANOVA) and myofibre 
number (*p < 0.01; 1-way GLM ANOVA) were greater in C2C12 cells 
treated with 25 nM and 100 nM dexamethasone compared to 
untreated control cells, and this increase was dose dependent (+p < 
0.05; 1-way GLM ANOVA). F) When compared to control cells, 
treatment with 100 nM dexamethasone increased the formation of 
nascent myofibres containing 3-4 myonuclei (*p < 0.001; 1-way GLM 
ANOVA). The number of myofibres with 5-9 nuclei was greater in 
cultures treated with 25 and 100 nM versus 0 nM dexamethasone 
(+p < 0.02 and †p = 0.03, respectively; 1-way GLM ANOVA), 
indicated that this increase was dose dependent. The number of 
myofibres with 10+ myonuclei was also increased following 
dexamethasone treatment (‡p < 0.001; 1-way GLM ANOVA) when 
compared to control cells. CK enzyme activity was calculated from n 
= 3 biological replicates performed in quadruplicate. The fusion 
index and myofibre number were calculated from n = 3 biological 
replicates performed in duplicate. Gene expression was determined 
from n = 3 biological replicates in triplicate. Error bars = S.E. 
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3.3.3 Dexamethasone regulates the expression of genes associated 
with transitional matrix synthesis and processing during myogenic 
differentiation 
Glucocorticoids have previously been described as being able to enhance 
myogenic differentiation by regulating the expression of genes associated with 
transitional matrix synthesis and processing. Specifically, 72 h of treatment with 
25 nM and 100 nM of dexamethasone reduced Tgfb1 mRNA transcripts by 50 % 
and 54 %, respectively (Figure 3.4 A). This is consistent with data from cultured 
hepatic stellate cells, where low doses of dexamethasone also reduced Tgfb1 
gene expression and protein secretion (442). TGFβ is a potent inhibitor of 
myogenesis which is reversible upon its decreased expression or removal (443), 
so a decrease in Tgfb1 gene expression suggests increased myogenesis, a result 
indeed observed. Furthermore, TGFβ is known to drive networks that increase 
the synthesis of ECM components such as collagens (285), and cultured human 
bronchial smooth muscle cells stimulated with Tgfb1 were also observed to have 
increased levels of collagen 1a1, fibronectin and versican (444). 
In accordance with increased myogenesis, the decreased Tgfb1 transcripts 
(Figure 3.4 A) were associated with a reduction in V0/V1 Vcan gene expression 
by up to 56 % (Figure 3.4 B) and Has2 (Figure 3.4 C) gene expression by up to 58 
% following glucocorticoid treatment. Has2 is the primary Has gene involved in 
hyaluronan synthesis in skeletal muscle (445) and hyaluronan is an important 
versican binding partner (18), so a decrease in hyaluronan is potentially 
suggestive for a decrease in versican.  
Furthermore, versican is cleaved by ADAMTS versicanases (316), and consistent 
with the decreased versican, Adamts1 mRNA transcripts were increased up to 3-
fold in dexamethasone treated C2C12 cells (Figure 3.4 D). This effect was isoform 
specific, as Adamts5 and Adamts15 mRNA levels were not significantly increased 
following dexamethasone treatment (Figure 3.4 E-F). This was unexpected as 
Adamts5 is the most highly upregulated ADAMTS transcript during myogenesis 
(17).   
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Figure 3.4 The expression of genes associated with the synthesis 
and processing of a versican-hyaluronan rich pericellular matrix is 
modulated by dexamethasone in differentiating C2C12 myoblasts.  
A-C) Compared to untreated control cells, 25 and 100 nM 
dexamethasone treatment decreased Tgfb1 (*p < 0.0001 and *p = 
0.0001, respectively; T-test), Vcan (V0/V1 variants) (*p = 0.005 and 
*p = 0.0006, respectively; T-test) and Has2 mRNA transcripts by 
approximately 2-fold (*p < 0.0001 and *p = 0.0001, respectively; T-
test). D) Adamts1 gene expression was increased up to 3-fold in 
response to 25 and 100 nM dexamethasone treatment (*p = 0.03 
and *p < 0.001, respectively; T-test). E-F) Adamts5 and Adamts15 
mRNA transcripts were not significantly increased. G-H) Pcsk3, but 
not Pcsk6, mRNA transcripts were decreased approximately 2-fold 
following treatment with 25 and 100 nM dexamethasone (*p < 
0.0001; T-test). I) Hyal2 mRNA levels were not altered by 
dexamethasone treatment. Gene expression was determined from 
n = 3 biological replicates in triplicate. Error bars = S.E. 
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Adamts1 is synthesised as a zymogen (pro-ADAMTS1) which undergoes 
proteolytic processing to form the active enzyme. Both Pace4 and Furin can 
cleave the zymogen to produce the mature form of Adamts1, but Furin is the 
most efficient (230). Treatments of 25 and 100 nM dexamethasone decreased 
Pcsk6 (Pace4) gene expression by 65 % and 68 %, respectively (Figure 3.4 G), 
whilst Pcks3 (Furin) mRNA levels were not significantly altered (Figure 3.4 H).  
Dexamethasone also had no effect on hyaluronidase-2 (Hyal2) mRNA transcripts 
(Figure 3.4 I), the enzyme necessary for HA degradation (446). Therefore the 
effects of dexamethasone on transitional matrix synthesis and cleavage, 
including any consequences regarding the catalytic activation of ADAMTS 
versicanases, particularly Adamts1, during myogenic differentiation require 
further investigation. 
Of all the gene expression changes, the effect of dexamethasone on the 
expression of versican was the one of most interest as it was overexpressed in 
the dystrophic mdx muscles, especially in the more severely affected diaphragm 
(See Figure 3.1 I). Indeed, western blotting further confirmed the gene 
expression data and that the dexamethasone treatments reduced versican 
protein levels (Figure 3.5 A-B) in a dose dependent manner. Dexamethasone 
treatment did not appear to affect versican remodelling, as indicated by 
versikine, the cleaved form of versican, remaining unchanged across all 
treatments (Figure 3.5 C).  
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Figure 3.5 Versican and versikine protein expression in 
differentiating C2C12 myoblasts following dexamethasone 
treatment. 
A) Representative western blots stained for versican and versikine, 
with the respective stain free protein gel image to demonstrate 
even protein loading. B) A dose dependent decrease in versican 
protein expression was observed following 25nM (*p = 0.00002; T-
test) and 100nM (*p = 0.0000001; T-test) dexamethasone 
treatment, and between 25nm and 100nm dexamethasone (#p = 
0.026; T-test). C) Versikine levels were not altered by 
dexamethasone treatment. Versican and versikine protein 
expression analysis was calculated from n = 3 biological replicates 
performed in quadruplicate. Error bars = S.E. 
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3.3.4 Dexamethasone rescues myofibre formation in differentiating 
myoblasts treated with exogenous versican and versikine  
Versican expression is increased in dystrophic muscles from patients with DMD 
(90) and in mdx mice (Figure 3.1 I). Excess versican may impair regenerative 
myogenesis, as versican processing is implicated in myoblast fusion (17). 
Reduced versican synthesis and favourable processing may contribute to the 
clinical efficacy of glucocorticoids in DMD and the improvement in regeneration 
observed in-vitro and in-vivo. To test this, differentiating C2C12 myoblasts were 
treated with V1 versican, versikine or empty vector conditioned media 
supplemented with 0 nM or 100 nM dexamethasone, see Figure 3.6 for 
representative images. These are challenging experimental conditions and it is 
worth noting that the increase in fusion index in response to dexamethasone 
treatment (see Figure 3.3), was blunted by the addition of versican and versikine 
conditioned media, ultimately decreasing myoblast fusion. This decrease in 
fusion was ameliorated upon treatment with 100 nm dexamethasone (Figure 3.7 
C). In agreement with the fusion index data, treatment with versican and 
versikine conditioned media also decreased myofibre number (Figure 3.7 D). 
Again, this effect was improved by glucocorticoid treatment.  
Alignment of myoblasts is essential for fusion, and this depends on carefully 
regulated migration (431, 432, 447). Versican is known to modulate cell 
migration and depending on the biological context, the effects can be 
stimulatory (448, 449) or inhibitory (450). Myoblast migration is known to be 
necessary for myoblast fusion and myotube formation (432, 447), but to date, 
the effects of versikine on myoblast migration have not been well characterised. 
Therefore, to investigate effects on myoblast migration C2C12 myoblasts were 
treated with versican or versikine conditioned media for up to 11 h, which 
resulted in myoblast migration rate being reduced by 12 % and 13 %, 
respectively (Figure 3.7 E). Thus, excess versican and versikine may impair 
regenerative myogenesis through a reduction in myoblast migration. 
Myoblast viability and number can be a confounding factor in determining the 
efficacy of myogenic differentiation. It is worth noting that an increase in cell 
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number is an indication of cell proliferation and in cell viability. Versican is 
associated with proliferation in various biological contexts (49, 336), including 
within primary myoblasts from turkey muscles (20), whilst versikine has been 
shown to be associated with apoptosis during interdigital web regression in 
embryonic mice (334). However no changes were observed in cell number within 
actively proliferating C2C12 myoblast cultures following 24 and 48 h of 
treatment with conditioned media (Figure 3.7 F), meaning cells remained viable 
upon both treatments, however, they also did not proliferate. These in-vitro 
observations in C2C12 myoblasts, including those mentioned above highlight the 
complexity and the importance of cellular context with regards to versican 
biology. 
  
105 
 
 
 
 
 
 
 
 
Figure 3.6 Representative images for differentiating C2C12 cells 
treated with dexamethasone and conditioned media.  
Representative images of differentiating C2C12 myofibres treated 
with A-B) EV conditioned media and C-D) EV conditioned media and 
100 nM dexamethasone; or E-F) Versican conditioned media and G-
H) Versican conditioned media and 100 nM dexamethasone; or I-J) 
Versikine conditioned media, and G-H) Versikine conditioned media 
and 100 nM dexamethasone. Cells were stained with phalloidin for 
F-actin (red) and DAPI for nuclei (blue). Scale bar = 200 µm. 
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Figure 3.7 Dexamethasone ameliorates the impairment in 
myogenic differentiation associated with excess versican.  
A-B) Representative western blots of conditioned media containing 
versican and versikine, along with representative images of stain 
free protein gels and GAPDH as a loading controls. C) The addition of 
versican and versikine conditioned media compromised myoblast 
differentiation, as assessed by fusion index (*p < 0.001 and +p < 0.02, 
respectively; main effect conditioned media; 2-way GLM ANOVA 
with factors being conditioned media and dexamethasone). Whilst, 
dexamethasone enhanced myoblast fusion in cells treated with 
empty vector (EV), as well as versican and versikine, conditioned 
media (#p < 0.001; main effect dexamethasone; 2-way GLM ANOVA 
with factors being conditioned media and dexamethasone). D) 
Myofibre number was also reduced in versican compared to EV 
conditioned media treated cells (*p < 0.001; main effect conditioned 
media; 2-way GLM ANOVA with factors being conditioned media 
and dexamethasone). Again, dexamethasone increased myofibre 
number in cells treated with EV, as well as versican and versikine, 
conditioned media (#p < 0.01; main effect dexamethasone; 2-way 
GLM ANOVA with factors being conditioned media and 
dexamethasone). E) Reduced cell migration may contribute to the 
impairment in myogenic differentiation efficacy associated with 
excess versican, as versican or versikine conditioned media reduced 
the migration rate of C2C12 myoblasts compared to EV conditioned 
media (*p = 0.01 and *p = 0.04, respectively; T-test). F) Myoblast cell 
number was not different following 24 h and 48 h of treatment with 
versican, versikine or EV conditioned media. Fusion index and 
myofibre number were calculated from n = 5 biological replicates 
performed in duplicate. Migration rate was measured from n = 5 
biological replicates performed in duplicate or triplicate. Myoblast 
proliferation was assessed from n = 3 biological replicates performed 
in 8 wells. Error bars = S.E. 
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3.4 Discussion 
The co-ordinated synthesis and remodelling of ECM proteins is essential for 
efficient skeletal muscle regeneration and myotube formation. The ECM 
regulates the bioavailability of growth factors, such as TGFβ, whilst signals from 
specific matrix proteins control muscle stem cell activation, proliferation, 
migration and fusion (451). Excess synthesis and inappropriate processing of 
ECM proteins leads to fibrosis and degeneration, and compromises muscle 
function (85, 107).  
Similarities between ECM expansion in patients with DMD and mdx mice most 
likely contribute to the impaired regenerative capacity and function of these 
muscles (285). For example, increased expression of collagen 6α1 has been 
observed in human DMD muscle biopsies (452), as well as in mdx mouse 
diaphragms (453). Furthermore, the proteoglycan versican is highly upregulated 
in muscle biopsies from patients with DMD compared to healthy controls (90), as 
is the deposition of chondroitin sulphate GAG side chains (116), of which V0 and 
V1 versican forms both contain (48).  
The significance of versican in the generation and activity of a transitional matrix 
during skeletal muscle development and regeneration is continuing to gain 
recognition (74). Indeed, the carefully regulated synthesis and processing of a 
versican rich transitional matrix is an important factor in differentiating between 
successful regenerative myogenesis, or degeneration and fibrosis. A better 
understanding of versican function in DMD is needed if progress is to be made in 
targeting the dysregulated ECM, a hallmark of DMD pathology. Versican is 
increased in the diaphragm and TA muscles of mdx mice compared to wild type 
diaphragm muscles (Figure 3.1). Despite greater levels of versican protein, low 
levels versikine were observed in mdx diaphragms. It has previously been shown 
that versican processing by ADAMTS5 helps facilitate myoblast fusion (17). The 
diaphragm muscle best resembles the human form of DMD in terms of muscle 
function and fibrosis (454, 455), with fibrosis being progressive and becoming 
more prominent in aged mdx mice (221). The fact that significantly increased 
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versican was observed in the 12 week old mdx diaphragms is therefore 
interesting, particularly as it matches a suggestion that a provisional matrix is 
persistently secreted in DMD during the early stages of fibrosis (107). 
In-vivo, centrally nucleated fibres are indicative of recent damage and repair, 
with myoblast fusion being essential for effective regeneration. In diaphragm 
muscles from mdx mice, the proportion of centrally nucleated fibres is much 
lower, up to 2-3 fold when compared to dystrophic TA muscles (433, 456). It was 
therefore hypothesised that excess versican accumulation and inadequate 
clearance, as indicated by the lack of increase in versikine levels, contributes to 
the impaired regeneration in the mdx diaphragm muscles.  
It is well known that versican is cleaved by ADAMTS versicanases, forming the 
fragment called versikine (316, 319). An increase of Adamts5 mRNA was 
reported in injured hindlimb muscles from mdx mice compared to wild type mice 
(423), which may enhance versican processing and promote more effective 
muscle repair. In support of this, myoblast fusion and the formation of 
multinucleated myotubes is associated with a reduction in chondroitin sulphate 
chains, which may be attributed to versican processing (457). Indeed, the data 
contained within this Chapter show a concentration dependent increase of CK 
gene expression, along with increased myoblast fusion following low dose, 25 
nM and 100 nM, dexamethasone treatment. This is in accordance with a number 
of studies reporting positive effects of glucocorticoids on myogenesis in-vitro 
(397, 430) and muscle regeneration in-vivo (285, 429).  
However, glucocorticoids need to be used with caution as side effects, including 
muscle atrophy, compromised muscle function and impaired myogenesis can 
occur (26,74,75). Nevertheless, the benefits are usually greater. Therefore 
disease context and glucocorticoid dosage need to be considered for optimal 
results for the patient. For instance, a high concentration of dexamethasone (10 
µM) was found to inhibit myogenic differentiation of C2C12 and primary mouse 
myoblasts through the activation of GSK-3β, a negative modulator of myogenic 
differentiation and adult muscle growth (458). This concentration of 
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dexamethasone was 100-400 fold higher than the low dose treatment used 
within Chapter 3. Furthermore, with lower concentrations of 10 nM and 100 nM 
dexamethasone, no significant decrease in myogenin or myosin heavy chain 
protein expression was reported (458), matching the observation that MyHC 
gene expression did not change (Figure 3.3 C). 
The increase in myotube formation following glucocorticoid treatment was 
associated with an approximate 50 % decrease in Versican, Has2 and Tgfb1 gene 
expression and a 3-fold increase in Adamts1 mRNA transcripts (Figure 3.4). 
These data suggest that in differentiating C2C12 myoblasts, dexamethasone may 
attenuate transitional matrix synthesis and enhance remodelling, thus 
facilitating membrane contact during fusion. The effects of glucocorticoids on 
reduced ECM synthesis and remodelling have previously been described in 
various biological contexts. Glucocorticoid induced skin atrophy is associated 
with reduced proteoglycan (459) and hyaluronan synthesis (460, 461). Relevant 
to the findings here in Chapter 3, glucocorticoids have also been reported to 
decrease versican expression in cultured rat mesangial cells and airway 
fibroblasts (428, 458).  
Myoblast fusion and myofibre number were reduced when differentiating C2C12 
myoblasts were treated with versican or versikine conditioned media, further 
supporting the hypothesis that excess versican impairs regenerative myogenesis. 
Indeed, inefficient cleavage by ADAMTS5 leading to an excess of versican has 
previously been suggested to impair myoblast fusion (17). Additionally, the 
observation that excess versikine impaired myoblast fusion is also not 
unexpected, given that hyaluronan may bind to versikine via the G1 N terminus 
link module (462), thus potentially contributing to the expansion of the 
pericellular matrix. However this reduction in fusion was ameliorated upon the 
addition of 100 nM dexamethasone (Figure 3.7 D), further highlighting the 
significance of V0/V1 versican reduction by glucocorticoids.  
To further investigate how versican can compromise myoblast fusion, the effects 
upon myoblast migration was assessed. Myoblast migration is critical for 
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myoblast fusion as cells need to migrate and align before fusion can occur (432, 
447). The observations from Figure 3.7 E showed that excess versican or 
versikine impairs the migration of myoblasts. Versican can signal through the 
CD44 receptor, either by binding directly to the receptor or through its binding 
to hyaluronan, to regulate myoblast migration during myogenic differentiation 
(296, 447, 463). 
These in-vitro observations support the hypothesis that excess accumulation of 
versican in dystrophic muscles contributes to their poor regenerative capacity. 
The accumulation of versican in dystrophic muscles may be attributed to 
elevated TGFβ levels. It has previously been confirmed that TGFβ centred 
signalling networks, induced by asynchronous regeneration in response to 
chronic contraction-induced injury, are key drivers for fibrosis and failed 
regeneration in dystrophic skeletal muscles (285). These TGFβ networks were 
suppressed when dystrophic mdx mice were treated with glucocorticoids (285). 
Indeed, consistent with this finding, Tgfβ1 gene expression was observed to 
decrease (see figure 3.3A). Therefore, the observation that dexamethasone 
regulates the expression of genes involved in transitional matrix synthesis and 
remodelling, in particular V0/V1 Vcan, Has2 and Adamts1, are highly relevant 
with regards to the potential of improving regenerative myogenesis in dystrophic 
muscles.  
The in-vitro studies upon versican in this Chapter are promising and ultimately 
highlight the need for regulated versican synthesis. This potentially may be 
beneficial within the context of dystrophic pathology, where a regulated 
transitional matrix would be crucial for efficient muscle repair. It may be that the 
conclusions drawn from this Chapter may also translate to other pro-
inflammatory diseases as well, further emphasising the importance of a 
regulated matrix. Therefore, future studies should look into reducing the level of 
versican in-vivo within mdx mice and investigate cellular processes crucial to 
inflammation, muscular damage and myogenesis, to ascertain that the in-vitro 
effects suggested within this Chapter are the same as those observed within a 
dystrophic murine model.   
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Chapter 4: Genetic reduction of versican improves 
fatigability and strength of diaphragm muscles from 
dystrophic mdx mice 
4.1 Introduction  
DMD is a paediatric disease arising from a mutation on the X chromosome 
leading to the loss of dystrophin protein and the dystrophin associated protein 
complex (108). This renders muscle fibres prone to persistent contraction 
induced damage. Muscle repair is inadequate, leading to the loss of muscle 
fibres, expansion of fibrosis, and adipocyte infiltration (107). Skeletal, respiratory 
and cardiac muscles are affected in DMD; leading to a loss of ambulation, and 
becomes life threatening when cardiac and respiratory function becomes 
compromised. The life expectancy of patients with DMD is approximately 30 
years of age, whereupon they succumb to cardiorespiratory failure (109, 111, 
416). 
Like patients with DMD, the mdx mouse also has a loss of dystrophin protein 
expression (464), and undergoes persistent cycles of muscle damage, 
degeneration and repair (126). The diaphragm muscles of mdx mice are most 
severely affected and mimic the pathology of DMD well (125, 454). As mdx mice 
age, there is a progressive increase in diaphragm fibrosis, which is associated 
with impaired contractile function (455).  
Fibrosis occurs when chronic and persistent muscle damage disrupts the balance 
between ECM synthesis and remodelling leading to the expansion of endomysial 
and interstitial matrices (87). Endomysial fibrosis is not just a consequence of 
dystrophy, it precedes overt degeneration within the muscle and expands during 
the course of the disease (94, 107). This fibrosis is comprised of various mature 
and transitional ECM proteins, including collagens (89) and proteoglycans. 
Versican, a proteoglycan decorated with CS GAG chains, is overexpressed in 
DMD (90, 347) and from Chapter 3, is highly upregulated in diaphragm muscles 
from mdx compared to wild type mice (465), highlighting an association of 
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versican with dystrophic pathology. Versican is decreased by dexamethasone in 
C2C12 muscle cells (465) and in various other biological contexts where 
heightened inflammation is a problem (427, 428). It is well recognised that the 
ECM is important for cell signalling and function. An abnormal matrix, however, 
disrupts cell signalling and function and ultimately results in pathology. Given 
that versican is such an important transitional matrix protein in development 
and disease (74), it can be assumed that its persistent overexpression 
contributes to DMD pathology, as has been observed in pulmonary and 
cardiovascular disease (341, 466).  
Versican is highly expressed in developing skeletal muscles, where together with 
hyaluronan, is a key component of the transitional matrix (74). To date, versican 
has been associated with various cellular processes relevant to the pathogenesis 
of muscular dystrophy. These processes include satellite cell proliferation (20), 
myoblast fusion and myofibre formation (17), and inflammation (51, 288). 
Indeed, versican can be linked to inflammation in a variety of mechanisms, 
though binding MCP-1 which attracts infiltrating monocytes (51), being involved 
in the monocyte to macrophage transition (290), and may bind leukocytes 
through interactions with its CS GAG chains (53). Versican is also strongly 
associated with TGFβ, which is highly overexpressed in DMD and thought to be a 
major driver of fibrosis (235, 280). TGFβ1 upregulates versican synthesis in 
smooth muscle airway cells (444). Similarly, in fibroblasts TGFβ1 can induce 
secretion of various ECM proteins, including versican (346). Overexpression of 
versican stimulates the differentiation of fibroblasts into myofibroblasts (348), 
and these expand fibrotic areas by secreting ECM proteins such as collagens I, III 
and IV (195). 
Given that versican is part of a transitional matrix (74), its remodelling by ECM 
proteases, including ADAMTS5, is very important for its biological function. 
During development, versican remodelling regulates interdigital web regression 
(334), formation of the cardiac outflow tract and endocardial cushions (308, 333) 
and facilitates myoblast fusion (17). Interestingly, ADAMTS5 levels are increased 
in serum from mdx mice and patients with DMD (349). Indeed, increased 
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Adamts5 gene expression has been observed in the hindlimb, specifically the 
gastrocnemius muscle, from male 3 month mdx mice when compared to those 
of 1.5 months (423). Similar to versican, ADAMTS5 has been associated with 
myogenesis (17). It has also been implicated in inflammation, as ADAMTS5 
expression can be mediated by pro-inflammatory cytokines such as IL-1β, TNF-α 
and IL-6, (351, 355, 467), and its mediated cleavage of versican is required for 
inflammatory cell migration (468). Additionally, versikine, the cleavage product 
formed through ADAMTS cleavage of V1 versican, is also bioactive. Versikine has 
been associated with apoptosis (334), and more recently has been shown to 
induce the upregulation of IL-1β and IL-6 in myeloma tumour cells (342). This is 
particularly interesting and relevant as these same cytokines are increased in 
dystrophic muscles (344). 
Given versican is upregulated in dystrophic muscles (90, 347), particularly in 
areas of degeneration, inflammation and fibrosis (465), it was hypothesised that 
it may modulate inflammation, fibrosis and disrupt regenerative myogenesis, 
thus exacerbating pathology of dystrophic muscles. Therefore, the aim of this 
chapter was to build upon the findings from Chapter 3, and to test the 
hypothesis that versican reduction is a relevant therapeutic target for DMD. 
Consequently, female mdx mice were bred with male heart defect (hdf) mice, 
which are haploinsufficient for the versican allele, in order to generate F1 male 
pups – specifically, mdx control littermates with two functional versican alleles 
and the mdx-hdf mice with a single functional allele and therefore a genetic 
reduction in versican. These mice have never before been produced and are 
therefore a novel strain. These mice were then used to assess the phenotypic 
effects of versican reduction on whole body metabolism, spontaneous physical 
activity, cardiac function and diaphragm muscle contractile properties, including 
ex-vivo strength and fatiguability. Histology, immunohistochemistry and qRT-PCR 
were then used to assess diaphragm muscle structure, versican expression and 
gene markers of myogenesis, inflammation and ECM synthesis and remodelling.  
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4.2 Methods 
4.2.1 Ethics statement and animal husbandry 
All mouse experiments were approved by Deakin University’s Animal Ethics 
Committee, under project numbers A79/2011 and G06/2015. Female mdx mice, 
obtained from the Animal Resource Centre (Canning Vale, Western Australia), 
were bred with male hdf (heart defect) mice, obtained from Hoffman-La Roche 
Pharmaceuticals. The hdf mice are haploinsufficient for the versican allele, being 
heterozygous for versican. The resulting F1 generation mdx and mdx-hdf male 
pups were confirmed through genotyping. All mice were maintained on an 
alternating 12 h light and 12 h dark cycle, with standard mouse chow and water 
provided ad libitum. All experimental procedures were completed on mice 
between 20 to 26 weeks of age. 
4.2.2 Echocardiography 
Using a nosecone, mice were lightly anaesthetised by inhalation of a 
maintained gas flow of 1.5 % isoflurane in oxygen. Echocardiography was 
performed by a specialist veterinarian (Dr Richard Woolley; 
http://cprvictoria.com.au), using a HD15 Purewave Ultrasound System (Phillips). 
Mice were replaced back into cages after completion of the procedure. Further 
details can be found within section 2.3.5. 
4.2.3 Metabolic cages and body composition 
Mice were acclimatised to the metabolic cages (Accuscan Fusion v3.6; Columbus 
Instruments International, OH, USA) for a 3 h period, 48 h prior to contractile 
function testing. Mice were then placed individually into the metabolic cages for 
24 h, whereupon volumes of oxygen consumed (VO2; mL/min), carbon dioxide 
exhaled (VCO2; mL/min) and respiratory exchange rate (RER; VCO2/VO2) were 
recorded per mouse. The resting energy expenditure (REE) was then calculated 
from the obtained VO2 and VCO2 data by using the abbreviated weir equation 
(469, 470). Furthermore, infrared sensors (Animal Activity Meter: Opto-Varimex-
Mini; Columbus instruments) lining the metabolic cage allowed for the 
measurement of total spontaneous physical activity for each mouse, as 
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determined by crossing ≥2 infrared beams. Immediately prior to contractile 
function testing, mice were weighed and placed into an EchoMRI (Body 
Composition Analyser ESF-005, EchoMRI; Houston, USA) to measure whole body 
composition. 
4.2.4 Contractile function 
Mice were anaesthetised with medetomidine (0.5mg/kg), midazolam (5mg/kg) 
and fentanyl (0.05mg/kg), administered via an IP injection in approximately 1 ml 
sterile saline, until unresponsive to tactile stimuli. The diaphragm was removed 
and a diaphragm muscle strip extending from the rib to the central tendon was 
prepared for contractile function testing. Using small increments in length and 1 
Hz twitches, the optimal length (Lo) was determined. This allowed for the 
assessment of twitch force normalised to muscle size (sPt), time to peak tension 
(TPT), ½ relaxation time (½ RT), and maximal rate of force production (max 
dx/dt). Following which, the maximal force producing capacity (sPo) for the 
diaphragm muscle was determined from a force frequency curve ranging from 1 
to 120 Hz, with 2 m rest in between each stimulation. To assess fatigability and 
endurance, the diaphragm was stimulated every 5 s for a total duration of 4 
minutes at a submaximal stimulation frequency of 60 Hz. Muscle recovery was 
then assessed by stimulating the diaphragm at 60 Hz at 2, 5 and 10 m post 
fatigue. Further details can be found within section 2.3.6.   
After contractile function testing had concluded, the diaphragm strip was 
trimmed of rib and tendon, weighed and snap frozen in liquid nitrogen. An 
additional 10 mm wide diaphragm section was frozen in thawing isopentane for 
histology and immunohistochemistry, with the remainder of the diaphragm 
muscle being snap frozen for gene expression analysis. Heart weight was also 
determined to complement the echocardiography data. 
4.2.5 Histology and immunohistochemistry 
Diaphragm strips were sectioned on a cryostat at -20 oC at a width of 8 μm. 
Diaphragm cross-sections from mdx and mdx-hdf were allocated as follows: 1) 
Stained with H&E in order to observe muscle structure, and analyse fibre area 
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(minimal feret diameter), central nucleation and areas of mononuclear infiltrate. 
2) Stained with wheat germ agglutinate in order to observe areas of fibrosis. 3) 
Were reacted with primary antibodies for versican or versikine. Or 4) Were 
reacted with a primary antibody for myosin heavy chain IIa (MyHC IIA). 
4.2.5.1 H+E staining 
For analysis of muscle morphology, two non-overlapping digital images were 
captured from H&E stained sections. Image analysis was completed using ImageJ 
1.47v (https://imagej.nih.gov/ij/) or Image-Pro Plus (version 7). To assess muscle 
fibre size, all fibres within the field of view were manually traced to obtain the 
fibre area (minimal feret diameter). Minimum ferets diameter is a method of 
measuring the cross sectional area minus any experimental discrepancies, such 
as the orientation of the muscle section (471, 472). The number of fibres 
analysed per image was 487 ± 18. In addition, the proportion of centrally 
nucleated fibres, a hallmark of recent damage and repair, was also determined. 
As a general indicator of degeneration and inflammation, regions of 
mononuclear infiltrate and degeneration were traced and expressed as a 
percentage of the total muscle area in the field of view.  
4.2.5.2 Wheat germ agglutinin staining 
Two non-overlapping images were captured of slides stained with wheat germ 
agglutinin (WGA), which can be used as a marker for fibrosis (415). Using the 
program Image-Pro Plus (version 7), the area stained with WGA was quantified 
by measuring the area of staining and expressing as a percentage of the total 
area of muscle in the field of view. For a more detailed description, please refer 
to section 2.3.10.3. 
4.2.5.3 Immunohistochemistry for versican and versikine 
Four non-overlapping images were captured of muscle cross-sections were 
immunohistochemically stained with versican and versikine primary antibodies. 
Using the program Image-Pro Plus (version 7), the areas stained were quantified 
by measuring the area of staining and expressing as a percentage of the total 
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area of muscle in the field of view. For a more detailed description, please refer 
to section 2.3.10.1.  
4.2.5.4 Immunohistochemistry for Myosin Heavy Chain IIa (MyHC IIa) 
Note that this experimental procedure and analysis was performed entirely by A. 
Addinsall. Sections from diaphragm muscle strips were immunohistochemically 
stained with a MyHC IIa primary antibody. The number of fibres expressing 
MyHC IIa staining, along with the number of MyHC IIa with central nuclei were 
counted using ImageJ 1.47v (https://imagej.nih.gov/ij/). For a more detailed 
description, please refer to section 2.3.10.2. 
4.2.6 Gene expression analysis 
Gene expression was performed using cDNA created from function tested 
diaphragms that were snap frozen (section 2.3.7). All samples were tested in 
duplicate. All gene expression data were calculated using the 2ΔCT method and 
were normalised to Oligreen. For a more detailed description, please refer to 
sections 2.2.4 and 2.2.5.  For primer sequences, please refer to Table 2.2. 
4.2.7 Statistics 
An independent sample t-test was undertaken for all histology, 
immunohistochemistry and gene expression analyses. For metabolic cage 
analyses, a 1- or 2-way General Linear Model (GLM) ANOVA were performed, 
followed by Tukey's post hoc analysis where appropriate. For contractile 
function activity analyses, 2-way general linear model (GLM) ANOVA were 
performed, followed by Tukey's post hoc analysis where appropriate. All data are 
presented as MEAN ± S.E. and were considered statistically significant when p < 
0.05. 
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4.3 Results 
4.3.1 Full length versican expression is decreased in mdx-hdf 
diaphragm muscles 
As previously observed in 12 week mdx diaphragms (465), the 21 week 
diaphragm muscle cross-sections from the mdx mice versican immunoreactivity 
was also localised to areas of endomysial fibrosis (Figure 4.1 A-B). Versican 
protein levels were reduced by approximately 50 % in diaphragm muscles from 
mdx-hdf mice (p = 0.0004; Figure 4.1 C). Versikine was also localised to 
endomysial fibrosis and regions of mononuclear infiltrate, with some nuclear co-
localisation also observed (Figure 4.1 D-E). Versikine protein expression did not 
differ between diaphragm muscles from mdx and mdx-hdf mice (Figure 4.1 F). It 
is worth noting that versikine is not the end product of versican remodelling and 
is likely further degraded. For example, versikine immunoreactivity is greater in 
developing embryonic E13.5 hind limb muscles than in hindlimb muscles from 3 
week old wild type mice (17). This could account for the lack of difference in 
versikine immunoreactivity in mdx and mdx-hdf diaphragm muscles.   
The decrease in V0/V1 versican immunoreactivity was supported with qRT-PCR 
analysis of diaphragm muscles. Indeed, the mRNA transcript abundance of V0/V1 
versican (V0/V1 Vcan) was lower in diaphragm muscles from mdx-hdf mice 
compared to mdx littermates (p = 0.005; Figure 4.1 G). Altogether, these results 
confirm the successful genetic reduction of versican in dystrophic diaphragm 
muscles. 
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Figure 4.1 V0/V1 versican and versikine expression in diaphragm 
muscles from 21 week old mdx and mdx-hdf mice.  
Versican and versikine immunoreactivity in red with nuclei stained 
blue (DAPI). A-B) Representative versican staining in mdx and mdx-
hdf mice. C) Versican immunoreactivity was reduced in diaphragm 
muscles from mdx-hdf mice compared to mdx littermates (*p = 
0.0004; T-test). D-E) Representative versikine staining in mdx and 
mdx-hdf mice. Arrows indicate areas of mononuclear infiltrate and 
degeneration. F) Versikine immunoreactivity did not differ between 
mdx and mdx-hdf diaphragm muscles (p = 0.192; T-test). G) V0/V1 
Vcan mRNA transcripts were reduced in diaphragm muscles from 
mdx-hdf mice (*p = 0.005; T-test). N = 11-13 mdx and n = 11-12 
mdx-hdf mice were used to assess versican and versikine 
immunoreactivity, while n = 12 mdx and n = 11 mdx-hdf mice were 
used to assess V0/V1 Vcan gene expression. Scale bar = 100 µm.  
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4.3.2. Body weight and composition of 26 week old mdx and mdx-
hdf mice 
The genetic reduction of versican did not affect body weight or composition, as 
lean mass and fat mass values were similar in mdx and mdx-hdf mice (Table 4.1). 
Accordingly, the percentage of body fat and lean mass did not differ between 
mice (Table 4.1).  
 
Table 4.1 Body weight, fat mass and lean mass as determined by ECHO-MRI. 
  mdx mdx-hdf P value 
Body weight (g) 32.24  ±  0.50 32.46  ±  0.70 0.80 
Fat (g) 1.44  ±  0.20 1.78  ±  0.15 0.18 
Fat (%) 4.41  ±  0.57 5.49  ±  0.44 0.14 
Lean mass (g) 29.77  ±  0.41   30.22  ±  0.66 0.58 
Lean mass (%) 92.40  ±  0.52 93.10  ±  0.68 0.43 
Data are means ± S.E. 
N = 14 mdx and n = 16 mdx-hdf 
 
 
4.3.3. The genetic reduction of versican is associated with increased 
spontaneous physical activity  
During 24 h in the metabolic cages, the mdx-hdf mice were observed to be more 
active than their mdx littermates (p = 0.024; Figure 4.2 A). Characteristic of 
dystrophic pathology in mdx mice is a reduction in spontaneous physical activity 
and exercise capacity, along with an increase in lean body weight due to on-
going cycles of degeneration and regeneration, resulting in muscle hypertrophy 
(470). Given the relevance of these variables to the dystrophic pathology of mdx 
mice, the total movement data were interrogated further by correlating it with 
body weight. Interestingly, as body weight increased, mdx mice moved less (p = 
0.0282; Figure 4.2 B). However, this negative correlation was not observed in the 
mdx-hdf mice, where increased body weight was not associated with a reduction 
in spontaneous physical activity within the metabolic cages (Figure 4.2 C). These 
data indicate positive effects of versican reduction on the whole body phenotype 
of dystrophic mdx mice. 
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Figure 4.2 The genetic reduction of versican is associated with an 
increase in spontaneous physical activity. 
The mdx and mdx-hdf mice were housed in metabolic cages for 24 h 
and total movement was measured with infrared activity sensors. A) 
The mdx-hdf mice were more active than their mdx littermates as 
indicated by an increase in total movement (*p = 0.024; T-test). B-C) 
In mdx (*p = 0.0282), but not mdx-hdf mice (p = 0.4147), a negative 
correlation between increasing body weight and reduced physical 
activity was observed. N = 12 mdx and n = 15 mdx-hdf mice. 
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4.3.4 The genetic reduction of versican shifts whole body 
metabolism to a more oxidative phenotype without affecting REE  
The dystrophic pathology of mdx mice is characterised by increased energy 
expenditure due to the high metabolic cost of inflammation and muscle 
regeneration that is associated with chronic contraction induced muscle damage 
(470). Patients with DMD exhibit both metabolic and mitochondrial dysfunction 
(90), while oxidative phosphorylation and ATP synthesis is compromised in mdx 
mice (473). As expected, lower RER values were observed during the 12 h light 
period (6am – 6pm), when mice are sleeping and typically less active, when 
compared to the more active 12 h dark period (6pm – 6am) (474). The mdx-hdf 
mice had lower RER values during the day and at night when compared to mdx 
littermates (p = 0.015 and p = 0.040, respectively; main effect strain; 2-way GLM-
ANOVA; Figure 4.3 A-B). This is indicative of a shift towards more oxidative 
metabolism and greater reliance on lipid as a substrate (475) with the genetic 
reduction of versican. Light or dark resting energy expenditure (REE) did not 
differ between mdx and mdx-hdf mice (Figure 4.3 C and D). Increased 
spontaneous physical activity in the mdx-hdf mice (Figure 4.2 A) may have 
contributed to this lack of difference in REE. 
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Figure 4.3 Effects of versican reduction on whole body metabolism 
and energy expenditure.  
Mice were singly housed in individual metabolic cages for 24 h. A-B) 
RER values for the light and dark periods were lower in mdx-hdf 
mice compared to mdx littermates (*p = 0.015 and *p = 0.040, 
respectively; main effect strain; 2-way GLM ANOVA with factors 
being strain and time). C-D) REE during the light or dark periods was 
not different between mdx and mdx-hdf mice (p= 0.945 and p = 
0.574, respectively; 1-way GLM ANOVA). Light Period = 6am – 6pm; 
dark period = 6pm – 6am; RER = respiratory exchange ratio; REE = 
resting energy expenditure. N = 9 mdx and n = 12 mdx-hdf mice. 
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4.3.5 Cardiac function is maintained in mdx-hdf mice despite 
increased heart mass and left ventricular dilatation 
Versican is essential for embryonic development of the heart (331). The hdf mice 
are referred to as the heart defect mice, as homozygous deletion of versican is 
embryonically lethal at E10.5 due to malformation of the heart, whereas 
heterozygous hdf mice are viable (331). Due to the loss of dystrophin, patients 
with DMD, and mdx mice, present with a dilated cardiac myopathy and 
increased myocardial fibrosis (133, 405, 406). It is likely that this increase in 
myocardial fibrosis is associated with an upregulation of versican (476). Thus, 
given the association of versican with fibrosis and the importance of versican for 
heart development, it was important to consider the effects of versican 
reduction on cardiac function in dystrophic mdx mice. This is especially 
important as it could potentially have implications for spontaneous physical 
activity.  
At 26 weeks of age, hearts from mdx-hdf mice were heavier than those from 
mdx littermates (p = 0.032; Figure 4.4 A), even when normalised to body weight 
(p = 0.020; Figure 4.4 B). 
 
 
Figure 4.4 Genetically reduced versican increases heart weight. 
A) The mdx-hdf mice had heavier hearts (*p = 0.032; T-test) than 
their mdx littermates at 26 weeks of age; B) even when normalised 
to body weight (*p = 0.020; T-test). n = 13 mdx and n = 16 mdx-hdf 
mice. 
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Echocardiography was performed to assess how the genetically reduced 
versican, and the associated increase in heart mass, affected cardiac function. 
When compared to their mdx littermates, mdx-hdf mice had a greater left 
ventricular internal diameter (LVIDs; p = 0.03; Table 4.2), a decreased ejection 
fraction (EF; p = 0.03; Table 4.2), and reduced fractional shortening (FS; p = 0.02; 
Table 4.2) indicating the mdx-hdf mice had a more dilated left ventricle 
compared to the mdx mice. However, contractile function did not appear to be 
severely compromised and these impairments were compensated for, as stroke 
volume (SV) was maintained in the mdx-hdf mice and did not differ from mdx 
littermates.  
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Table 4.2 Heart echocardiography data from mdx and mdx-hdf mice hearts at 25 weeks 
of age 
 Units mdx mdx-hdf P value 
LVIDs (MM) cm 0.122  ±  0.011 0.173  ±  0.015     0.03 * 
EF (MM-cubed) % 90.5  ±  2.5 80.7  ±  3.0     0.03 * 
FS (MM-cubed % 56.8  ±  4.0 44.1  ±  3.2     0.02 * 
LV Mass (cubed) g 0.678  ±  0.004 0.697  ±  0.011 0.20 
SV (MM-cubed ml 0.021  ±  0.002 0.027  ±  0.005 0.36 
Data are means ± SEM. 
LVIDs = left ventricle internal diameter (systole); EF = ejection fraction; FS = fractional 
shortening; LV = left ventricle; SV = stroke volume. 
* Statistical significance at p < 0.05 for all measurements, analysed by 2-tailed T-test. 
n = 8 mdx and n = 12 mdx-hdf. 
129 
 
4.3.6 The genetic reduction of versican improved the diaphragm 
muscle strength and resistance to fatigue ex-vivo 
The genetic reduction of versican had minimal effects on the twitch contractile 
properties of the dystrophic diaphragm muscles. The optimum muscle length 
(Lo), body mass to muscle mass ratio (BM:MM) and muscle cross sectional area 
(CSA), were similar between mouse strains (Table 4.3). In response to a 1 Hz 
stimulation, modelling a single action potential, twitch force (Pt), specific twitch 
force (sPt), rate of force development (dx/dt) and ½ relaxation time (½ RT) did 
not differ between diaphragm muscle strip from mdx and mdx-hdf mice (Table 
4.3). Although, the time to peak tension (TPT) was increased in mdx-hdf mice 
(Table 4.3). Factors contributing to this increase in TPT may include a shift to a 
different fibre type MyHC isoform composition or differences in regeneration 
efficacy.  
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Table 4.3 Ex-vivo diaphragm twitch contractile properties from mdx and mdx-hdf mice 
at 21 weeks of age  
Units mdx mdx-hdf P value 
Lo mm 6.86  ±   0.16    7.22  ±  0.23 0.26 
BM:MM  0.26  ±  0.01 0.24  ±  0.01 0.43 
CSA mm2 1.12  ±  0.07 1.05  ±  0.08 0.51 
Pt mN 15.83  ±  2.04 18.35  ±  1.74 0.36 
sPt kN/m2 14.45  ±  1.80 17.97  ±  1.64 0.17 
TPT s 0.2301  ±  0.0005 0.2314  ±  0.0004 0.03 * 
½ RT s 0.031  ±  0.002 0.035  ±  0.002 0.11 
Max dx/dt mN/s 749.48  ±  99.70 848.76  ±  83.74 0.45 
Data are means ± standard error of mean. 
* Statistical significance at p < 0.05 for all measurements, analysed by 2-tailed T-test. 
Lo = optimum muscle length; BM:MM = body mass to muscle mass ratio; CSA = cross 
sectional area; Pt = peak twitch; sPt = specific peak twitch; TPT = time to peak tension; ½ 
RT = half relaxation time; Max dx/dt = maximal rate of force development. 
n = 11 mdx and n = 15 mdx-hdf. 
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The ex-vivo maximal force producing capacity (sPo) of the diaphragm muscle 
strips was determined from a force frequency curve (1 to 120 Hz). Diaphragm 
muscle strength was increased in mdx-hdf mice when compared to mdx 
littermates, as indicated by an upward shift of the force frequency curve (p < 
0.001; Figure 4.5) 
 
 
Figure 4.5 The genetic reduction of versican increased diaphragm 
muscle strength in mdx-hdf mice. 
A force frequency curve was used to assess the strength of 
diaphragm muscle strips from mdx and mdx-hdf mice. The genetic 
reduction for versican increased the force producing capacity of 
diaphragm muscles, as indicated by the upward shift in the force 
frequency curve (*p < 0.001; main effect strain; 2-way GLM-ANOVA 
with factors being frequency and strain). n = 11 mdx and n = 15 
mdx-hdf mice. 
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Following completion of the force frequency protocol, the diaphragm muscle 
strips were subjected to a 4 m period of intermittent, submaximal 60Hz 
stimulations followed by a single 60 Hz stimulation at 2, 5 and 10 minutes post 
fatigue to assess fatigability and force recovery (408-411). During the 4 m of 
intermittent submaximal stimulation, diaphragm muscles from mdx-hdf mice 
fatigued less compared to their mdx littermates (p < 0.001; Figure 4.6), and force 
recovery at 2, 5 and 10 m post fatigue was also improved (p < 0.001; Figure 4.6). 
Altogether, the genetic reduction of versican improved diaphragm muscle 
function in mdx-hdf mice. Therefore, the increase in movement displayed by the 
mdx-hdf mice (Figure 4.2 A) may be mediated by this increase in diaphragm 
muscle strength and endurance. To gain better insight into how the genetic 
reduction of versican may improve diaphragm contractile function, muscle 
morphology, along with gene markers of inflammation, regenerative myogenesis 
and matrix remodelling were further investigated.  
 
 
Figure 4.6 Reduced fatigability and improved force recovery in 
diaphragm muscle strips from mdx-hdf mice.  
During 4 m of intermittent, submaximal stimulation, diaphragm 
muscle strips from mdx-hdf mice fatigued less (*p < 0.001; main 
effect strain; 2-way GLM ANOVA) and produced more force during 
recovery (*p < 0.001; main effect strain; 2-way GLM ANOVA with 
factors being time and strain) when compared to diaphragm muscle 
strips from mdx mice. N = 11 mdx and n = 13 mdx-hdf.  
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4.3.7 The genetic reduction of versican had modest effects on 
diaphragm muscle fibre size 
Morphological analysis of H&E stained diaphragm muscle cross-section was 
undertaken for mdx and mdx-hdf diaphragms (Figure 4.7 A-B). Typical of 
dystrophic diaphragm muscles from mdx mice, extensive fibrosis and 
mononuclear infiltrate, comprising of inflammatory cells, fibroblasts and muscle 
progenitor cells, were observed. Myofibres were centrally nucleated, indicating 
recent damage and repair, and fibre size was variable due to ongoing 
degeneration-regeneration and fibre splitting (477). The number of myofibres 
per mm2 did not differ between diaphragm muscles from mdx and mdx-hdf mice 
(Figure 4.7 C). Although, the genetic reduction of versican tended to increase the 
proportion of centrally nucleated fibres in mdx-hdf mice (p = 0.086; Figure 4.7 
D). 
Given the variability in fibre morphology, minimal ferets diameter was used to 
asses muscle fibre cross-sectional area, which was binned to better observe 
differences in fibre size. Diaphragm muscles of mdx-hdf mice had significantly 
fewer very small myofibres in size (< 9.99 µm; p = 0.031), and all together the 
data suggests a slight shift towards increased cross-sectional areas when 
compared to mdx mice (Figure 4.7 E). This could contribute the increase in force 
production and the upward shift of the force frequency curve in mdx-hdf 
compared to mdx mice (Figure 4.5), as larger fibres produce more force.  
The percentage of muscle cross-section comprised of mononuclear infiltrate did 
not differ between mdx and mdx-hdf mice (Figure 4.7 F). Given that this 
mononuclear infiltrate includes inflammatory cells and muscle precursory cells, 
the effects of versican reduction on gene markers of inflammation and myogenic 
differentiation were characterised. 
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Figure 4.7 A reduction in versican had no effect on diaphragm 
muscle properties.  
A-B) Representative H&E stained sections of mdx and mdx-hdf 
diaphragms at x20 magnification. C) No differences were observed 
in the number myofibres (p = 0.450; T-test). D) The percentage of 
centrally nucleated fibres tended to be increased in diaphragm 
muscles from mdx-hdf mice (p = 0.086; T-test) compared to mdx 
littermates. E) Additionally, analysis of minimal ferets diameter 
revealed the diaphragm muscles from mdx-hdf had fewer very small 
fibres, less than 9.99 µm in diameter (*p =  0.031; T-test). F) 
Mononuclear infiltrate and degeneration did not differ between 
diaphragm muscles from mdx and mdx-hdf mice (p = 0.791; T-test). 
Scale bar = 100 µm. N = 11 mdx and n = 11 mdx-hdf mice.  
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4.3.8 Genetic reduction of versican and gene markers of 
inflammation 
To gain preliminary insight into the effects of versican reduction on inflammation 
in dystrophic diaphragm muscles, the mRNA transcript abundance of Has2, Mcp-
1, Tgfβ1 and F4/80 were quantified using qRT-PCR. Has2 is the predominant 
form of hyaluronan synthase in skeletal muscle, involved in the synthesis of 
hyaluronan (446). Hyaluronan forms a complex with versican, together 
modulating inflammatory processes by binding inflammatory cells (48, 240). 
Furthermore, versican also binds MCP-1, an attractant protein for monocytes 
and macrophages (478). Has2 mRNA transcripts had a trending decrease in mdx-
hdf mice (p = 0.057; Figure 4.8 A), whereas Mcp-1, Tgfβ1 and F4/80 mRNA 
transcript abundance did not differ between mdx and mdx-hdf mice (Figure 4.8 
C, E and G). F4/80 is a rather non-specific inflammatory cell marker, being 
expressed by monocytes, macrophages and other inflammatory cells (479, 480).  
The pathology of mdx mice is highly variable, as shown through indicators of 
damage such as Evans blue dye staining and creatine kinase activity (481). The 
damage to mdx muscles can therefore significantly impact gene expression data. 
Further analysis was therefore undertaken to investigate a possible correlation 
between versican mRNA transcript abundance and gene markers of 
inflammation, as versican has been associated with a pro-inflammatory state 
(47, 48). Has2, Mcp-1 or Tgfβ1 mRNA transcript abundance was not correlated 
with V0/V1 Vcan gene expression (Figures 4.8 B, D and F). However, F4/80 mRNA 
transcript abundance was positively correlated with V0/V1 Vcan gene expression 
in mdx (*p = 0.0044; Figure 4.8 H) but not mdx-hdf diaphragms. This is 
interesting as both monocytes and macrophages can produce versican (290, 390, 
391). Therefore, these observations should be followed up in future studies with 
an assessment of monocyte and macrophage infiltration in mdx and mdx-hdf 
diaphragm muscles using immunohistochemistry or flow cytometry, along with 
additional markers specific for neutrophils, monocytes, and pro-inflammatory 
M1 and anti-inflammatory M2 macrophage subsets. 
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Figure 4.8 Gene markers of inflammation in diaphragm muscles 
from mdx and mdx-hdf mice.  
A) Has2 mRNA transcripts had a trending decrease in diaphragm 
muscles from mdx-hdf versus mdx mice (p = 0.057); C, E and G) 
whilst Mcp-1, Tgfβ1 and F4/80 mRNA transcripts did not differ 
between diaphragm muscles from mdx and mdx-hdf mice (p = 
0.118, p = 0.288 and p = 0.307, respectively; T-test). B, D and F) The 
mRNA transcript abundance of Has2, Mcp-1 or Tgfβ1 did not 
correlate with V0/V1 Vcan gene expression in diaphragm muscles 
from mdx and mdx-hdf mice; H) whilst F4/80 mRNA transcript 
abundance was correlated with V0/V1 Vcan gene expression in 
diaphragm muscles from mdx mice (*p = 0.0044) but not mdx-hdf 
mice (p = 0.8045). N = 9 mdx; n = 11-12 mdx-hdf mice. 
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4.3.9 Genetic reduction of versican and gene markers of 
regenerative myogenesis 
As muscle regeneration has a large role in muscular dystrophy, the 
characterisation of genes relevant to myogenesis were of particular interest. The 
mRNA transcript abundance of Pax7, Desmin, MyoD and Myogenin did not differ 
between diaphragm muscles from mdx and mdx-hdf mice (Figure 4.9 A, C, E and 
G).  
Again, given the association of versican with myogenesis (17, 20), a possible 
correlation between versican mRNA transcript abundance and gene markers of 
myogenesis was investigated. No correlation between V0/V1 Vcan gene 
expression and Pax7 or Desmin mRNA transcript abundance was observed in 
diaphragm muscles from mdx or mdx-hdf mice (Figure 4.9 B and D). Pax7 is a 
transcription factor important for regulating satellite cell proliferation (482) and 
desmin is highly expressed by proliferating satellite cells, as well as newly 
regenerated myotubes (483, 484). MyoD mRNA transcript abundance and V0/V1 
Vcan gene expression were positively correlated in diaphragm muscles from mdx 
mice (p = 0.0469; Figure 4.9 F). Myogenin mRNA transcript abundance also 
tended to be positively correlated (p = 0.0673; Figure 4.9 H), whereas, in 
diaphragm muscles from mdx-hdf mice, no correlation was observed for MyoD 
or Myogenin (Figure 4.9 F and H). The association of versican with a gene marker 
of satellite cell differentiation and myoblast fusion in mdx diaphragm muscles is 
interesting. Especially given that highest transient upregulation of versican 
mRNA transcripts is observed in developing embryonic muscles between E14.5 
and E15.5 (17), which correlates with myoblast differentiation and fusion (485). 
No gene correlations tested here were of any significance in the mdx-hdf 
diaphragms. Altogether, these data suggest an association between versican and 
regenerative myogenesis, although the specific cellular pathways regulated by 
versican and the consequences of versican reduction on the regenerative 
capacity of dystrophic muscles requires further investigation. 
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Figure 4.9. Gene markers of regenerative myogenesis in diaphragm 
muscles from mdx and mdx-hdf mice. 
A, C, E and G) The mRNA transcript abundance of Pax7, Desmin, 
MyoD and Myogenin were similar in diaphragms from mdx and 
mdx-hdf mice (p = 0.286, p = 0.369, p= 0.378 and p = 0.374, 
respectively; T-test). B and D) No correlation between the mRNA 
transcript abundance of Pax7 or Desmin and V0/V1 Vcan gene 
expression was observed in diaphragms from mdx and mdx-hdf 
mice. F) MyoD mRNA transcript abundance was correlated with 
V0/V1 Vcan gene expression in diaphragms from mdx mice (*p = 
0.0469), but not mdx-hdf mice (p = 0.9795). H) Myogenin mRNA 
transcript abundance tended to be positively correlated with V0/V1 
Vcan gene expression in diaphragms from mdx mice (*p = 0.0673) 
but not mdx-hdf mice (p = 0.6042). N = 9 mdx and n = 11-12 mdx-
hdf mice.  
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4.3.10 Genetic reduction of versican and ECM gene markers 
Upon the conclusion of regeneration, the transitional matrix is remodelled and 
replaced with a mature matrix rich in collagens and CS proteoglycans, such as 
decorin and biglycan (486). The differential expression of collagen isoforms 
distinguishes the interstitial matrix collagens (e.g. collagen I and III) from those in 
the basement membrane matrix (e.g. collagen IV and VI) (21, 36, 37). Col1a1 and 
Col4a1 gene expression did not differ between diaphragm muscles from mdx 
and mdx-hdf mice (Figure 4.10 A and E). However, a trend for reduced Col3a1 
mRNA transcript abundance was observed in diaphragm muscles from mdx-hdf 
mice (p = 0.075; Figure 4.10 C).  
As was done for the gene markers of inflammation and myogenesis, the 
potential correlation between versican gene expression and collagen mRNA 
transcript abundance was determined in the diaphragms. Col1a1 mRNA 
transcript abundance and V0/V1 Vcan gene expression were positively 
correlated in mdx mice (p = 0.0388; Figure 4.10 B), but not mdx-hdf mice. 
However Col3a1 and Col4a1 mRNA transcripts were not correlated with versican 
gene expression in either mdx or mdx-hdf diaphragm muscles (Figure 4.10 D-F). 
No gene correlations tested here were of any significance in the mdx-hdf 
diaphragms. 
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Figure 4.10 Collagen mRNA transcript abundance in diaphragm 
muscles from mdx and mdx-hdf mice.  
A, C and E) Col3a1 gene expression tended to be lower in 
diaphragm muscles from mdx-hdf diaphragms compared to mdx 
littermates (p = 0.075; T-test), whereas Col1a1 and Col4a1 were 
similar between mdx and mdx-hdf diaphragms (p = 0.152 and p = 
0.915, respectively; T-test). B) Col1a1 mRNA transcript abundance 
was positively correlated with V0/V1 Vcan gene expression in 
diaphragms from mdx mice (*p = 0.0388), but not mdx-hdf mice (p = 
0.1403). D and F) Col3a1 and Col4a1 mRNA transcript abundance 
did not correlate with V0/V1 Vcan gene expression in diaphragms 
from mdx or mdx-hdf mice. N = 9 mdx and n = 11-12 mdx-hdf mice. 
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The gene expression of Decorin and Biglycan was also investigated, as both are 
upregulated in dystrophic muscles (42, 487) and are highly relevant to the 
pathogenesis of the disease. Decorin has been shown to regulate the 
bioavailability of TGFβ (488) and biglycan is thought to be important in 
stabilising the sarcolemmal expression of utrophin, the functional homologue of 
dystrophin (62). The gene expression of smooth muscle alpha actin 2 (Acta2) 
was also measured, as Acta2 is a marker for myofibroblasts (489), and because 
versican has been implicated in driving the differentiation of fibroblasts to 
myofibroblasts (265, 348). In dystrophic muscles, myofibroblasts are thought to 
significantly contribute to collagen synthesis and fibrosis (107). 
The mRNA transcript abundance of Decorin, Biglycan and Acta2 was similar in 
diaphragm muscles from mdx and mdx-hdf mice (Figure 4.11 A, C and E). The 
mRNA transcript abundance of Decorin was not correlated with versican gene 
expression in either mdx or mdx-hdf diaphragm muscles (Figure 4.11 B). 
Whereas, Biglycan mRNA transcript abundance and V0/V1 Vcan gene expression 
were positively correlated in diaphragm muscles from mdx mice (p = 0.0266; 
Figure 4.9 D), but not mdx-hdf mice. Interestingly, Acta2 mRNA transcript 
abundance and V0/V1 Vcan gene expression were negatively correlated in 
diaphragm muscles from mdx mice (p = 0.0221; Figure 4.9 F), but not mdx-hdf 
mice. This was somewhat surprising given that versican may mediate the 
fibroblast to myofibroblast transition (265, 348). Although, as correlations do 
not indicate causality, given that myofibroblasts secrete a collagen rich matrix 
rather than a transitional matrix, it can be speculated that perhaps the muscles 
with the highest Acta2 gene expression had the most severe pathology and 
fibrosis. No gene correlations tested here were of any significance in the mdx-
hdf diaphragms. 
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Figure 4.11. Decorin, Biglycan and Acta2 mRNA transcript 
abundance in diaphragm muscles from mdx and mdx-hdf mice. 
A, C and E) The mRNA transcript abundance for the small 
proteoglycans Decorin and Biglycan, and for Acta2, a myofibroblast 
marker, did not differ between diaphragm muscles from mdx and 
mdx-hdf mice (p = 0.251 p = 0.462 and p = 0.308, respectively; T-
test). B) No correlations were present between Decorin or V0/V1 
Vcan gene expression. D) Biglycan was positively correlated with 
V0/V1 Vcan gene expression in mdx diaphragms (*p = 0.0266), but 
not mdx-hdf mice (p = 0.5877). F) Acta2 was negatively correlated 
with V0/V1 Vcan gene expression in the mdx diaphragms (*p = 
0.0221), but not mdx-hdf mice (p = 0.1407). N = 9 mdx and n = 11-12 
mdx-hdf mice.   
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Previous studies investigating fibrosis have used a fluorescently labelled wheat 
germ agglutinin (WGA) to stain affected areas (415, 490). WGA is known to bind 
to a variety of ECM components (491), including proteoglycans and GAG rich 
regions of the matrix (492), along with collagen I (415). WGA is also routinely 
used to stain cell membranes (493, 494), where it binds to glycoproteins and 
glycolipids (495). These factors limit the sensitivity of WGA for analysis of 
fibrosis. The percentage of diaphragm muscle cross-section stained with WGA 
did not differ between mdx and mdx-hdf mice (Figure 4.12 C). However, given 
the limitations of WGA staining, this finding needs to be confirmed with a more 
quantitative marker of collagen deposition and fibrosis, such as muscle 
hydroxyproline content. 
 
Figure 4.12. Fibrosis in diaphragm muscles from mdx and mdx-hdf 
mice as determined by WGA staining. 
Fibrosis (WGA positive tissue) is red, nuclei are stained blue (DAPI). 
A-B) Representative mdx and mdx-hdf diaphragm sections stained 
with WGA, taken at x20 magnification. C) The proportion of muscle 
cross-section stained with WGA did not differ between the 
diaphragm muscles from mdx and mdx-hdf mice (p = 0.251; T-test). 
Scale bar = 200 µm. n = 9 mdx and n = 10 mdx-hdf mice. 
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4.3.11 The genetic reduction of versican and mRNA transcript 
abundance of ECM proteases 
Fibrosis encompasses not only aberrant ECM synthesis, but also remodelling 
through protease upregulation in DMD (496, 497). The versican-hyaluronan rich 
transitional matrix (74) is remodelled by ADAMTS versicanases, including 
ADAMTS1, -5 and -15 (315, 316, 319) and by hyaluronidases, with Hyal2 being 
the predominant isoform in muscle (446). Hyal2, Adamts1 and Adamts5 mRNA 
transcript abundance was similar in diaphragm muscles from mdx and mdx-hdf 
mice (Figure 4.13 A, C and E). Although, Adamts15 gene expression tended to 
increase in mdx-hdf mice (p = 0.061; Figure 4.13 G). The biological relevance of 
this modest difference in Adamts15 gene expression is likely minimal, as 
versikine levels (as determined from immunohistochemical analysis in Figure 4.1 
F) did not differ between diaphragm muscles from mdx and mdx-hdf mice. 
Whereas Hyal2, Adamts1 and Adamts15 mRNA transcripts did not correlate with 
V0/V1 Vcan (Figure 4.13 B, D and H), the Adamts5 mRNA transcript tended to 
have a positive correlation with V0/V1 Vcan gene expression in mdx diaphragms 
(p = 0.0761; Figure 4.13 F), but not mdx-hdf diaphragms. 
  
147 
 
 
 
 
 
  
148 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Gene markers of transitional matrix remodelling in 
diaphragm muscles from mdx and mdx-hdf mice. 
A, C and E) Hyal2, Adamts1 or Adamts5 mRNA transcript abundance 
did not differ between mdx and mdx-hdf diaphragm muscles (p = 
0.626, p = 0.844 and p = 0.337, respectively; T-test). G) Adamts15 
gene expression tended to be increased in mdx-hdf diaphragm 
muscles (p = 0.061; T-test). B, D, and H) Hyal2, Adamts1, and 
Adamts15 mRNA transcript abundance did not correlate with V0/V1 
Vcan gene expression in diaphragm muscles from mdx or mdx-hdf 
mice. F) Adamts5 mRNA transcript abundance tended to positively 
correlate with V0/V1 Vcan gene expression in diaphragms from mdx 
(p = 0.0761), but not mdx-hdf mice (p = 0.1554). N = 9 mdx and n = 
12 mdx-hdf mice. 
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4.3.12 The improved fatigability of mdx-hdf diaphragm muscles is 
not mediated by a shift in the proportion of type IIa fibres 
Diaphragm muscles from 3-4 month old mdx mice contain approximately 55 % 
type IIa fibres and 10 % type I fibres, and together these account for the 
endurance phenotype of the diaphragm muscle (498). The proportion of fast, 
glycolytic type IIx fibres is much lower, being less than 20 % (498). To test 
whether a shift to a more oxidative phenotype accounted for the improvement 
in fatigability (see Figure 4.6) and the increase in TPT (see Table 4.3), the 
proportion of type IIa fibres was assessed. As previously reported (498), the 
proportion of type IIa fibres in mdx diaphragm muscles is approximately 55 %. 
However, the proportion of type IIa fibres in diaphragm muscles did not differ 
here between diaphragms from mdx and mdx-hdf mice (Figure 4.14 C). To 
conclusively rule out a fibre type shift with the genetic reduction of versican, the 
proportion of type I fibres will also need to be assessed in future studies. 
Interestingly, type IIa fibres from mdx-hdf mice tended to have a lower 
proportion of centrally nucleated fibres (p = 0.087; Figure 4.14 D). This in 
contrast to analysis of the H&E stained diaphragm muscle cross-sections, where 
muscles from mdx-hdf mice tended to have an increase in in the percentage of 
centrally nucleated fibres when compared to mdx littermates (Figure 4.7 D). 
However, whether this is of functional significance with regards to endurance or 
strength remains to be determined. 
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Figure 4.14 The genetic reduction of versican does not affect 
proportion of type IIa fibres in diaphragm muscles.  
MyHC IIa staining is green. A-B) Representative cross-sections of 
MyHC IIa immunoreactivity along with corresponding bright field 
images for orientation. C) The percentage of type IIa fibres was 
similar in diaphragms from mdx and mdx-hdf mice (p = 0.713; T-
test). D) In type IIa fibres, the genetic reduction of versican tended 
to reduce the proportion of centrally nucleated fibres in mdx-hdf 
mice (p = 0.087; T-test). N = 6 mdx and n = 10 mdx-hdf mice. Scale 
bar = 100 µm. 
  
151 
 
4.4 Discussion 
In DMD, fibrosis is not just a disease end point, but rather precedes overt muscle 
degeneration and actively contributes to the progression of disease pathology 
(94, 124). The aberrant ECM synthesis and remodelling associated with fibrosis 
in dystrophic muscles dysregulates inflammation and regenerative myogenesis. 
This potentiates further fibrosis, which in turn compromises contractile function 
(207). The fibrosis in DMD is associated with an upregulation of mature proteins, 
such as collagen I and collagen IV, and transitional matrix proteins such as 
fibronectin and versican (90, 119, 221). It can therefore be proposed that that a 
novel approach to target fibrosis in dystrophic muscles is to modulate the 
transitional matrix. Of particular relevance to DMD pathology is versican, as it is 
overexpressed in dystrophic muscles and downregulated by glucocorticoids (90, 
465), the only treatment with clinical efficacy in DMD (371). This hypothesis was 
tested in this Chapter by genetically reduced versican in mdx mice, thereby 
modulating the transitional matrix in order to characterise the effects on whole 
body physiology, and diaphragm muscle structure and function. It should also be 
noted that this is the first time this strain of mice has been bred, and is hence a 
novel strain of dystrophic mice. In dystrophic mdx mice, the diaphragm is the 
most severely affected muscle with regards to fibrosis and deficits in contractile 
function, and as such most closely resembles the human form of the disease 
(454, 455). V0/V1 versican expression was found upregulated in diaphragm and 
hindlimb muscles from mdx mice, compared to wild type muscles (465). 
Furthermore, it is the worsening respiratory function in patients with DMD 
which contributes to the loss of ambulation and reduction in life expectancy 
(111, 499). 
Male heterozygous heart defect (hdf) mice were bred with female mdx mice to 
produce male F1 mdx or mdx-hdf pups. The successful genetic reduction of 
versican was initially confirmed through genotyping, but was further confirmed 
by qRT-PCR analysis and immunohistochemistry. Despite a genetic reduction in 
V0/V1 versican expression, versikine (the cleaved form of versican) 
immunoreactivity did not differ between muscles from mdx and mdx-hdf mice. 
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This observation is not entirely unexpected, as versikine is not the end product 
of versican remodelling and is perhaps further degraded, as shown by the 
decreased expression in the 3 week old hind limb compared to an embryonic 
hindlimb at E13.5 (17). Similarly, versikine immunoreactivity did not differ 
between diaphragm muscles from mdx and wild type mice, despite greater 
V0/V1 versican gene and protein expression in the dystrophic diaphragm 
muscles (465). These observations are further supported by findings in Chapter 
3, where significantly increased amounts of versican are present in 12 week old 
mdx mice when compared to normal and healthy wild type mice of the same 
age. 
Given that versican is a transitional matrix component (74), its synthesis and 
remodelling are key to regulating cellular processes relevant to inflammation 
and regeneration in dystrophic muscles. As previously reported in hindlimb 
muscles (465), versikine was also localised to regions of mononuclear infiltrate in 
diaphragm muscles in this thesis. Mononuclear infiltrate is comprised of cells 
that are known to secrete versican and ADAMTS versicanases, such as myoblasts 
(17, 20, 465), macrophages (228, 500, 501) and fibroblasts (265, 502). Nuclear 
localisation of versikine was also observed within nuclei of centrally nucleated 
fibres, as well as in nuclei of unidentified cells in the endomysium. Previously, it 
has been suggested that nuclear versikine may have an important role in mitotic 
spindle organisation during cell proliferation (336). 
In mdx mice, the genetic reduction of versican had no effect on body 
composition, including relative and absolute lean mass and fat mass, and had a 
modest effect on heart size, as indicated by an increase in absolute and 
normalised heart mass and a more dilated left ventricle. Nonetheless, cardiac 
function was compensated for, as indicated by a similar stroke volume in mdx 
and mdx-hdf mice. As 26 weeks of age equals 6 months, the heart weight, heart 
weight to body weight ratio, and stroke volume in these mdx mice are therefore 
similar to the data published for 7 month old mdx mice (503). The ejection 
fraction however, was much higher in this Chapter than what was published for 
the 7 month mice (503), possibly because the 7 month mice have a more 
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developed cardiomyopathy than the younger mice in this thesis. At this point, it 
is unclear whether the effects of versican reduction on the left ventricle are due 
to versican expression in the dystrophic myocardium or due to development 
effects of versican heterozygosity, as versican is known to affect the hdf heart 
(331).  
Understanding how targeting versican affects the heart is important, given that 
cardiac myopathies are first observed from approximately 10 years of age and 
progressively increase over the lifespan of the patient (406). Indeed, 98.7 % of 
DMD patients, aged 18 and above, presented with cardiomyopathy; 71.7 % of 
patients had the predominant dilated cardiomyopathy, while 26.1 % had a less 
common hypertrophic cardiomyopathy (406). Mdx mice also begin to acquire 
the characteristics of a dilated cardiomyopathy between 29-42 weeks of age 
(133). Furthermore, it remains controversial as to whether the heart pathology is 
ameliorated (504), remains unchanged (505) or becomes worsened (506) after 
skeletal muscle was specifically targeted and treated in mdx mice. When exon 
skipping was used to partially restore dystrophin to skeletal muscle, although 
increasing the locomotor activities of mdx mice was beneficial, the increased 
activity put extra pressure on the dystrophic heart and thereby worsened cardiac 
pathology by damaging myocardiocytes and increasing fibrosis (507). A similar 
outcome was observed when mdx mice were treated for 6 months with 
streptomycin to block calcium channels, although improving the pathology in the 
TA muscle, the pathology of the heart became worsened, with increased 
necrosis and fibrosis (508). Additionally, there are also studies that highlight 
treatments which were beneficial in mice, but when trialled in humans, was 
found to have the opposite effect. For example, Sildenafil, a drug commonly 
used in treating erectile dysfunction and pulmonary hypertension, was found to 
have cardioprotective effects and improved the cardiac function of mdx mice 
(509). However when Sildenafil was trialled in dystrophy patients,  with 
cardiomyopathy, the study was cancelled prematurely due to a number of 
patients having worsened heart function (510). It is known that therapeutic 
strategies that aim to reduce fibrosis, or improve the contractile function of 
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dystrophic skeletal muscles, can have deleterious effects on the dystrophic 
heart, and thus, for any future therapeutics, any potential cardiac side effects 
will need to be considered (511, 512). A limitation of this study is that the mdx 
and mdx-hdf hearts, although collected, were not examined further, therefore 
no morphological data is available. 
The defects in contractile function in dystrophic limb and respiratory muscles 
from patients with DMD include a reduction in muscle strength, as well as a 
decrease in muscle endurance (513, 514). Abnormalities in mitochondrial 
function and substrate metabolism are thought to contribute to this defect in 
muscle endurance (473). Improved endurance and metabolism are important 
therapeutic outcomes for improving muscle health in DMD, as insulin resistance 
and metabolic abnormalities are common co-morbidities in DMD (515). 
Interestingly, the therapeutic benefits of glucocorticoids in patients with DMD 
are thought to include pro-ergogenic effects on metabolic programming, leading 
to increased muscle endurance and exercise capacity (516). Hence, mdx-hdf 
mice and mdx littermates were placed into metabolic cages for 24 h to assess 
spontaneous physical activity and whole body metabolism. Mdx-hdf mice moved 
more than their mdx littermates, irrespective of body weight. Whereas, in the 
mdx littermates an increasing body weight was associated with a reduction in 
spontaneous physical activity. It is worth noting that the activity levels observed 
here for the mdx and mdx-hdf mice were slightly lower than those in a 
previously published study where, under similar conditions to the study in this 
thesis, 14 week old male mdx mice exhibited a total of approximately 40,000 
movements over a 24 h period (470). Although the mdx-hdf mice match the 
heightened activity levels reported in these much younger mice, the mdx mice in 
this thesis had 30,000 movements. This may be due to dystrophic pathology 
being more progressed and prevalent in the older mdx mice used here in this 
thesis. 
The genetic reduction of versican was associated with reduction in the RER, but 
not resting energy expenditure (REE), during both the light and dark periods, 
indicating a shift towards a more oxidative metabolism, and thus a greater 
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reliance on lipids as a substrate. Additional support of the observation that 
versican reduction might affect oxidative metabolism, is the reduction in 
fatigability and improved force recovery of diaphragm muscles from mdx-hdf 
mice following 4 m of intermittent, submaximal stimulation ex-vivo. This is a very 
novel observation, in that the downregulation of a single ECM protein can 
modulate whole body metabolism and ex-vivo diaphragm fatigability. It was 
hypothesised that in the context of insulin resistance and diabetes, the 
remodelling of the skeletal muscle ECM alters mechanosignal transduction, 
which disrupts the expression of genes relevant to oxidative metabolism and 
mitochondrial biogenesis (517). Indeed, defects in mitochondrial function and 
ATP synthesis have been well described in dystrophic muscle (473, 518). As such, 
improving the metabolic phenotype and endurance of dystrophic muscles is 
especially important.      
In addition to the effects on diaphragm muscle endurance, there was an increase 
in ex-vivo force output, as indicated by an upward shift in the force frequency 
curve, in diaphragm muscles from mdx-hdf mice when compared to mdx 
littermates. Altogether, these data indicate that the genetic reduction of 
versican improves the contractile function of dystrophic diaphragm muscles. A 
reduction in proportion of very small muscle fibres (< 9.99 um in diameter), may 
mediate this increase in diaphragm muscle strength following the genetic 
reduction of versican. The force producing capacity of very small muscle fibres is 
likely quite limited, and the positive correlation between fibre size and strength 
is well established (519). There was also a trend for increased proportion of 
centrally nucleated fibres, along with a decreased proportion of centrally 
nucleated type IIa fibres, in mdx-hdf diaphragms when compared to mdx 
littermates. In-vitro, the clearance of a hyaluronan and versican rich transitional 
matrix potentiates myoblast fusion and myotube growth (17). In addition to the 
genetic reduction of versican, hyaluronan synthase 2 (Has2) mRNA transcript 
abundance tended to be lower in the diaphragms from mdx-hdf mice when 
compared to mdx littermates. Whether this correlated with reduced hyaluronan 
content remains to be determined. Perhaps, based on these findings, improved 
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fusion may have contributed to the observed changes in myofibre size and the 
proportion of centrally nucleated fibres through the reduction of versican and its 
chondroitin sulphate GAG chains (17, 457). Lending support to this theory, in 
Chapter 3 of this thesis, the treatment of C2C12 muscle cells was associated with 
the reduction of versican and hyaluronan gene expression, and improved 
myoblast fusion in-vivo. The hypothesis therefore requires further analysis, and 
in future studies, the proportion of recently regenerated fibres expressing 
embryonic and developmental myosin heavy chain isoforms should be quantified 
in mdx and mdx-hdf diaphragms (520, 521).  
To gain some insight into how versican reduction might affect muscle repair, the 
mRNA transcript abundance of gene markers associated with satellite cell 
proliferation and myoblast differentiation was determined. However, Pax7, 
Desmin, MyoD and Myogenin gene expression did not differ between 
diaphragms from mdx and mdx-hdf mice. However, since versican has been 
linked to myogenesis during development through satellite cell proliferation and 
differentiation (20), and given the inherent variability of dystrophic muscle 
pathology in mdx mice (481), additional correlation analysis was therefore 
completed on the gene expression data. In diaphragm muscles from mdx mice, 
but not mdx-hdf mice, the mRNA transcript abundance of MyoD was positively 
correlated, while Myogenin tended to be positively correlated, with versican 
gene expression. Altogether, the gene expression and histological analyses 
suggest that altering versican levels in dystrophic muscles may have an effect on 
regenerative myogenesis. However, more detailed mechanistic studies are 
required. These may include studies upon single fibres, which could be 
immunohistochemically stained to investigate the effect of reduced versican on 
satellite cells (522), or investigations involving muscular injury, such as treadmill 
running or crushing the muscle, in order to observe the regenerative processes 
though immunohistochemical and histological staining. 
The increased diaphragm muscle ex-vivo force output and effects on muscle 
morphology may also be due to the effects versican reduction may have on 
inflammation. Indeed, attenuating inflammation has been shown to improve 
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muscle function in mdx mice due to a reduction in necrosis and an improvement 
in regeneration (377, 523). To begin to assess the effects of versican reduction 
on inflammation in diaphragm muscles, an analysis of H&E stained sections for 
area of mononuclear infiltrate was undertaken (413, 414). However, no 
differences between diaphragm muscles from mdx or mdx-hdf mice were 
observed. H&E analysis of mononuclear infiltrate is a rather non-specific marker 
of inflammation. It does not take into account any differences in cell types such 
as satellite cells, myoblasts, fibroblasts, nor any of the inflammatory cell 
populations, such as neutrophils, monocytes, or the differing subsets of M1 or 
M2 macrophages. Further analysis of neutrophil, monocyte and macrophage 
infiltration in dystrophic diaphragm muscles therefore needs to be undertaken 
via immunohistochemistry or flow cytometry, with markers for the different cell 
types.  
Versican can modulate inflammation directly by binding leukocytes on its CS 
GAG chains (53), or through regulating the bioavailability of chemokines and 
cytokines, including MCP-1 (51). Additionally, versican can regulate inflammation 
indirectly through its interactions with hyaluronan, which in skeletal muscle is 
predominantly synthesised by HAS2 (446). To gain additional insight into the 
effect versican reduction on inflammation in dystrophic diaphragm muscles, 
Has2, MCP-1, TGF-β1 and F4/80 gene expression was assessed. However, it 
should be noted that F4/80 is an unspecific marker for monocytes, M1 and M2 
macrophages alike (524). Although Has2 mRNA gene expression tended to be 
lower in diaphragm muscles from mdx-hdf mice, the other gene markers of 
inflammation were unaffected by versican reduction. When the gene expression 
data was further interrogated, a positive correlation between F4/80 mRNA 
transcript abundance and V0/V1 versican was observed. This is interesting, 
because monocytes and macrophages both produce versican (290, 390, 391). 
Given that the mdx-hdf mice would have reduced versican in cells, due to being 
happloinsufficient for a versican allele, thereby being heterozygous for versican 
(331), perhaps there is less versican being made by monocytes and macrophages 
in the mdx-hdf mice. A reduction of versican would therefore have implications 
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on monocyte migration (389) and differentiation into macrophages (290). 
However, given that there was no difference in F4/80 gene expression, it could 
therefore be possible that the genetically reduced versican in mdx-hdf mice may 
result in an impaired differentiation of monocytes to macrophages, or may even 
affect the transition of the pro-inflammatory M1 macrophages to anti-
inflammatory M2 macrophages. 
The data acquired thus far suggests minimal effects of versican reduction on 
inflammation in mdx diaphragm muscles. However, the experimental model and 
analysis are limited to fully justify such a conclusion. Future experiments 
involving contraction induced injury protocol (e.g. voluntary wheel running or 
forced treadmill running) to heighten inflammation in dystrophic mdx muscles 
(525), should be used to assess whether versican does indeed modulate pro- and 
anti-inflammatory responses in dystrophic muscles.  
Additionally, the increased force exhibited by the mdx-hdf diaphragm could be 
due to a decrease in fibrosis. It was hypothesised that reducing versican levels 
might attenuate fibrosis when the transitional matrix is remodelled and replaced 
with a mature matrix. As such the mRNA transcript abundance of interstitial and 
basement membrane collagen isoforms and mature matrix proteoglycans were 
measured. Only the basement membrane Col3a1 showed a trend for decreased 
gene expression in diaphragm muscles from mdx-hdf compared to mdx mice, 
whereas Col1a1 and Col4a1 were similar. Decorin, Biglycan and Acta2 gene 
expression were also not affected by the genetic reduction of versican. 
Interestingly, although Acta2 gene expression was negatively correlated, the 
mRNA transcript abundance of interstitial Col1a1 and Biglycan was positively 
correlated with V0/V1 versican gene expression in diaphragm muscles from mdx 
mice, but not mdx-hdf mice. These observations are suggestive that perhaps the 
genetic reduction of versican does affect ECM synthesis. However, the regions of 
fibrosis, as determined from WGA staining, remained similar between the mdx 
and mdx-hdf mice. Therefore, this hypothesis needs to be rigorously tested with 
specific measures of interstitial and basement membrane collagens, along with 
biglycan and Acta2 content in mdx and mdx-hdf diaphragm muscle, through, for 
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example, the use of a hydroxyproline assay, immunoblotting techniques or 
proteomic analysis. The genetic reduction of versican had minimal effects on the 
expression of genes associated with the remodelling of versican and hyaluronan 
rich transitional matrix, specifically Hyal2, Adamts1 and Adamts5 – a highly 
upregulated ADAMTS protease in dystrophic muscles (349, 465). This is in 
concordance with the observation of similar versikine immunoreactivity in mdx 
and mdx-hdf diaphragm muscles. Furthermore, although similar levels of Hyal2 
and Adamts5 gene expression were also observed in the glucocorticoid treated 
C2C12 cells of chapter 3, Adamts1 gene expression was found to be increased. 
This is suggestive that glucocorticoids may still influence pathways that are not 
affected by low levels of versican. However this is highly speculative and remains 
to be elucidated. 
In conclusion, the genetic reduction of versican was associated with an increase 
in spontaneous physical activity, a shift to oxidative whole body metabolism, and 
improved ex-vivo diaphragm muscle strength and endurance in 21 week old 
mdx-hdf mice. An overview of data obtained in Chapter 4, and the hypothesized 
mechanisms, can be viewed in Figure 4.15. Although it is still unclear as to why 
the mdx-hdf mice display increased locomotion along with improved force and 
endurance, it can be speculated that in addition to the changes in ECM, it may 
have also led to an improvement in regeneration and metabolism – although, 
the underlying mechanisms require further analysis. Furthermore, to more 
comprehensively establish the benefits of versican reduction, the effects of 
muscle fibre types and growth must be considered, as the developmental matrix 
is extensively remodelled during growth to maturity. Therefore, further studies 
were then undertaken in fast and slow twitch hindlimb muscles from young, 
growing (6 weeks) and adult (26 weeks) mdx and mdx-hdf mice.  
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Figure 4.15 Overview of Chapter 4 diaphragm results and possible 
mechanisms. 
This figure summarises the data obtained from the diaphragm in 
Chapter 4 and also outline the possible mechanisms that were 
hypothesized. 
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Chapter 5: The genetic reduction of versican 
differentially modulates function and pathology of 
dystrophic hindlimb muscles depending on muscle 
type and postnatal growth 
 
5.1 Introduction  
DMD is caused by a mutation in the dystrophin gene leading to loss of expression 
of the functional protein (464). This results in sarcolemma fragility, causing 
skeletal muscles to become highly susceptible to contraction induced injury. 
Pathology is comprised of persistent and ongoing bouts of damage and 
regeneration, which progressively become dysregulated (285). This ultimately 
results in the loss of myofibres, which are replaced by adipose tissue and fibrosis 
(107), leading to decreased strength and weakness in the muscles (207). Fibrosis 
is first observed as an expansion of connective tissue in muscle biopsies from 
patients with DMD as young as 2.5 weeks of age (94). Fibrosis reaches its peak 
during a period of growth in DMD patients, at approximately 6-7 years of age 
(124). As glucocorticoids can reduce fibrosis (526), glucocorticoids should 
therefore be administered before patients reach 6-7 years of age, as fibrosis 
determines, and may impair, the efficiency of the treatment (124). There is also 
increasing evidence that a dysregulated and fibrotic matrix may contribute to 
the metabolic dysfunction observed in dystrophic muscles (see Chapter 4). 
Therefore, this highlights the need to better understand the fibrotic matrix, as 
any effective therapeutic intervention for DMD must consider the ECM. 
In dystrophic muscles from patients with DMD and mdx mice, the expansion of 
the ECM encompasses interstitial and basement membrane proteins. These 
include collagens and fibronectin (221, 285). Additionally, there is an increase in 
proteoglycans, particularly those containing GAG side chains (116); specifically, 
decorin, biglycan (42, 487), and versican (90, 465). 
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Normally, following an injury and as part of the regenerative response, there is 
the carefully regulated synthesis and secretion of a transitional matrix rich in 
versican, hyaluronan, tenascin and fibronectin (73, 74). This transitional matrix is 
loose and hydrated, functioning as a specialised structural support for the 
infiltration and guidance of inflammatory cells, satellite cells and fibroblasts (74, 
527). Successful regeneration also requires remodelling of this transitional 
matrix and the deposition of a mature matrix, rich in collagens (382, 528) and CS 
proteoglycans, such as decorin and biglycan (486). However, in DMD, where 
fibrosis is aberrant due to persistent injury and regeneration, repair is ineffective 
and transitional matrix proteins remain overexpressed, contributing to the 
continual increase in fibrosis. 
This dysregulation of the transitional matrix is observed not only in patients with 
DMD, but also in mdx mice. Fibronectin and tenascin-C are increased in muscles 
from DMD patient and mdx mice (421, 529, 530). Likewise, hyaluronan content 
and synthesis, shown via increased Has1 and Has2 mRNA transcripts, is also 
increased in mdx mouse muscles (435), while versican is overexpressed in 
muscles from DMD patients (90) and mdx mice (465). Hence, the transitional 
matrix proteins are also aberrantly synthesized in DMD. 
Versican is a developmental protein, its expression being low in mature muscle, 
unless there is damage or a disease, whereupon its expression becomes 
upregulated (311). Highly relevant to DMD pathology, is the fact that versican 
can be synthesised by inflammatory cells, fibroblasts and myoblasts (17, 265, 
290). Through its synthesis and remodelling, versican may affect myoblast 
proliferation (20) and differentiation of myoblasts (17), monocytes  and 
fibroblasts (265, 348). Carefully regulated ECM synthesis and remodelling is not 
just important for muscle regeneration and pathology in DMD, it is also likely 
quite relevant to normal postnatal growth. As such, the skeletal muscles of 
patients with DMD experience the stress of dystrophin deficiency alongside 
normal growth. This is rarely considered in experimental studies investigating 
ECM remodelling and fibrosis in mdx mice, yet it is absolutely crucial, as carefully 
regulated ECM synthesis by fibroblasts is needed for satellite cell function (531). 
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Furthermore, results from Chapter 4 hinted at a change in fibre type, which 
brings about another limitation in that fibre types were not well investigated. It 
is well known that fast and slow fibre types have differing matrices. Slow twitch 
fibres contain more dystrophin (64), utrophin (65) and collagen IV (11), leading 
to a more stabilised and flexible basement membrane and allowing for the 
dissipation of contractile produced force. However, the fast twitch fibres contain 
more laminin (11) which provides more adhesion to the matrix, and as such, fast 
twitch fibres not only produce the most force (66), but are also the most 
damaged, being prone to contraction induced injuries (68). Further 
differentiating the fibre types are their contractile differences and metabolic 
requirements (532). 
In Chapter 4, it was observed that in adult (21 week old) mdx mice, the genetic 
reduction of versican improved the strength and endurance of diaphragm 
muscles and increased spontaneous physical activity. Here, these observations 
were followed up taking postnatal growth and fibre type into account when 
considering the effects the genetic reduction of versican might have on the 
function and pathology of mdx hindlimb muscles. The strength, endurance and 
pathology of fast twitch EDL muscles and slow twitch soleus muscles were 
assessed in young, growing (6 week old) and adult (26 week old) mdx and mdx-
hdf mice. 
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5.2 Methods 
5.2.1 Ethics statement and animal husbandry 
All mouse experiments were approved by Deakin University’s Animal Ethics 
Committee, under projects numbers A79/2011 and G06/2015. Female mdx mice 
obtained from the Animal Resource Centre (Canning Vale, Western Australia), 
were bred with male hdf (heart defect) mice obtained from Hoffman-La Roche 
Pharmaceuticals. The hdf mice are haploinsufficient for the versican allele. All 
male pups underwent an ear punch biopsy and the resulting F1 generation mdx 
and mdx-hdf male pups were confirmed through genotyping. For a more 
detailed description, please refer to section 2.3.2. All mice were maintained on 
an alternating 12 h light and 12 h dark cycle, with standard mouse chow and 
water provided ad libitum. All experimental procedures in the Chapter were 
completed on mice at 6 or 26 weeks of age. 
5.2.3 Contractile function 
Mice at 6 and 26 weeks of age were anaesthetised with medetomidine 
(0.5mg/kg), midazolam (5mg/kg) and fentanyl (0.05mg/kg), administered via an 
IP injection in ~1 ml sterile saline, until unresponsive to tactile stimuli. The EDL 
and soleus were removed and prepared for contractile function testing. Using 
small increments in length and 1 Hz twitches, the optimal length (Lo) was 
determined. This allowed for the assessment of twitch force (Pt), twitch force 
normalised to muscle size (sPt),  time to peak tension (TPT), ½ relaxation time (½ 
RT), and maximal rate of force production (max dx/dt). Following which, the 
maximal force producing capacity for the EDL and soleus muscle was determined 
from a force frequency curve (sPo), ranging from 1 to 120 Hz with 2 m rest in 
between each stimulation. Afterward, at a submaximal stimulation frequency of 
60 Hz, the muscles were stimulated every 5 s for a total duration of 4 mins, in 
order to fatigue the muscle. Muscle recovery was then assessed by stimulating 
the muscles at 60 Hz at 2, 5 and 10 mins post fatigue. For a more detailed 
description, please refer to section 2.3.6. 
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After contractile testing had concluded, the 6 and 26 week EDL and soleus 
muscles were removed of tendon, weighed and snap frozen in liquid nitrogen for 
gene expression analysis. The remaining EDL and soleus from the opposing and 
untested hindlimb were frozen in thawing isopentane for histological and 
immunohistochemical analysis. Furthermore, before mice were humanely culled, 
blood was collected via cardiac puncture for use in the total creatine kinase 
assay. 
5.2.4 Histology and immunohistochemistry 
The 6 and 26 week EDL and soleus muscles frozen in OCT were sectioned on a 
cryostat at -20 oC at a thickness of 8 μm. Slides from mdx and mdx-hdf were 
allocated as follows: 1) Stained with H&E in order to observe muscle structure, 
including fibre area (minimal feret diameter), central nucleation and area of 
mononuclear infiltrate; 2) Were reacted with primary antibodies for versican or 
versikine.  
5.2.4.1 H&E staining 
For analysis of muscle morphology, two non-overlapping digital images were 
captured from H+E stained sections at x10 magnification for analysis, and x20 
magnification for representative images. Image analysis was completed on the 
x10 images using ImageJ 1.47v, a program freely available on the internet 
(https://imagej.nih.gov/ij/), along with Image-Pro Plus (version 7). To assess 
muscle fibre size, all fibres within each the field of view were manually traced to 
obtain the fibre area (minimal feret diameter). In addition, the proportion of 
centrally nucleated fibres, a hallmark of recent damage and repair, was also 
determined. However, note that in the soleus, only the 6 week data is presented, 
as data could not be obtained for the 26 week soleus due to the singular large 
internalised holes within the majority of fibres. Furthermore, as a very general 
indicator of degeneration and inflammation, regions of mononuclear infiltrate 
and degeneration were traced and expressed as a percentage of the total muscle 
area for the given field of view. For a more detailed description, please refer to 
section 2.3.9.  
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5.2.4.2 Immunohistochemistry  
Four non-overlapping images were captured of muscle cross-sections 
immunohistochemically stained with versican and versikine primary antibodies 
at x60 magnification. Using the program Image-Pro Plus (version 7), the areas 
stained were quantified by measuring the area of staining and expressing as a 
percentage of the total area of muscle in the field of view. For a more detailed 
description, please refer to section 2.3.10.1. 
5.2.5 Serum creatine kinase activity 
Blood was collected from 6 and 26 week old mdx and mdx-hdf mice via cardiac 
puncture. Immediately after collection, blood was allowed to clot at 4 ○C and 
then spun in a benchtop centrifuge at 12,000 rpm to form a pellet. The serum 
was carefully collected into a new tube, and was stored at -80 oC until analysis of 
total creatine kinase activity, a marker of muscle damage, using a commercially 
available kit, according to manufacturer’s directions (Abcam). Note that the 
assay measures brain, heart and muscle isoforms of creatine kinase within the 
serum, and is not specific for the muscle isoform. 
5.2.6 Gene expression analysis 
Gene expression was performed using cDNA created from snap frozen 6 and 26 
week EDL and soleus muscles that were function tested (section 2.3.7). All mRNA 
samples were tested in duplicate. All gene expression data was calculated using 
the 2ΔCT method, and normalised to Oligreen (sections 2.2.4 and 2.2.5). For 
primer sequences, please refer to Table 2.2. 
5.2.7 Statistics 
An independent sample T-test was undertaken for all histology, 
immunohistochemistry and gene expression analyses. To assess muscle strength 
and fatigability, a 2-way general linear model (GLM) ANOVA was performed and 
followed by Tukey's post hoc analysis where appropriate. All data are presented 
as Mean ± S.E. and were considered statistically significant when p < 0.05. 
Additionally, it should be noted that the mice ages in this Chapter were not 
considered for statistical analysis for a few of reasons. The first being that the 6 
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and 26 week mice were 2 separate experimental models, one looking purely at 
differences in postnatal growth and the acute bout of degeneration and 
regeneration. The 26 week mice have reached maturity and reached growth, 
with satellite cells subjected to recurring cycles of damage and repair. The other 
investigating differences once growth has ceased and maturity reached. 
Furthermore, it is well recognised that each age group has distinct differences in 
dystrophic pathology and therefore cannot accurately be compared.   
5.3 Results for fast twitch EDL muscles from mdx and mdx-
hdf mice at 6 and 26 weeks of age 
5.3.1 Reduced versikine expression in EDL muscles from mdx-hdf 
mice 
Similar to observations in TA and diaphragm muscles (Chapters 3 (465), and 4), 
at 6 and 26 weeks of age, the versican staining was localised to areas of 
endomysial fibrosis and mononuclear infiltrate in EDL muscles from mdx and 
mdx-hdf mice (Figure 5.1 A-D). Unlike the diaphragm muscles from Chapter 4 
(Figure 4.1 C), the immunoreactivity of versican was similar in EDL muscles from 
mdx and mdx-hdf mice at both 6 and 26 weeks of age (Figure 5.1 E). Again, 
unlike the diaphragm muscles in Chapter 4 (Figure 4.1 G), the decrease in V0/V1 
Vcan gene expression did not reach statistical significance in EDL muscles from 
mdx and mdx-hdf mice at either 6 or 26 weeks of age (Figure 5.1 F).  
  
168 
 
 
 
Figure 5.1 The genetic reduction of versican had no effect on EDL 
muscles from 6 and 26 week old mdx-hdf mice.  
V0/V1 versican is stained red and nuclei blue (DAPI). A-D) 
Representative versican images in mdx and mdx-hdf EDL muscles 
showed versican was localised to areas of endomysial fibrosis and 
mononuclear infiltrate at 6 and 26 weeks of age. E) Versican 
immunoreactivity were similar in EDL muscles from mdx and mdx-
hdf mice at 6 and 26 weeks of age (p = 0.658 and p = 0.447, 
respectively; T-test). F) Quantitation of V0/V1 Vcan gene expression 
transcripts were also similar in mdx and mdx-hdf mice at both ages 
(p = 0.248 and p = 0.100, respectively; T-test). White asterisks 
denote areas of mononuclear infiltrate. To assess versican 
immunoreactivity, n = 5 mdx and n = 5 mdx-hdf mice at 6 weeks of 
age, and n = 10 mdx and n = 10 mdx-hdf at 26 weeks of age. To 
assess V0/V1 Vcan gene expression, n = 8 mdx and an n = 8 mdx-hdf 
mice at 6 weeks of age, and n = 9 mdx and an n = 13 mdx-hdf mice 
at 26 weeks of age. Scale bar = 100 µm.  
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In addition to the expected expression in regions of endomysial fibrosis, very 
strong versican immunoreactivity was also associated with muscle spindles in 
EDL muscles from 26 week old mdx and mdx-hdf mice (Figure 5.2 A-B and E-F). 
Whereas, the intensity of versican staining in nerves was much lower (Figure 5.2 
C, D, E and F). The versican antibody used in this thesis is specific for the GAGβ 
region, specific to the V0/V1 versican variants (289, 302). V0/V1 versican has 
been observed internally within peripheral nerves, where it was thought to be 
due to capillaries or fibroblasts (533). The observation of reduced versican 
staining in nerves is therefore unsurprising, especially given that the V2 versican 
variant, which contains only the GAGα domain, is the predominate form within 
the central nervous system and neuronal tissues (289, 302, 304).  
 
 
 
 
Figure 5.2 V0/V1 versican immunoreactivity in EDL muscle spindles 
and nerves.  
Versican is stained red and nuclei are blue (DAPI). Representative 
versican stained and brightfeild images of A-B) muscle spindle and 
C-D) nerve found within EDL muscles from a 26 week old mdx 
mouse. E-F) Representative versican and brightfeild images of a 
versican stained muscle spindle next to a nerve in an EDL muscle 
from a 26 week old mdx-hdf mouse. White arrows indicate muscle 
spindles and white arrowheads indicate nerves. Scale bar = 100 µm.  
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The EDL muscles were also stained with versikine, the cleaved product of V1 
versican (315). In EDL muscles from 6 week mdx mice, versikine 
immunoreactivity was especially intense around individual muscle fibres (Figure 
5.3 A). Whilst the general pattern of versikine immunoreactivity was similar in 
EDL muscles at 6 weeks of age, the staining intensity was reduced in mdx-hdf 
EDLs compared to mdx littermates (Figure 5.3 A and B), and was confirmed 
through quantification (*p = 0.037; Figure 5.3 E). At 26 weeks of age, versikine 
immunoreactivity was localised to the endomysial matrix in EDLs from both mdx 
and mdx-hdf mice (Figure 5.3 C and D). Again, image analysis revealed decreased 
versikine levels in EDL muscles from 26 week old mdx-hdf mice compared age 
matched mdx littermates (*p = 0.028; Figure 5.3 E). This reduction in versikine, 
but not versican (Figure 5.1 E and F), immunoreactivity in mdx-hdf EDL muscles, 
highlights the importance of considering the synthesis and remodelling of 
versican, given its role as a transitional matrix protein.  
Furthermore, it is also worth noting that muscles from 6 week old mdx mice are 
still undergoing postnatal growth, and are regenerating from an acute bout of 
muscle degeneration which typically occurs at 3-4 weeks of age (126). At 6 
weeks of age, versikine immunoreactivity was higher than in EDL muscles from 
26 week old mice, where growth has ceased and the pathology has stabilised. In 
concordance with previous observations within the diaphragm (Chapter 4), 
nuclear localisation of versikine in the EDL was also observed in centrally 
localised myonuclei nuclei of newly regenerated fibres, as well as myonuclei 
within the mononuclear infiltrate, of mdx and mdx-hdf EDLs at both 6 and 26 
weeks of age.  
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Figure 5.3 Decreased versikine expression in EDL muscles from 6 
and 26 week old mdx-hdf mice.  
Versican is stained red and nuclei are blue (DAPI). A-B) 
Representative images of EDL muscles from 6 week old mice 
showing versikine immunoreactivity localised to the endomysial 
matrix surrounding muscles fibres, as well as reduced staining in EDL 
muscles from 6 week old mdx-hdf mice. C-D) Representative images 
of EDL muscles from 26 week old mice, where versikine staining was 
also localised to the endomysial matrix, and again immunoreactivity 
was reduced in mdx-hdf mice. Note, that nuclear localisation of 
versikine was especially prominent in EDL muscles from the 26 week 
old mdx and mdx-hdf mice. E) Quantitation of versikine 
immunoreactivity revealed reduced versikine expression in EDL 
muscles from the mdx-hdf mice compared to mdx littermates at 6 
and 26 weeks of age (*p = 0.037 and *p = 0.028, respectively; T-
test). White arrowheads denote nuclei with internalised versikine 
staining. N = 6 mdx and n = 5 mdx-hdf mice at 6 weeks of age, and n 
= 9 mdx and n = 10 mdx-hdf at 26 weeks of age. Scale bar = 100 µm.   
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In complete contrast to the strong versican staining observed in EDL muscle 
spindles from mdx and mdx-hdf mice, versikine immunoreactivity was very much 
reduced and only very faint staining was observed (Figure 5.4 A-D). Versikine 
immunoreactivity in the nerve however, was essentially absent (Figure 5.4 A-D), 
which was not surprising given the low staining of versican (Figure 5.2 C-F).  
 
 
Figure 5.4 Versikine immunoreactivity in EDL muscle spindles and 
nerves.  
Versican is stained red and nuclei are blue (DAPI). Representative 
versican and brightfeild images of A-B) a muscle spindle and nerves 
in EDL muscles of a 26 week old mdx mouse. C-D) Representative 
image of a versican stained muscle spindle next to a nerve in an EDL 
muscle from a 26 week old mdx-hdf mouse. White arrows depict 
muscle spindles, and white arrowheads depict nerves. Scale bar = 
100 µm.  
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5.3.2 The genetic reduction of versican improved the endurance of 
fast twitch EDL muscle at 6 weeks, but not 26 weeks of age 
At 6 and 26 weeks of age, bodyweight, EDL muscle mass, body mass to muscle 
mass ratio (BM:MM), optimal muscle length (Lo) and muscle cross sectional area 
(CSA), were all similar between mdx and mdx-hdf mice (Table 5.1). Irrespective 
of age, the genetic reduction of versican had no effect on the twitch contractile 
properties of EDL muscle. Specifically, in response to a 1 Hz stimulation, which 
corresponds to a single action potential, twitch force (Pt), specific twitch force 
(sPt), time to peak tension (TPT), ½ relaxation time (½ RT) and maximal rate of 
force development (max dx/dt), did not differ between EDL muscles from mdx or 
mdx-hdf mice at either age (Table 5.1).
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Table 5.1. Body weight, EDL mass and ex-vivo twitch contractile properties from mdx and mdx-hdf at 6 and 26 weeks of age 
  6 weeks 26 weeks 
 Units mdx mdx-hdf P value mdx mdx-hdf P value 
Body weight g 22.00  ±  0.78 21.75  ±  0.49 0.80 32.32  ±  0.64  32.79  ±  0.58 0.60 
EDL mass mg 9.32  ±   0.62   9.57  ±  0.41 0.75 16.94  ±  0.84 18.27  ±  0.93 0.32 
BM:MM  0.42  ±  0.02 0.44  ±  0.01 0.43 0.52  ±  0.02   0.55  ±  0.02 0.37 
Lo mm 11.16  ±  0.35 11.33  ±  0.24 0.71 12.78  ±  0.35 12.58  ±  0.22 0.62 
CSA mm2 1.79  ±  0.10 1.81  ±  0.06 0.89 2.84  ±  0.12 3.14  ±  0.19 0.24 
Pt mN 62.65  ±  5.47 57.24  ±  3.55 0.45 105.63  ±  7.64 113.74  ±  6.27 0.42 
sPt kN/m2 35.97  ±  3.39 31.79  ±  2.01 0.34 37.64  ±  3.00 37.48  ±  2.66 0.97 
TPT s 0.188  ±  0.021 0.179  ±  0.026 0.77 0.021  ±  0.001 0.027  ±  0.008 0.48 
½ RT s 0.025  ±  0.002   0.025 ±  0.002 0.85 0.019  ±  0.002 0.017  ±  0.001 0.12 
Max dx/dt mN/s 11,450  ±  3,068   11,553  ±  2,599 0.98 6,282  ±  471 7,006  ±  368 0.23 
Data are means ± S.E. 
Lo = optimum muscle length; BM:MM = body mass to muscle mass ratio; CSA = cross sectional area; Pt = peak twitch;  sPt = 
specific twitch force; TPT = time to peak tension; ½ RT = half relaxation time; Max dx/dt = maximal rate of force development. 
N = 13-14 mdx and n = 10-11 mdx-hdf at 6 weeks of age, and n = 9 mdx and an n = 12 mdx-hdf mice at 26 weeks of age. 
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The ex-vivo maximal force producing capacity of EDL muscles was determined 
from a force frequency curve (1 to 120 Hz stimulation).  When normalised to 
muscle size (specific force; sPo), the strength of EDL muscles from mdx-hdf mice 
was similar to EDL muscles from mdx littermates at 6 and 26 weeks of age 
(Figure 5.5 A-B).  
 
 
Figure 5.5 Genetic reduction of versican did not affect EDL muscle 
strength.  
A force frequency curve was used to assess the specific force output 
(sPo) of EDL muscles from mdx and mdx-hdf mice. The genetic 
reduction of versican had no effect on EDL strength at A) 6 weeks of 
age (p = 0.169; main effect strain; 2-way GLM ANOVA with factors 
being frequency and strain), or at B) 26 weeks of age (p = 0.849; 
main effect strain; 2-way GLM ANOVA with factors being frequency 
and strain). N = 13 mdx and n = 10 mdx-hdf mice at 6 weeks of age, 
and n = 9 mdx and n = 12 mdx-hdf mice at 26 weeks of age.  
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Following the force frequency protocol, EDL muscles underwent 4 m of 
intermittent, submaximal 60 Hz stimulations followed by a single 60 Hz 
stimulation at 2, 5 and 10 m post fatigue to assess fatigability and force recovery. 
During the 4 m of intermittent, submaximal (60 Hz) stimulation, the EDL muscles 
from the 6 week old mdx-hdf mice fatigued less (*p = < 0.001; Figure 5.6 A) when 
compared to mdx littermates. Force recovery, at 2, 5 and 10 m post fatigue was 
also improved in EDL muscles from 6 week old mdx-hdf mice (*p = < 0.001; 
Figure 5.6 A). By 26 weeks of age, this improvement in muscle endurance was 
lost. Fatigability, in response to 4 m of intermittent, submaximal stimulation, was 
similar in EDL muscles from mdx and mdx-hdf mice at 26 weeks of age, whilst 
force recovery was significantly reduced in mdx-hdf EDL muscles (*p = 0.035; 
Figure 5.6 B). Therefore, in dystrophic EDL muscles, postnatal growth and 
regeneration following the acute bout of degeneration at 3-4 weeks of age, 
modulates the consequences of versican reduction on contractile function in fast 
twitch hindlimb muscles. Therefore, to gain more insight into how the genetic 
reduction of versican affects EDL contractile function, muscle morphology and 
gene markers for inflammation, regenerative myogenesis, and matrix 
remodelling were investigated. 
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Figure 5.6 Genetic reduction of versican improved the endurance 
of EDL muscles at 6 weeks of age. 
A) During 4 m of intermittent, submaximal (60 Hz) stimulation, EDL 
muscles from mdx-hdf mice fatigued less (*p = < 0.001; main effect 
strain; 2-way GLM ANOVA with factors being time and strain) and 
produced more force during 2 to 10 m of recovery (*p = < 0.001; 
main effect strain; 2-way GLM ANOVA with factors being time and 
strain) when compared to EDLs from mdx mice. B) By 26 weeks of 
age, this improvement was lost, as the fatigability of EDL muscles 
was similar between mdx and mdx-hdf mice (p = 0.523; main effect 
strain; 2-way GLM ANOVA with factors being time and strain). 
Furthermore, force recovery was decreased in EDL muscles from 
mdx-hdf mice (*p = 0.035; main effect strain; 2-way GLM ANOVA 
with factors being time and strain). N = 12 mdx and n = 10 mdx-hdf 
mice at 6 weeks of age, and n = 9 mdx and n = 11 mdx-hdf mice at 
26 weeks of age. 
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5.4.3 The genetic reduction of versican has a greater effect on the 
morphology of dystrophic EDL muscles at 26 weeks than at 6 weeks 
of age 
Morphological analysis of H&E stained EDL muscle cross sections was completed 
at 6 and 26 weeks of age (Figure 5.7 A-D for representative images). As 
expected, EDL muscle cross sections from 6 week old mdx and mdx-hdf mice 
contained small isolated regions of mononuclear infiltrate, endomysial fibrosis 
was very limited, and approximately 40 % of muscle fibres showed signs of 
recent regeneration, as indicated by one or two centrally localised nuclei (Figures 
5.7 A-B). At 6 weeks of age, the total number of myofibres per mm2, the 
percentage of centrally nucleated myofibres, muscle fibre size and percent area 
of mononuclear infiltrate did not differ between EDL muscles from mdx and 
mdx-hdf mice (Figure 5.7 E-F, G and I). 
However, by 26 weeks of age, subtle differences in the morphology of EDL 
muscles from mdx and mdx-hdf mice became apparent. EDL muscle cross-
sections from mdx mice exhibited increased fibrosis, and mononuclear infiltrate 
and degeneration, including visibly necrotic fibres (Figure 5.7 C-D). The 
morphology of EDL muscles from mdx-hdf mice appeared to have less fibrosis 
and mononuclear infiltrate and perhaps fewer necrotic fibres. 
Similar to 6 weeks, the total number of myofibres per mm2 did not differ 
between EDL muscles from 26 week old mdx and mdx-hdf mice (Figure 5.7 E). 
However, with age there was a progressive increase in the percentage of 
centrally nucleated fibres with 73 % of fibres being centrally nucleated in 26 
week EDL muscle cross-sections from mdx mice, and 68 % of in the 26 week 
mdx-hdf mice (Figure 5.7 F). 
The genetic reduction of versican tended to reduce the percentage of centrally 
nucleated fibres in the mdx-hdf mice (p = 0.060; Figure 5.7 F) compared to mdx 
mice. The percentage of mononuclear infiltrate and degeneration in EDL muscle 
cross-sections also tended to be lower in 26 week old mdx-hdf mice compared to 
age matched mdx littermates (p = 0.055; Figure 5.7 I). The genetic reduction of 
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versican appeared to have a subtle, yet beneficial effect on the pathology of 
dystrophic EDL muscles at 26 weeks of age; although, this difference in muscle 
morphology was not enough to result in a functional improvement in muscle 
strength. Nonetheless, given that areas of mononuclear infiltrate are comprised 
of inflammatory cells, muscle precursor cells and fibroblasts, these observations 
were investigated further by testing the effect of reduced versican upon gene 
expression markers of inflammation, regenerative myogenesis and fibrosis.  
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Figure 5.7 Morphological analysis of EDL muscles from mdx and 
mdx-hdf mice at 6 and 26 weeks of age. 
A-D) Representative H&E images of EDL muscle cross-sections from 
6 and 26 week old mdx and mdx-hdf mice. E) Total myofibre number 
per mm2 was similar in EDL muscles from mdx and mdx-hdf mice at 
6 and 26 weeks of age (p = 0.118 and 0.436, respectively; T-test). F) 
At 6 weeks of age, the genetic reduction of versican had no effect 
on the percentage of centrally nucleated fibres between mdx or 
mdx-hdf mice (p = 0.678; T-test). However, at 26 weeks of age, the 
EDL muscles from mdx-hdf mice tended to have a lower percentage 
of centrally nucleated fibres compared to mdx littermates (p = 
0.060; T-test). G-H) Based on analysis of minimal feret diameter, the 
genetic reduction of versican had no effect on muscle fibre size at 6 
or 26 weeks of age. I) The percent area of mononuclear infiltrate 
and degeneration was similar between mdx and mdx-hdf mice at 6 
weeks of age (p = 0.193; T-test). By 26 weeks of age, EDL muscle 
cross-sections from mdx-hdf mice tended to have a reduced 
percentage mononuclear infiltrate and degeneration (p = 0.055; T-
test) than their age matched mdx littermates. N = 8 mdx and n = 8 
mdx-hdf mice at 6 weeks of age, and n = 10-11 mdx and n = 10-12 
mdx-hdf at 26 weeks of age. Scale bar = 100 µm. 
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5.3.4 Genetic reduction of versican and gene markers of 
inflammation in EDL muscles 
In order to gain insight as to how the reduction of versican affects gene markers 
of inflammation in the fast twitch EDL muscles, the mRNA transcript abundance 
of Has2, Mcp-1, Tgfβ1 and F4/80 was quantified using RT-PCR. As described in 
previous chapters, Has2 is the main hyaluronan synthase (HAS) in skeletal 
muscle, involved in the synthesis of hyaluronan (446). Hyaluronan forms a 
complex with versican, together binding inflammatory cells (74, 240). However, 
hyaluronan can also be degraded by hyaluronidase enzymes to a low-molecular 
weight pro-inflammatory form (236), which stimulates macrophages to produce 
pro-inflammatory cytokines (240, 241). Additionally, versican can bind MCP-1 
(51), which is able to attract infiltrating monocytes and macrophages into the 
area of injury (478). TGFβ1 on the other hand, is a cytokine which can be both 
pro-inflammatory or anti-inflammatory depending on the context (534). In DMD, 
the elevated TGFβ1 levels contributes to failed regeneration and drives fibrosis 
(345). Finally, although F4/80 is a marker for macrophages (479), it does not 
differentiate between monocytes, or the M1 and M2 macrophages subsets 
(524). Furthermore, F4/80 can also be expressed by other inflammatory cells 
(479). 
In EDL muscles, the mRNA transcript abundance of Has2, Mcp-1 and Tgfβ1 was 
similar between mdx and mdx-hdf mice, irrespective of age (Figure 5.8 A-C). At 6 
weeks of age, F4/80 gene expression also did not differ between EDL muscles 
from mdx and mdx-hdf mice. However, at 26 weeks of age, F4/80 gene 
expression was significantly lower in EDL muscles from mdx-hdf mice compared 
to mdx littermates (*p = 0.040; Figure 5.8 D). In future studies, this observation 
should be followed up through an assessment of neutrophil, monocyte and 
macrophage infiltration in mdx and mdx-hdf muscle using 
immunohistochemistry or flow cytometry, using additional markers that are 
specific for monocytes and the pro-inflammatory M1 and anti-inflammatory M2 
macrophage subsets.  
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Figure 5.8 The genetic reduction of versican was associated with a 
reduction in F4/80 gene expression in dystrophic EDL muscles at 26 
weeks of age.  
A-C) The mRNA transcript abundance of Has2 (p = 0.773 and p = 
0.790, respectively; T-test), Mcp-1 (p = 0.932 and p = 0.385, 
respectively; T-test) and Tgfβ1 (p = 0.350 and p = 0.839, 
respectively; T-test) did not differ between EDL muscles from 6 or 
26 week old mdx and mdx-hdf mice. D) At 6 weeks of age, the 
genetic reduction of versican did not alter F4/80 mRNA transcript 
abundance in EDL muscles (p = 0.179; T-test). By 26 weeks of age, 
EDL muscles from mdx-hdf mice displayed decreased F4/80 gene 
expression (*p = 0.040; T-test). N = 8 mdx and n = 8 mdx-hdf mice at 
6 weeks of age, and n = 9 mdx and n = 13 mdx-hdf mice at 26 weeks 
of age. 
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5.3.5 Genetic reduction of versican and gene markers of 
regenerative myogenesis in EDL muscles 
Ineffective regenerative myogenesis has an important role in the pathogenesis 
of DMD (285) and versican has been implicated in the proliferation and 
differentiation of satellite cells (17, 20). Hence, the mRNA transcript abundance 
of MyoD and Myogenin was quantified. Similar to previous observations in 
diaphragm muscles from chapter 4 (Figure 4.9 E and G), MyoD and Myogenin 
gene expression were also similar in EDL muscles from mdx and mdx-hdf mice, 
irrespective of age (Figure 5.9 A-B). These observations are suggestive that 
myogenic processes were unaffected in the EDL muscles of mdx-hdf mice.  
 
 
 
 
Figure 5.9 Genetic reduction of versican did not affect the 
expression of gene markers of myogenesis in dystrophic EDL 
muscles.  
A-B) At 6 and 26 weeks of age, mRNA transcript abundance of MyoD 
(p = 0.408 and 0.752, respectively; T-test) and Myogenin (p = 0.355 
and 0.539, respectively; T-test) did not differ between EDL muscles 
from mdx and mdx-hdf mice. N = 8 mdx and n = 8 mdx-hdf mice at 6 
weeks of age and n = 9 mdx, and n = 13 mdx-hdf mice at 26 weeks 
of age. 
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5.3.6 Genetic reduction of versican and ECM gene markers in EDL 
muscles 
During development, a transitional matrix rich in versican is remodelled by ECM 
proteases, including ADAMTS5 (289). Upon maturity, the transitional matrix is 
replaced with a collagen rich mature matrix (382, 528). At 6 and 26 weeks of age, 
the genetic reduction of versican had no effect on the mRNA transcript 
abundance of Adamts5 and Col1a1 in dystrophic EDL muscles (Figure 5.10 A-B).  
 
 
Figure 5.10. The genetic reduction of versican did not effect gene 
markers of ECM remodelling in dystrophic EDL muscles. 
A-B) At 6 and 26 weeks of age, mRNA transcript abundance of 
Adamts5 (p = 0.669 and 0.127, respectively; T-test) and Col1a1 (p = 
0.467 and 0.778, respectively; T-test) did not differ between EDL 
muscles from mdx and mdx-hdf mice. N = 8 mdx and n = 8 mdx-hdf 
mice at 6 weeks of age, and n = 9 mdx and n = 13 mdx-hdf mice at 
26 weeks of age. 
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5.4 Results for slow twitch soleus muscles from mdx and 
mdx-hdf mice at 6 and 26 weeks of age 
5.4.1 The genetic reduction of versican led to decreased versican 
expression in soleus muscles of mdx-hdf mice 
In Chapters 3 -5, versican and versikine immunoreactivity was localised to areas 
of endomysial fibrosis and mononuclear infiltrate in dystrophic diaphragm, and 
fast twitch EDL and TA muscles. However, versican or versikine expression, and 
their localisation, has not yet been characterised in dystrophic slow twitch soleus 
muscles. The characterisation of versican and versikine is interesting, as the 
soleus is a postural hindlimb muscle and is therefore more actively recruited 
than the EDL (535). This constant usage of the soleus muscle is perhaps why 
soleus muscles of mdx mice have such a severe pathology when compared to 
other dystrophic muscles (130). 
In soleus muscles from 6 week old mdx mice, versican immunoreactivity was 
observed around individual muscle fibres, and was localised to regions of 
endomysial fibrosis and mononuclear infiltrate. The intensity of versican staining 
was lower in soleus muscles from 6 and 26 week old mdx-hdf mice compared to 
mdx littermates (Figure 5.11 A-D). The analysis of versican immunoreactivity in 
soleus muscles found that mdx-hdf mice expressed less versican than age 
matched mdx littermates at both 6 and 26 weeks of age in the soleus (*p = 
0.0001 and *p = 0.046, respectively; Figure 5.11 E). However, analysis of V0/V1 
Vcan gene expression did not differ between soleus muscles from mdx and mdx-
hdf-mice, irrespective of age (Figure 5.11 F).   
Although muscle spindles and nerves were evident in dystrophic EDL muscles 
from 26 week old mice, none were observed in 26 week soleus. This is not 
unusual as muscle spindles follow nerves which are randomly dispersed, and 
therefore may not be located within the midbelly sections of soleus muscle 
tested within this Chapter (536).  
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Figure 5.11. V0/V1 versican expression was reduced in soleus 
muscles from 6 and 26 week old mdx-hdf mice.  
Versican is stained red and nuclei are blue (DAPI). A-D) 
Representative images of versican staining in soleus muscles from 6 
and 26 week old mdx and mdx-hdf mice, with reduced versican 
immunoreactivity observed in soleus muscles from mdx-hdf mice at 
both ages. Soleus muscles at 26 weeks contained less versican 
staining than those at 6 weeks of age. E) Quantitation of versican 
immunoreactivity revealed that the mdx-hdf mice contained less 
versican than the soleus muscles of the mdx mice at 6 and 26 weeks 
of age (*p = 0.0001 and *p = 0.046, respectively; T-test). F) V0/V1 
Vcan gene expression did not differ between mdx and mdx-hdf mice 
at both 6 and 26 weeks of age (p = 0.096 and 0.713, respectively; T-
test). White asterisks denote areas of mononuclear infiltrate. To 
assess versican immunoreactivity, n = 7 mdx and n = 8 mdx-hdf mice 
at 6 weeks of age, and n = 8 mdx and n = 11 mdx-hdf mice at 26 
weeks of age. To assess V0/V1 Vcan gene expression, n = 6 mdx and 
an n= 8 mdx-hdf mice at 6 weeks of age, and n = 9 mdx and an n = 
12 mdx-hdf mice at 26 weeks of age. Scale bar = 100 µm.  
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In soleus muscle cross-sections at 6 weeks of age, versikine immunoreactivity 
was localised to the endomysial matrix surrounding muscle fibres, and to regions 
of mononuclear infiltrate and fibrosis, with similar staining intensity in muscles 
from mdx and mdx-hdf mice (Figure 5.12 A-B). By 26 weeks of age, versikine 
immunoreactivity was reduced, with sparse endomysial staining observed in 
soleus muscle cross-sections from mdx and mdx-hdf mice (Figure 5.12 C-D). In 
contrast to EDL muscles (Figure 5.3 C-D), nuclear localisation of versikine was 
absent or very limited in soleus muscles from 26 week old mdx and mdx-hdf 
mice. Analysis of versikine reactivity in soleus muscle cross-section did not differ 
between mdx and mdx-hdf mice at 6 or 26 weeks of age (Figure 5.12 E).    
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Figure 5.12 Versikine immunoreactivity was similar in soleus 
muscles from 6 or 26 week old mdx and mdx-hdf mice.  
Versican is stained red and nuclei are blue (DAPI). A-B) 
Representative images of versikine staining in soleus muscles from 6 
week old mdx and mdx-hdf mice. C-D) Representative images of 
versikine staining in soleus muscles from 26 week old mdx and mdx-
hdf mice. E) Quantitation of versikine immunoreactivity, indicated 
similar expression in mdx and mdx-hdf mice at 6 and 26 weeks of 
age (p = 0.386 and 0.249, respectively; T-test). White asterisks 
denote areas of mononuclear infiltrate, and white arrowheads 
denote nuclei with internalised versikine staining. N = 6 mdx and n = 
7 mdx-hdf mice at 6 weeks of age, and n = 8 mdx and n = 12 mdx-
hdf mice at 26 weeks of age. Scale bar = 100 µm 
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5.4.2 The genetic reduction of versican improved the strength and 
endurance of 6 week soleus muscles of mdx-hdf mice 
Similar to EDL muscles (Table 5.1), the soleus muscle mass, muscle mass ratio 
(BM:MM), optimal muscle length (Lo) and muscle cross sectional area (CSA), did 
not differ between mdx and mdx-hdf mice at 6 or 26 weeks of age (Table 5.2). 
Furthermore, the genetic reduction of versican had modest effects on the twitch 
contractile properties of soleus muscles. At 6 weeks of age, in response to a 1 Hz 
twitch stimulation, the twitch force (Pt) and specific twitch force (sPt) did not 
differ between muscles from mdx and mdx-hdf mice. At 26 weeks of age, Pt was 
similar, however sPt was lower (*p = 0.04; Table 5.2), in soleus muscles from the 
mdx-hdf mice compared to age matched mdx littermates. The time to peak 
tension (TPT), ½ relaxation time (½ RT) and the maximal rate of force 
development (dx/dt) were similar in soleus muscles from mdx and mdx-hdf mice 
at 6 and 26 weeks of age (Table 5.2).   
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Table 5.2. Body weight, soleus mass and ex-vivo twitch contractile properties from mdx and mdx-hdf at 6 and 26 weeks of age 
  6 weeks 26 weeks 
 Units mdx mdx-hdf P value mdx mdx-hdf P value 
Body weight g 22.00  ±0.78 21.75  ±  0.49 0.80 32.32  ±  0.64  32.79  ±  0.58 0.60 
Soleus mass mg 8.74  ±  0.94 8.47  ±  0.64 0.82 14.67  ±  0.88 15.26  ±  0.82 0.63 
BM:MM  0.39  ±  0.03 0.38  ±  0.02 0.85 0.45  ±  0.02 0.46  ±  0.02 0.70 
Lo mm 10.38  ±  0.22 11.51  ±  1.15 0.28 10.99  ±  0.19 10.73  ±  0.22 0.39 
CSA mm2 1.11  ±  0.10 1.06  ±  0.09 0.72 1.77  ±  0.10 1.90  ±  0.11 0.41 
Pt mN 22.91  ±  1.56   25.43  ±  2.05 0.33 50.65  ±  4.74 41.63  ±  4.28 0.18 
sPt kN/m2 21.02  ±  1.13 24.44  ±  3.07 0.26 28.64  ±  2.01 21.99  ±  2.13  0.04 * 
TPT s 0.200  ±  0.021 0.193  ±  0.027 0.83 0.033  ±  0.001 0.032  ±  0.001 0.64 
½ RT s 0.045  ±  0.003 0.052  ±  0.005 0.28 0.054  ±  0.004 0.062  ±  0.006 0.30 
Max dx/dt mN/s 9,764  ±  3,117 12,889  ±  3,941 0.53 2,335  ±  241 1,938  ±  201 0.22 
Data are mean ± S.E. 
* Statistical significance at p < 0.05 for all measurements, analysed by 2-tailed T-test. 
Lo = optimum muscle length; BM:MM = body mass to muscle mass ratio; CSA = cross sectional area; Pt = peak twitch; sPt = 
specific twitch force; TPT = time to peak tension; ½ RT = half relaxation time; Max dx/dt = maximal rate of force development   
N = 11-14 mdx and n = 8-11 mdx-hdf mice at 6 weeks of age, and n = 9 mdx and n = 12 mdx-hdf mice at 26 weeks of age. 
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The ex-vivo maximal force producing capacity, the specific force (sPo), of soleus 
muscles was determined from a force frequency curve (1 to 120 Hz). At 6 weeks 
of age, soleus muscles from mdx-hdf mice were stronger than those from mdx 
littermates, as indicated by an upward shift in the force frequency curve (*p = 
0.001; Figure 5.13 A). However, by 26 weeks of age, this improvement in muscle 
strength was lost and soleus muscles from mdx-hdf mice produced less force 
than those from age matched mdx littermates (*p < 0.001; main effect strain; 2 
way GLM-ANOVA; Figure 5.13 B). 
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Figure 5.13 At 6 and 26 weeks of age, the genetic reduction of 
versican has differential effects on the strength of dystrophic 
soleus muscles. 
A force frequency curve was used to assess the strength of soleus 
muscles from mdx and mdx-hdf mice. A) At 6 weeks of age, soleus 
muscles from mdx-hdf mice produced more force than soleus 
muscles from mdx littermates (*p = 0.001; main effect strain; 2 way 
GLM-ANOVA with factors being frequency and strain). B) By 26 
weeks of age, soleus muscles from mdx-hdf mice produced less 
force than soleus muscles from mdx littermates (*p < 0.001; main 
effect strain; 2 way GLM-ANOVA with factors being frequency and 
strain). N = 11 mdx and n = 8 mdx-hdf mice at 6 weeks of age, and n 
= 9 mdx and n = 12 mdx-hdf mice at 26 weeks of age. 
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Following the force frequency protocol, the fatigability of soleus muscles was 
assessed using 4 m intermittent, submaximal (60 Hz) stimulations, followed by a 
single 60 Hz stimulation at 2, 5 and 10 m post fatigue to assess force recovery. 
During the 4 m of intermittent submaximal stimulation, the soleus muscles from 
the 6 and 26 week old mdx-hdf mice fatigued less (*p = 0.028 and *p = 0.021, 
respectively; Figure 5.14 A-B) when compared to mdx littermates. However, 
irrespective of age, the genetic reduction of versican had no effect upon force 
recovery (Figure 5.14 A-B). As was done for EDL muscles, to gain more insight 
into how the genetic reduction affected the contractile function, muscle 
morphology and gene markers for inflammation, regenerative myogenesis and 
matrix remodelling were then investigated. 
  
195 
 
 
 
 
Figure 5.14 The genetic reduction of versican improved the 
fatigability of dystrophic soleus muscles. 
A-B) During 4 m of intermittent, submaximal (60 Hz) stimulation, at 
both 6 and 26 weeks of age, soleus muscles from mdx-hdf mice 
fatigued less compared to soleus muscles from age matched mdx 
littermates (*p = 0.028 and *p = 0.021, respectively; main effect 
strain; 2-way GLM ANOVA with factors being time and strain). 
However, force recovery at 2, 5 and 10 m post fatigue, was similar in 
soleus muscles from aged matched mdx and mdx-hdf mice (p = 
0.645 and p = 0.494, respectively; 2-way GLM ANOVA with factors 
being time and strain). N = 12 mdx and n = 10 mdx-hdf mice at 6 
weeks of age, and n = 9 mdx and n = 11 mdx-hdf mice at 26 weeks 
of age. 
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5.4.3 The genetic reduction of versican had differential effects on 
the morphology of dystrophic soleus muscles depending upon 
mouse age 
Morphological analysis of H&E stained soleus muscle cross sections was 
undertaken at 6 and 26 weeks of age (Figure 5.15 A-H for representative 
images). At 6 weeks of age, soleus muscles at both ages contained scattered, 
small regions of endomysial fibrosis and mononuclear infiltrate, as well as 
centrally nucleated fibres, indicative of recent damage and regeneration (Figure 
5.15 A-B). At this time point, modest differences in the morphology of soleus 
muscles from mdx and mdx-hdf mice were observed. The number of fibres per 
mm2  tended to be lower in soleus muscles from 6 week old mdx-hdf mice 
compared to age matched mdx littermates (p = 0.055; Figure 5.16 A). Whilst the 
percentage of centrally nucleated fibres was not significantly different in soleus 
muscle cross-sections from 6 week old mdx and mdx-hdf mice (Figure 5.16 B). 
Minimal feret diameter was used to assess muscle fibre cross sectional area, and 
the resultant data were binned in order to better observe differences in fibre 
size. Soleus muscles of mdx-hdf mice tended to have more large fibres (>70 µm 
in diameter; p = 0.062; Figure 5.16 C) than mdx littermates at 6 weeks of age. 
The binned data of fibre size data indicates a rightward shift towards larger 
fibres in the mdx-hdf mice. This is in concordance with a reduction in the number 
of myofibres per mm2 and may contribute to the increase in force production of 
mdx-hdf soleus muscles at 6 weeks of age (Figure 5.13 A), as larger muscle fibres 
produce more force (519). At 6 weeks of age, the percentage of soleus muscle 
cross-section comprised of mononuclear infiltrate and degeneration did not 
differ between mdx and mdx-hdf mice (Figure 5.16 E). Additionally, total serum 
creatine kinase activity, a non-specific marker of muscle damage, also did not 
differ mdx and mdx-hdf mice (Figure 5.16 F).   
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Figure 5.15 Representative H&E images of soleus muscle cross-
sections from 6 and 26 week old mdx and mdx-hdf mice.  
A-B) Representative H&E images from soleus muscle cross-sections 
from 6 week old mdx and mdx-hdf mice containing undamaged 
fibres, recently regenerated centrally nucleated fibres, occasional 
necrotic fibres and regions of mononuclear infiltrate and 
endomysial fibrosis. C-H) Representative H&E images from 26 week 
old mdx and mdx-hdf mice depicting the varying severity of 
dystrophic pathology. Specifically, C-D) depicts muscle cross-
sections with a moderate dystrophic pathology; specifically, intact 
undamaged muscle fibres, centrally nucleated muscles fibres, and 
expansion of endomysial fibrosis and mononuclear infiltrate. E-F) 
Depicts soleus muscle cross-sections from mdx and mdx-hdf mice 
with a more severe dystrophic pathology; including fibres containing 
large internalised holes, degenerating fibres, large areas of ghost 
fibres (empty spaces surrounding by basement membrane) and 
mononuclear infiltrate. While G-H) shows soleus muscle cross-
sections from mdx and mdx-hdf mice with the most severe 
dystrophic pathology, including extensive degeneration and 
mononuclear infiltrate and a further increase in ghost fibres. Note 
that a few intact undamaged and centrally nucleated fibres are still 
evident. Black arrows denote degenerating fibres, and black 
arrowheads denote ghost fibres. Scale bars = 100 µm. 
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Figure 5.16 H&E analysis of the 6 and 26 week mdx and mdx-hdf 
soleus.  
A) The mdx-hdf mice had a trend for decreased fibre numbers at 6 
weeks of age, whereas fibre numbers remained similar at 26 weeks, 
when compared to mdx littermates (p = 0.055 and p = 0.770, 
respectively; T-test). B) At 6 weeks of age, the percentage of 
centrally nucleated fibres did not significantly differ between soleus 
muscle cross-sections from mdx and mdx-hdf mice (p = 0.869; T-
test). C) Analysis of minimal feret diameter at 6 weeks of age 
revealed that soleus muscle cross-sections from mdx-hdf mice 
tended to an increase in the percentage of large muscle fibres  >70 
µm in diameter compared to soleus muscle cross-sections from mdx 
littermates (T-test; p = 0.062). D) Analysis of minimal feret diameter 
at 26 week of age, revealed a shift towards a reduction in myofibre 
size in soleus muscles from mdx-hdf mice. Specifically, soleus 
muscles cross-sections from mdx-hdf mice had a greater percentage 
of small myofibres between 10-19.99 µm and 30-39.99 µm in 
diameter (*p = 0.023 and *p = 0.023, respectively; T-test), and fewer 
large myofibres between 60-69.99µm and >70µm in diameter (*p = 
0.022 and *p = 0.006, respectively; T-test). E) The percentage area 
of soleus muscle cross-section comprised of mononuclear infiltrate 
and degeneration did not differ between mdx and mdx-hdf mice at 
6 weeks of age (p = 0.753). Whilst, soleus muscle cross-sections 
from the 26 week old mdx-hdf contained significantly more 
mononuclear infiltrate and degeneration (*p = 0.018; T-test). F) 
Total serum creatine kinase activity, a non-specific marker of muscle 
damage, was similar in mdx and mdx-hdf mice irrespective of age (p 
= 0.513 and p = 0.598, respectively; T-test). To assess soleus muscle 
morphology, n = 8 mdx and n = 9 mdx-hdf mice at 6 weeks of age, 
and n = 9 mdx and n = 13 mdx-hdf mice at 26 weeks of age. To 
assess total serum creatine kinase activity, n = 8 mdx and n = 6 mdx-
hdf mice at 6 weeks of age, and n = 8 mdx and n = 9 mdx-hdf at 26 
weeks of age. 
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By 26 weeks of age, soleus muscles from mdx and mdx-hdf mice had undergone 
morphological changes of varying severity, indicative of increased degeneration 
and a more severe dystrophic pathology. Therefore, three representative muscle 
cross-sections from three different mdx and mdx-hdf mice were chosen to help 
depict the range of dystrophic pathology in the 26 week soleus (Figure 5.15 C-H). 
All mdx and mdx-hdf soleus sections at 26 weeks contained an increase in 
mononuclear infiltrate and endomysial fibrosis and muscle fibres of variable size 
and morphology, ranging from undamaged fibres, centrally nucleated fibres, 
fibres with centrally internalised holes, and fibres that were undergoing 
degeneration and necrosis.  
Soleus muscle fibres were clustered together in groups separated by multiple 
gaps which appear to contain mononuclear infiltrate and remnants of ECM. It 
appears that fibres with a large internal hole were in the early stages of 
degeneration, and when the fibres are completely degraded, leave behind empty 
areas surrounded by ECM. These empty spaces are commonly called ghost fibres 
(537). Soleus muscles from 26 week old mdx and mdx-hdf mice were the only 
muscle type examined in this thesis to exhibit this morphology of internalised 
myofibre holes and the ghost fibres between groups of myofibres. This 
morphological phenotype is unlikely to be caused by freezer damage. Rather, 
these ghost fibres are formed after a previously occupying fibre has been 
removed, leaving behind a structural hollow matrix ‘tube’, which is not 
degraded, and thereby remains structurally intact (537).  
At 26 weeks of age, the number of myofibres per mm2 was similar in soleus 
muscle cross-sections from mdx and mdx-hdf mice (Figure 5.16 A). In contrast to 
soleus muscles from 6 week old mdx-hdf mice, where myofibre size tended to be 
increased compared to mdx litters (Figure 5.16 C), by 26 weeks of age soleus 
muscles from mdx-hdf mice had a noticeable shift towards a reduction in 
myofibre size when compared to mdx littermates (Figure 5.16 D). Specifically, 
soleus muscle cross-sections from mdx-hdf mice had a greater percentage of 
small sized fibres between 10-19.99 µm and 30-39.99 µm in diameter (*p = 
0.023 and *p = 0.023, respectively; Figure 5.16 D), and fewer large fibres 
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between 60-69.99 µm and >70 µm in diameter (*p = 0.022 and *p = 0.006, 
respectively; Figure 5.16 D). Furthermore, soleus muscle cross-sections from 26 
week old mdx-hdf had a greater percentage of mononuclear infiltrate and 
degeneration compared to age matched littermates (*p = 0.018; Figure 5.16 E). 
The shift in myofibre size towards more small fibres and fewer large fibres, along 
with the increase in mononuclear infiltrate and degeneration, likely accounts for 
the reduced force output of soleus muscles from 26 week old mdx-hdf mice 
(refer to Figure 5.13 B). At 26 weeks of age, and as observed in 6 week old mice, 
the genetic reduction of versican had no effect on total serum creatine kinase 
activity (Figure 5.16 F). This assessment of soleus muscle morphology was 
supported by analysis of gene markers for inflammation, regenerative 
myogenesis and ECM remodelling.  
5.4.4 Genetic reduction of versican and gene markers of 
inflammation in soleus muscles 
In order to gain insight as to how the genetic reduction of versican might affect 
inflammation in the slow twitch soleus muscles, the mRNA transcript abundance 
of Has2, Mcp-1, Tgfβ1 and F4/80 were quantified using RT-PCR. As described in 
section 5.3.4 of this chapter, all of these genes can be linked to inflammation, 
either directly binding or attracting inflammatory cells, or through the 
modulation of inflammatory processes. The mRNA transcript abundance for 
Has2, Mcp-1, Tgfβ1 and F4/80 were all similar between mdx and mdx-hdf mice 
at 6 and 26 weeks of age (Figure 5.17 A-D). This was somewhat surprising given 
the increase in mononuclear infiltrate and degeneration observed in soleus 
muscle cross-sections from 26 week old mdx-hdf mice. Therefore, given these 
results, it would be beneficial to confirm the gene expression data via an 
assessment of monocyte, pro-inflammatory M1 and anti-inflammatory M2 
macrophage infiltration in mdx and mdx-hdf muscle using 
immunohistochemistry or flow cytometry. 
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Figure 5.17 Genetic reduction of versican did not affect the 
expression of gene markers of inflammation in dystrophic soleus 
muscles.  
At 6 and 26 weeks of age, soleus muscles from mdx and mdx-hdf 
mice did not differ in the mRNA transcript abundance of A) Has2 (p 
= 0.814 and 0.303, respectively; T-test); B) Mcp-1 (p = 0.166 and 
0.545, respectively; T-test); C) Tgfβ1 (p = 0.468 and 0.110, 
respectively; T-test); and D) F4/80 (p = 0.521 and 0.526, 
respectively; T-test). N = 6 mdx and n = 8 mdx-hdf mice at 6 weeks 
of age, and n = 9 mdx and n = 12 mdx-hdf at 26 weeks of age. 
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5.4.5 Genetic reduction of versican and gene markers of 
regenerative myogenesis in soleus muscles 
As previously described in section 5.3.5 of this chapter, regenerative myogenesis 
has a large role in DMD pathology. Similar to observations in dystrophic EDL 
muscles (Figure 5.9 A-B), MyoD and Myogenin gene expression did not differ 
between soleus muscles from mdx and mdx-hdf mice, irrespective of age (Figure 
5.18 A-B). 
 
 
Figure 5.18 Genetic reduction of versican did not affect the 
expression of gene markers of myogenesis in dystrophic soleus 
muscles.  
At 6 and 26 weeks of age, soleus muscles from mdx and mdx-hdf 
mice did not differ in the mRNA transcript abundance of A) MyoD (p 
= 0.908 and 0.432, respectively; T-test) and B) Myogenin (p = 0.719 
and 0.530, respectively; T-test). N = 6 mdx and n = 8 mdx-hdf mice 
at 6 weeks of age, and n = 9 mdx and n = 12 mdx-hdf at 26 weeks of 
age. 
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5.4.6 Genetic reduction of versican and gene markers of ECM 
remodelling in the soleus muscles 
The genetic reduction of versican no differences in either Adamts5 or 
collagen1a1 gene expression in mdx or mdx-hdf mice at 6 or 26 weeks of age 
(Figure 5.19 A-B). Although, it is worth noting that in line with the increase in 
dystrophic pathology, mRNA transcript abundance of collagen1a1 was increased 
in 26 weeks soleus compared to those at 6 weeks. Similar to dystrophic EDL 
muscles, these results do not consider basement membrane proteins, therefore 
more detailed biochemical investigations into the ECM should be undertaken. 
This is especially important given the differences in the percentage of 
mononuclear infiltrate between soleus muscles from 26 week old mdx and mdx-
hdf mice (Figure 5.16 E).  
 
 
Figure 5.19 Genetic reduction of versican did not effect ECM 
markers in dystrophic soleus muscles. 
At 6 and 26 weeks of age, soleus muscles from mdx and mdx-hdf 
mice did not differ in the mRNA transcript abundance of A) Adamts5 
(p = 0.790 and 0.380, respectively; T-test) and B) Col1a1 (p = 0.981 
and 0.212, respectively; T-test). N = 6 mdx and n = 8 mdx-hdf mice 
at 6 weeks of age, and n = 9 mdx and n = 12 mdx-hdf at 26 weeks of 
age. 
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5.5 Discussion 
DMD is characterised by skeletal muscle degeneration concurrent with the 
progressive deposition of extracellular matrix proteins. Expansion of the 
endomysial matrix is observed in patients with DMD as early as 2.5 weeks of age 
(94) and precedes any overt degenerative or regenerative changes. Fibrosis in 
dystrophic muscles is comprised of proteins from the interstitial and basement 
membrane matrices, such as collagen 1, collagen IV and fibronectin (119, 221); 
as well as transitional matrix proteins, with versican being overexpressed in DMD 
and therefore of particular interest (90, 465). From Chapter 3 of this thesis, 
versican expression was found to be downregulated by dexamethasone (465), 
significant as glucocorticoids are the only treatment with clinical efficiency in 
DMD. Furthermore, the breeding of female mdx mice with male hdf mice 
produced a novel strain of a dystrophic mdx-hdf pups with reduced versican. This 
genetic reduction of versican was associated with improved strength and 
endurance of mdx-hdf mouse diaphragms (Chapter 4), the muscle group with the 
most similar pathology to DMD (125, 454). Together, these data are suggestive 
that versican plays a role in the pathology of DMD. 
The skeletal muscles of patients with DMD are subjected to the stress of 
dystrophin deficiency in addition to muscle growth, a process in which muscle 
fibres increase in length and cross-sectional area (538). The initial study on the 
effects of genetically reduced versican on diaphragm muscle function did not 
take into account the potentially confounding factors of postnatal growth and 
fibre type when investigating the potential benefits of versican reduction in 
dystrophic muscles. Hence, this Chapter describes the functional benefits of 
genetically reduced versican in fast twitch EDL and slow twitch soleus muscles, 
which were more evident in 6 week compared to 26 week old mdx mice. Similar 
to the diaphragm in Chapter 4, in soleus muscles from young mdx mice, the 
genetic reduction of versican was associated with improved ex-vivo strength and 
endurance, whilst only endurance was improved in EDL muscles. This greater 
improvement in contractile function in 6 week mdx-hdf mice compared to 26 
week mdx-hdf mice may be mediated by age related differences in versican 
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expression. These findings highlight the dynamic nature of the dystrophic ECM 
and the importance of considering age and postnatal growth in pre-clinical 
studies investigating strategies that target aberrant synthesis and remodelling in 
dystrophy.  
Immunohistochemical staining for versican and versikine was used to assess 
versican synthesis and remodelling in EDL and soleus muscles from mdx and 
mdx-hdf mice, and to confirm the efficacy of the versican reduction in the 
muscles from mdx-hdf mice. In fast twitch EDL and slow twitch soleus muscles, 
versikine immunoreactivity was greater at 6 weeks compared to 26 weeks of 
age. Furthermore, V0/V1 versican immunoreactivity was also greater in soleus 
muscles at 6 weeks of age, indicative of fibre type differences in versican 
expression. At 6 weeks of age, versikine immunoreactivity was localised to the 
endomysium surrounding muscle fibres and to regions of mononuclear infiltrate, 
comprised of satellite cells, inflammatory cells and fibroblasts. These hindlimb 
muscles are also likely to be completing the regenerative process following the 
acute bout of degeneration and regeneration at approximately 3 weeks of age 
(126). This high level of versikine staining highlights the biological relevance of 
versican remodelling to growth and repair in dystrophic muscles. Given the 
improvements in EDL and soleus muscle ex-vivo contractile function in 6 week 
old mice, and the difference in versican and versikine expression, it is likely that 
the remodelling of the endomysial matrix is quite different in these two hindlimb 
muscles. Aside from a well characterised increase in collagen deposition in 
patients and mdx mice (119, 221), the effects of postnatal growth and 
differences in fibre type on the composition and remodelling of transitional 
matrix proteins in dystrophic muscles has not been well described. Although, the 
versicanase ADAMTS5, which is implicated in versican remodelling during 
myogenesis (17), is increased in muscles of mdx mice (423). 
As observed in dystrophic diaphragm and TA muscles in Chapters 3 and 4, 
nuclear localisation of versikine was observed in dystrophic EDL muscles. This 
observation was associated with centralised nuclei of recently regenerated 
myofibres and nuclei of cells localised to the endomysium, which could include 
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inflammatory cells, fibroblasts and muscle precursor cells. The nuclear 
localisation of versikine was especially pronounced in EDL muscles from 26 week 
old mdx and mdx-hdf mice. It has previously been suggested that versican may 
play a role in mitotic spindle organisation during cell proliferation (336), however 
careful reading of the methods used revealed that the antibody used for the 
study was specific for versikine and was the exact same antibody used within this 
thesis. Nuclear localisation of versikine was very limited in dystrophic soleus 
muscles irrespective of age, an interesting observation given the more severe 
pathology of soleus compared to EDL muscles at 26 weeks of age. Indeed, the 
soleus is one of the most affected muscles in mdx mice (130). Furthermore, 
these differences in the nuclear localisation of versikine between EDL and soleus 
further supports the hypothesis that the fibres and their matrices are quite 
different between fast and slow twitch dystrophic muscles.    
An additional novel observation was the strong versican, and weak versikine, 
immunoreactivity in muscle spindles in EDL muscles from 26 week old mdx mice. 
Located parallel to muscle fibres, muscle spindles are sensory receptors that 
provide information about muscle length to the central nervous system, 
ultimately preventing the muscle from overstretching (536, 539). They can 
contain anywhere between 2-10 intrafusal muscle fibres which are surrounded 
by a viscous fluid, with the entirety enclosed within a capsule comprised of 
connective tissue (536, 540). The capsule of muscle spindles contains 
components of the transitional matrix, specifically hyaluronan (435), and this 
Chapter provides the first known instance of both versican and versikine being 
present within the capsule, and also surrounding the intrafusal muscle fibres. 
During the advancement of DMD pathology, although fibres within the muscle 
undergo degeneration and are eventually lost, the muscle spindles and their 
intrafusal fibres are structurally preserved, although are enclosed by an 
abnormally thickened capsule (541, 542). This preservation may possibly be due 
to having greater regenerative capabilities. Intrafusal muscle fibres have been 
observed to contained desmin (541), a marker for newly regenerated muscle 
fibres (484), along with hyaluronan and versican, transitional matrix proteins 
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which are associated with myogenesis and regeneration (17, 435). Perhaps the 
presence of hyaluronan and versican may provide a permissive extracellular 
environment for muscle spindle regeneration. As hyaluronan was present in 
muscle spindles of wild type mice (435), it would be beneficial, therefore, to 
assess versican and versikine expression in muscle spindles from a wild type 
mouse to determine whether the upregulation of versican is inherent to muscle 
spindles, or is indeed part of the dystrophic pathology. 
The results indicate that in dystrophic hindlimb muscles from mdx mice, age and 
fibre type can all differentially affect versican synthesis and remodelling. This 
was especially apparent when versican and versikine immunoreactivity was 
quantified in EDL and soleus muscle cross-sections from mdx and mdx-hdf mice 
to confirm the genetic knock-down of versican. At 6 and 26 weeks of age, 
versikine immunoreactivity was lower in EDL muscles from mdx-hdf mice 
compared to age matched mdx littermates, whereas versican immunoreactivity 
did not differ. Whereas, in soleus muscles from 6 and 26 week old mice, versican 
immunoreactivity was lower in mdx-hdf mice compared to age matched mdx 
littermates, however versikine was not. This mirrors findings of reduced 
versican, but not versikine, immunoreactivity in diaphragm muscles from 21 
week old mdx mice (Chapter 4). A reduction in either V0/V1 versican or versikine 
immunoreactivity is indicative of a successful genetic reduction of versican at the 
protein level in mdx-hdf mice. The reduction of versikine, rather than full length 
versican, in fast twitch EDL compared to slow twitch soleus or diaphragm 
muscles indicates fibre type differences in versican remodelling in mdx mice, and 
as such, the expression of ADAMTS versicanases should be further investigated 
in these muscles. Given versican and versikine have been implicated in regulating 
cellular processes all relevant to DMD pathology, the observations detailed 
within this chapter highlights the need to consider synthesis and remodelling 
when targeting versican to ameliorate the pathology of dystrophic muscles. It 
should be noted that versikine itself is also likely further degraded, as seen 
through its clearance between E13.5 and 3 weeks of age in wild type mice (17), 
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although the pathophysiological significance of this process has not yet been 
well described. 
Given that age and fibre type modulated versican synthesis and remodelling in 
dystrophic hindlimb muscles, it is not surprising that the genetic reduction of 
versican had differential effects on the contractile function of dystrophic 
hindlimb muscles from 6 or 26 week old mdx mice. At 6 weeks of age, the 
genetic reduction of versican attenuated the fatigability and improved the force 
recovery of isolated EDL muscles following 4 m of intermittent, submaximal 
stimulation. However, this improvement in EDL muscle endurance was lost by 26 
weeks of age. This was in contrast to observations in the 21 week old mdx-hdf 
diaphragm muscles, which continued to have improved fatigability and force 
recovery ex-vivo, alongside data from metabolic cages that demonstrated 
increased spontaneous physical activity (Chapter 4). 
Unlike the dystrophic diaphragm muscles in Chapter 4, the genetic reduction of 
versican did not improve the force producing capacity of EDL muscles from 6 or 
26 week old mdx mice. In line with these functional observations is the fact that 
the genetic reduction of versican had minimal effects on muscle morphology. 
The dystrophic pathology of EDL muscles when compared to diaphragm muscles 
or soleus muscles, especially in adult mice, was overall quite modest with 
minimal myofibre degeneration, endomysial fibrosis and mononuclear infiltrate 
observed. The most striking effect of versican reduction is the decrease in F4/80 
gene expression in EDL muscles from 26 week mdx-hdf mice, associated with a 
trending decrease in mononuclear infiltrate and degeneration. These data might 
be indicative of a suppressed inflammation in EDL muscles from mdx-hdf mice, 
and the reduction of versican may therefore impair the differentiation of 
monocytes to macrophages (290). This may be a potential reason why mdx-hdf 
muscle function was similar to that of the mdx mice. Therefore, more detailed 
investigations of monocytes and both pro-inflammatory M1 and anti-
inflammatory M2 macrophage subsets using immunohistochemical techniques 
or flow cytometry, are therefore required to gain further insight on whether 
versican does indeed modulate inflammation in mdx-hdf mice. An excessive 
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inflammatory response can be potentially driven by a dysregulated ECM (285), 
and may contribute to muscle damage and degeneration in DMD. Alternatively, 
attenuating inflammation reduced muscle necrosis and degeneration in mdx 
mice (377, 523). The proportion of centrally nucleated fibres tended to be lower 
in EDL muscles from 26 week old mdx-hdf mice and could therefore be 
associated with a reduction in myofibre damage. To assess myofibre damage 
within EDL muscles, immunohistochemical staining for albumin should be used 
to positively label myofibres sarcolemmal damage (543). 
Myogenesis requires the cleavage of versican in order for myoblasts to fuse 
together (17), however, versican was similar between the mdx and mdx-hdf EDLs 
at 26 weeks. This is in contrast with results from Chapter 3 from glucocorticoid 
treated C2C12 cells which were associated with a reduction in versican and 
hyaluronan and had an increase in myoblast fusion, and hence improved 
regeneration in-vitro. In addition to similar V0/V1 versican, the myogenic genes 
tested, MyoD and Myogenin, also remained similar within the mice. This is 
suggestive that unlike the reduced versican in glucocorticoid treated C2C12 cells, 
a reduction of versican may not influence myogenic properties in the 26 week 
EDL. As myogenesis is a very complex process, containing a range of signalling 
pathways (246), a more in depth study into the mdx and mdx-hdf EDLs is 
required in future studies. This may be achieved through histological or 
immunohistological staining, as well as gene expression covering myogenic 
pathways in order to better understand the regenerative processes that are 
occurring in this muscle.  
Similar to the EDL muscles at 6 weeks of age and diaphragm muscles at 21 weeks 
of age, the genetic reduction of versican was associated with improved 
fatigability ex vivo in soleus muscles from 6 and 26 week old mdx mice. Although, 
this improvement was more modest when compared to EDL and diaphragm 
muscles, and force recovery post fatigue was not affected. At 6 weeks of age, the 
genetic reduction in versican also increased in the strength of dystrophic soleus 
muscles, as indicated by an upward shift in the force frequency curve. 
Contributing to this increase in strength, might be an increase in muscle fibre 
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size, as soleus myofibres from mdx-hdf mice tended to an increase in the 
proportion of large muscle fibres  (>70 µm in diameter) when compared to 
soleus myofibres from mdx littermates. This improvement in strength and slight 
increase in myofibre size was also observed in diaphragm muscles from mdx-hdf 
mice at 21 weeks age. However, by 26 weeks of age, soleus muscles from mdx-
hdf mice produced less force than muscles from age matched mdx littermates. 
The increased mononuclear infiltrate and smaller fibre size are most likely the 
cause of the reduced soleus strength at 26 weeks, as both inflammation (544) 
and small fibre size (545), results in decreased force production. As previously 
discussed, this mononuclear infiltrate is comprised of inflammatory cells, 
satellite cells and fibroblasts. Although no differences were observed for the 
mRNA transcripts of MyoD, Myogenin, F4/80 and Collagen1a1 in the 26 week old 
soleus muscles, given the increase in mononuclear infiltrate, future studies 
would be required to investigate the populations of neutrophils, monocytes, 
macrophages, satellite cells, myoblasts and fibroblasts in soleus muscles from 
the 26 week old mdx and mdx-hdf mice.  
It is generally thought that fast twitch muscle fibres are more susceptible to 
contraction induced injuries than slow twitch muscle fibres (68, 546). It was 
therefore surprising that the 6 week EDL had a lower amount of centrally 
nucleated fibres, and at 26 weeks had less mononuclear infiltrate and 
degeneration, when compared to the soleus at the same ages. Furthermore, 
H&E sections revealed the dystrophic pathology of soleus muscles was indeed 
more severe when compared to the EDL muscles from mdx and mdx-hdf mice at 
26 weeks of age. This was similar to previous findings reporting the soleus of 
mdx mice to be the most damaged hindlimb muscle at 3-4 weeks of age (128), 
during the period of spontaneous degeneration and regeneration (126), and was 
still the most damaged hindlimb muscle at 26 months of age, displaying 
increased fibrosis and mononuclear infiltrate (130). This may be because the 
soleus is a postural muscle and is permanently in use, hence being more highly 
recruited than the EDL (127, 535). 
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Furthermore, the diaphragm is said to be the muscle in mdx mice that most 
closely resembles a limb muscle in the human form of the disease, due to its 
increased fibrosis, degeneration and functional decline (455), however in 
chapter 4, the diaphragms did not have differing severity levels of pathology as 
the soleus muscles did in this chapter. Although the diaphragm is in constant 
use, stated to be one of the most used muscles in sedentary laboratory mice 
(130), the postural soleus muscle also has constant use during ambulation (127, 
535), but may be influenced to work harder by the weight of the mouse. 
Furthermore, it has also been suggested that the severity of dystrophic 
pathology is not directly related to muscle fibre types, given that the diaphragm, 
tongue and soleus muscles are all comprised of differing fibre types, yet all 
exhibit worsened pathology (130). Therefore, perhaps the soleus pathology is 
worsened upon ambulation, leading to an increase in degeneration and an 
apparent disruption of regenerative processes, potentially caused by satellite cell 
depletion (547). 
The H&E stained soleus muscle cross-sections contained extensive regions of 
mononuclear infiltrate, with necrotic and degenerating myofibres observed 
alongside ghost fibres. Ghost fibres are formed when a damaged myofibre 
becomes necrotic and is removed by inflammatory cells, leaving behind the ECM 
which remains structurally intact (537, 548). This allows for the stability of the 
surrounding environment, including other myofibres, blood vessels and nerves 
(537). These hollow tubes of ECM also act as a guide for the migration of satellite 
cells and formation of new myofibres, ensuring their correct orientation within 
the old basement membrane (548, 549). The ECM surrounding the ghost fibres 
did not stain for versican or versikine, nor were any nuclei observed within ghost 
fibres during H&E analysis. As versican is known to be associated with the 
proliferation of satellite cells (20) and myogenesis (17), the results are therefore 
suggestive that the ghost fibre scaffolds may be incompatible for myogenesis or 
that regeneration may potentially be impaired in the 26 week old soleus 
muscles.  
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Indeed, it known that the loss of dystrophin negatively affects satellite cells, 
leading to a dysregulated function and regenerative impairment in mdx mice 
(114). Additionally, satellite cell exhaustion has previously been reported in mdx 
mice, potentially arising through an exhausted supply due to dystrophic 
pathology with ongoing cycles of degeneration and regeneration, or through a 
natural decline with age (547). From the results detailed within this Chapter, it 
can be hypothesised that multiple bouts of degeneration and repair, such as the 
increased amounts of mononuclear degeneration in the 26 week mdx-hdf soleus, 
potentially contribute to the exhaustion of satellite cells within dystrophic 
muscles. Hence, further investigations into the effects of satellite cell 
proliferation in fast and slow twitch muscles, with and without the reduction of 
versican, should be undertaken. This could be achieved through single fibre 
studies in fast and slow twitch muscles of mdx and mdx-hdf mice, by 
immunohistochemically staining single muscle fibres in order to view the 
activation, proliferation, migration and differentiation of the attached satellite 
cells (522). 
Modulating the transitional matrix in mdx mice by genetically reducing versican 
tended to improve the pathology of the 26 week EDL, as seen through the 
trending decrease in mononuclear infiltrate, however it worsened the pathology 
of the 26 week soleus by increasing the amount of mononuclear infiltrate. This 
further highlights the importance of the ECM, being muscle and fibre type 
specific. The downstream effects on muscle structure and function, as well as 
versican synthesis and remodelling, are all modulated by muscle fibre type and 
mouse age, and altogether determine postnatal growth and regenerative 
capacity of skeletal muscle. In hindlimb muscles, the greatest functional benefits 
of versican reduction were observed in the 6 week mdx mice. Specifically, in the 
mdx-hdf mice, the genetic reduction of versican resulted in a modest and 
transient improvement in ex-vivo force producing capacity in slow twitch soleus 
muscles at 6 weeks, but not 26 weeks, of age. The association between versican 
reduction, improved muscle endurance and a shift towards a more oxidative 
whole body metabolism has been a consistent observation of this thesis, 
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although the underlying mechanisms remain to be elucidated. Similar to the 
diaphragm muscles observed in Chapter 4, the genetic reduction of versican also 
did not affect time to peak tension (TPT) or ½ relaxation time (½ RT) in response 
to a single twitch stimulation in EDL and soleus muscles at 6 or 26 weeks of age. 
This is suggestive that a fibre type shift towards a more slower phenotype is less 
likely and perhaps the improvement in ex-vivo endurance was mediated by an 
increase in mitochondrial oxidative capacity. Future studies should therefore 
investigate this hypothesis by using gene expression markers for glucose and 
fatty acid oxidation to gain a better insight into the metabolic properties of the 
mice. Furthermore, the functional significance of these findings should be 
investigated in more detail by using exercise protocols to assess maximal 
exercise capacity and endurance training adaptations (550). In mdx mice treated 
with tranilast, an antiallergic drug, an association between improved endurance 
and a reduction in fibrosis was observed in the diaphragm and TA muscles (551). 
Furthermore, glucocorticoids prolonged ambulation in patients with DMD (552) 
and reduced fibrosis in mdx mice (526), perhaps due to a reduction of versican. 
Indeed, versican is associated with the transition of fibroblasts to myofibroblasts 
(265, 348). Myofibroblasts are constantly stimulated in DMD (107) and hence 
secrete copious amounts of collagens I, III and IV, thereby expanding fibrosis in 
dystrophic muscles (271). The effect of reduced versican upon fibroblasts and 
myofibroblasts will need to be investigated in future studies. This could be 
undertaken by immunohistochemically staining muscle sections with antibodies 
specific for fibroblasts and myofibroblasts. Furthermore, fibrosis would also 
need to be investigate in more detail, and a hydroxyproline assay which allows 
for total collagen content (553) would be beneficial. However as versican is an 
abnormally overexpressed transitional matrix protein in fibrotic muscle of DMD 
patients and mdx mice (90, 465), future studies detailing the composition of the 
fibrotic ECM would also be required. Additionally, it remains unknown as to 
whether fast and slow twitch muscles elicit any fibre type differences in the 
composition of fibrotic tissue. Therefore, future studies would require detailed 
studies involving immunohistochemically stained muscle sections and qRT-PCR 
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techniques, in both fast and slow twitch muscles, in order to investigate reduced 
versican on the composition of fibrotic ECM in differing fibre types. 
Altogether, the results detailed within this Chapter demonstrate significant 
differences in the synthesis and remodelling of a versican-rich transitional matrix 
in fast and slow twitch hindlimb muscles from young 6 week, and adult 26 week 
mdx and mdx-hdf mice. An overview of EDL and soleus data obtained in Chapter 
5 and the associated mechanisms that were hypothesized, can be viewed in 
Figure 5.20 for the EDL, and Figure 5.21 for the soleus. To effectively target 
fibrosis in dystrophy, the transitional matrix, and the factors which modulate its 
synthesis and remodelling, need to be better understood. The data detailed 
within this Chapter has important implications for the design of pre-clinical 
studies that target fibrosis in mouse models of DMD disease treatment, 
highlighting the growing and urgent need to consider age, growth and fibre 
types when designing and administering therapeutics to patients with DMD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20 Overview of Chapter 5 EDL results and possible 
mechanisms.  
This figure summarises the data obtained from the soleus in Chapter 
5 and also outline the possible mechanisms that were hypothesized.  
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Figure 5.21 Overview of Chapter 5 soleus results and possible mechanisms. 
This figure summarises the data obtained from the soleus in Chapter 5 and 
also outline the possible mechanisms that were hypothesized. 
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Chapter 6: Discussion and future directions 
6.1 Research problem 
It has been thirty-one years since dystrophin was identified as the genetic cause 
of DMD (464). There is no cure for the disease, although advancements in 
therapeutics have led to improvements in the quality of life of patients with 
DMD. Medical interventions targeting cardiac (554) and respiratory function 
(555) have increased the life expectancy of patients with DMD, and survival into 
the third decade of life is becoming more common (556, 557). To further 
improve health outcomes for patients with DMD, there is an urgent need for 
more effective therapeutic strategies, which target fibrosis in skeletal muscles 
and the heart. In DMD, a dysregulated ECM is not just a consequence of the 
disease, but actively contributes to skeletal muscle degeneration and loss of 
function (119). Therefore, the ECM should be a target for novel therapeutics. 
Despite intensive research efforts, glucocorticoids remain the only 
pharmacological intervention with clinical efficacy in DMD. Indeed, ambulation is 
prolonged in patients treated with glucocorticoids (552), and fibrosis is 
attenuated (526). However, glucocorticoids are not without significant side 
effects (365, 376), and to reduce these, intermittent administration is used 
(526). In dystrophic muscles from patients with DMD and in mdx mice, 
glucocorticoids attenuate fibrosis (526), enhance regenerative myogenesis (397, 
430) and improve skeletal muscle function (366). A better understanding of 
underlying cellular mechanisms by which glucocorticoids exert their effects upon 
dystrophic muscles, particularly during postnatal growth, should lead to the 
development of more effective therapeutic strategies for DMD.  
6.2 Relevance of versican in DMD 
Chapter 3 of this thesis identified versican as an important downstream target of 
dexamethasone during myogenic differentiation, which builds on previous 
studies describing enhanced myogenesis (397, 430), and in other models, 
pleiotropic effects on the extracellular matrix (123, 373, 375). As expected, 
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treating differentiating C2C12 myoblasts with a low dosage (25 nM or 100 nM) 
dexamethasone enhanced fusion and myotube formation. An important 
contributing mechanism to this enhancement in myogenesis was the decreased 
expression of genes associated with the synthesis of a transitional matrix; in 
particular, V0/V1 versican and Has2, Has2 being a key enzyme in hyaluronan 
synthesis within muscle that synthesises hyaluronan (435). Both hyaluronan and 
versican are removed during myogenesis (17). Furthermore, hyaluronan forms a 
complex with versican, and together are an important part of the transitional 
matrix (73, 74). This transitional matrix is crucial for successful development and 
tissue repair, being secreted into an injured area where it directs cellular 
processes such an inflammation and regeneration. There is significant interest in 
the transitional matrix because of its association with various diseases, such as 
idiopathic pulmonary fibrosis (558) and myocardial infarction (527). The 
transitional matrix is dysregulated in DMD, as indicated by the increased 
expression of versican (90), hyaluronan (420) and tenascin-C (421). As described 
in Chapter 3, versican is also upregulated in DMD, being observed in the TA 
muscle, and to much larger extent, in the more severely affect diaphragm 
muscle (465). In skeletal muscle, the carefully regulated synthesis and 
remodelling of versican is important for the proliferation of satellite cells and 
myogenic differentiation (17, 20). Versican has also been implicated in regulating 
inflammation and fibrosis, by directly binding chemoattractant proteins and 
leukocytes (51, 53), and being associated with the differentiation of monocytes 
into macrophages, and fibroblasts into myofibroblasts (265, 290). These 
observations strengthen the relevance of versican as an ECM target for DMD.  
The signalling pathways that regulate the promoter and expression of versican 
are well known (306, 559). Quite interestingly, some of the pathways that 
modulate the expression of versican are also pathways regulated by 
glucocorticoids, which are the only treatment with clinical relevance for DMD. 
For instance, the canonical wingless and sonic hedgehog pathways are known to 
modulate versican expression (306). Glucocorticoids have been shown to supress 
the canonical wingless pathway in human osteoblast cell cultures (560), and 
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inhibited the sonic hedgehog pathway which led to the inhibition of cerebellar 
growth and proliferation of cerebellar granule neuron precursor cells in 7 day old 
postnatal mice (561). Furthermore, based on in-vitro data from fibroblasts, 
another modulator of versican is TGFβ (346). Glucocorticoids can downregulate 
TGFβ (285), which in turn can then down regulate versican expression. These 
observations are suggestive that some of the signalling pathways that regulate 
versican expression are also modulated by glucocorticoids. This further 
strengthens the relationship between versican and glucocorticoids, a major 
theme of Chapter 3 in this thesis.  
The most common glucocorticoids administered to patients with DMD are 
prednisone, prednisolone and deflazacort (562). There is also increasing interest 
in dissociative glucocorticoids, modified versions created to have fewer side 
effects, yet still retaining all the benefits such as muscle membrane stability and 
reduced inflammation (371). One such dissociative glucocorticoid is VBP15 (377), 
more recently known as vamorolone (563). In mdx mice, vamorolone increased 
muscle strength and reduced inflammation, with a reduced side effect profile 
(377). Vamorolone is currently in phase II clinical trials in human patients with 
DMD (564). 
Given that versican is suppressed by glucocorticoids in-vitro, and is upregulated 
in dystrophic diaphragm and hindlimb muscles, a genetic approach was taken to 
reduce versican expression in mdx mice and to establish its relevance as a target 
in DMD. Specifically, female mdx mice were mated with male hdf mice, which 
have a transgene insertional mutation in the versican gene, to generate F1 male 
mdx and mdx-hdf pups. It should be noted that this breeding has never before 
been undertaken, and the creation of the mdx-hdf mice, a dystrophic mouse 
with reduced versican, represents a new novel strain of dystrophic mice. 
Chapters 4 and 5 of this thesis detailed the characterisation on whole body 
physiology, muscle morphology and contractile function in diaphragm and 
hindlimb muscles from young 6 week, and adult 26 week mdx and mdx-hdf mice.  
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The results in Chapter 3 (12 week diaphragm), Chapter 4 (21 week diaphragm) 
and Chapter 5 5 (6 and 26 week EDL and soleus) all show that versican is 
differentially expressed diaphragm and hindlimb muscles in the mdx and mdx-
hdf muscles at different ages. Of particular note was the expression of versican 
in the 12 week mdx diaphragm, which remained at a similar level of expression 
in the 21 week mdx diaphragm. This was despite an expected worsening of 
pathology and fibrotic progression at an older age (107). Furthermore the mdx 
diaphragm at 12 weeks and the mdx soleus at 6 weeks had similar levels of 
versican. This is of great interest as the soleus was the most damaged hindlimb 
muscle in mdx mice during the period of spontaneous degeneration and 
regeneration, at approximately 3-4 weeks of age (126, 128). As expected, the 21 
week old mdx diaphragm still had the highest amount of versican out of any 
muscle tested. However the 26 week mdx soleus had the lowest amount, which 
was unexpected considering the soleus is most damaged hindlimb muscle at 26 
months of age (130). Also unexpected was the versikine level for the 6 week mdx 
EDL, which was at a much higher level than any muscle tested at any age, 
however, by 26 weeks the levels had reduced to that similar to the 21 week old 
diaphragm. Furthermore, it wasn’t just the levels of versican and versican 
fluctuating between the mdx muscles, but also the levels of versican and 
versikine expressed by the mdx-hdf mice. In the 6 and 26 week EDL, mdx-hdf 
mice were found to have similar levels of versican, with significantly reduced 
versikine expression, however in the 6 week soleus and 21 week diaphragm 
muscles of mdx-hdf mice, the opposite occurred with significantly reduced 
versican and similar expression levels of versikine when compared to the control 
mdx mice. This signifies that the differential expression patterns of both versican 
and versikine in these muscles are highly dependent upon muscle type and age. 
Muscle function was also differentially expressed amongst the different ages and 
muscles tested. The reduced versican in the diaphragm was found to be very 
beneficial, being observed to increase muscle strength, and resistance to fatigue. 
Additionally, the relationship between reduced versican in the hindlimb and 
muscle function appeared to be more complex, however the majority of benefits 
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were observed in the younger 6 week old mice. It was originally hypothesized 
that the reduction of versican would attenuate inflammation and fibrosis, and 
increase regeneration. However, this was proven to be incorrect. When the 
mononuclear infiltrate and collagen gene expression was investigated, neither 
the diaphragm (Chapter 4), nor the 6 or 26 week EDL, or 6 week soleus (Chapter 
5) had differences in inflammation, fibrosis or pathology. However, in the 26 
week soleus however, the mdx-hdf mice had significantly increased mononuclear 
degeneration, yet gene expression markers for MCP-1 and F4/80 remained 
unchanged. This is suggestive that the soleus was undergoing degeneration but 
with possible limited inflammation, however this remains to be tested in future 
studies. In contrast the other hindlimb muscle tested, the 26 week mdx-hdf EDL, 
although only a trending decrease in the mononuclear infiltrate was observed, 
the gene expression of the macrophage marker F4/80 was reduced. 
Furthermore, in Chapter 3, the in-vitro treatment of C2C12 muscle cells with 
glucocorticoids was associated with both the reduction of Vcan and Has2 gene 
expression, and with an increase in myogenesis. Myogenesis was not affected in 
the mdx-hdf EDL or soleus, as no differences in fibre numbers were observed, 
while the gene expression for Vcan and Has2, and the myogenic markers MyoD 
and myogenin, all remained similar in both muscles. However a trend existed in 
the mdx-hdf diaphragm for increased centrally nucleated fibres, an indicator of 
recently regeneration. Additionally, the mdx-hdf diaphragm also had a reduction 
in Vcan and a trending reduction in Has2 gene expression (Chapter 4). This is in 
accordance not only with the findings in Chapter 3, but also with a study which 
found both versican and hyaluronan is cleaved prior to muscle fusion (17). 
Furthermore, the mdx-hdf diaphragm also was similar to the glucocorticoid 
treated C2C12 cells of Chapter 3, as expression of both Hyal2 and Adamts5 
remained similar in both models. Interestingly, unlike the mdx-hdf diaphragm, 
the glucocorticoid treated cell culture model had increased gene expression 
levels of Adamts1. However, a cell culture model is very simple, and does not 
have the complex interplay of processes, such as inflammation and regeneration, 
like a mouse model would have. This may account for the differences observed. 
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The observations that versican and versikine were differentially expressed in the 
diaphragm, EDL and soleus, and at different ages suggested that the matrix was 
mostly likely fibre type specific in the different muscles tested. However, many 
of the conclusions in this thesis were limited by the experimental procedures 
performed, and therefore more comprehensive studies are required to fully 
elucidate the effects that genetically reduced versican may have on dystrophic 
pathology, and what differences may exist between the mechanism or signalling 
pathways of reduced versican and glucocorticoids. Hence there are a number of 
limitations in the next section that are listed accordingly for this thesis.  
6.3 Limitations of this thesis 
6.3.1 Limitation of chapter 3 
A limitation for Chapter 3 is that only C2C12 mouse myoblasts were used for the 
experiments with dexamethasone. It would be interesting to use a DMD cell line, 
which would have been valuable in order to gain an understating of how 
glucocorticoids worked in dystrophic cells, such as myoblasts and fibroblasts. It 
also would have allowed the identification of any dystrophic specific results.  
Another limitation of Chapter 3 is that glucocorticoid induced reduction of 
versican was only shown in an in-vitro cell culture model using C2C12 myoblasts. 
This cell culture model recapitulates signalling pathways relevant to myogenesis, 
but does not model the complexities of muscle repair in dystrophic muscles in-
vivo, where there is a complex interplay between cell populations involved in 
inflammatory, myogenic and fibrotic processes. Hence future experiments 
involving mdx mice being treated with dexamethasone would be required to see 
if it does indeed reduce versican in-vivo. Additionally mdx-hdf mice could also be 
treated to elucidate if there would be any effects of glucocorticoid action even 
with reduced versican. These experimental mouse models would help better 
understand the role of versican and glucocorticoids in dystrophy. 
6.3.2 Limitations of chapters 4 and 5 
There are a number of limitations that can be listed for Chapter 4 and 5 of this 
thesis. Versican is a transitional matrix protein with low levels expressed in wild 
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type mice, however versican becomes largely upregulated in dystrophic mdx 
mice (Chapter 3). In this thesis, hdf mice were bred with mdx mice to produce 
dystrophic offspring with reduced versican, which were characterised in Chapter 
4 and 5 of this thesis. A limitation therefore arises in that no C57BL/10 wild type 
mice, the background strain of the mdx mice, or any C57BL/6 wild type mice, the 
background strain for the hdf mice, were utilised in these chapters. The inclusion 
of the C57BL/10 wild type mice would have allowed for a more comprehensive 
analysis, allowing for a comparison on how effective the reduced versican was at 
restoring normal function when compared to mdx mice. Additionally by including 
the C57BL/6 wild type mice into the study, it would have allowed a comparison 
to be made between all strains, allowing for the determination of what effects 
were specific to genetically reduced versican in the dystrophic mdx phenotype, 
and which were specific to the hdf phenotype.  
Furthermore, as the mdx-hdf mice have never before been bred, and as 
inflammation and regeneration were not thoroughly investigated in this thesis, it 
represents a lost opportunity to characterise these processes during known 
points in DMD where degeneration and regeneration occur. Hence, future 
studies should be performed on mdx and mdx-hdf mice during the known bout 
of spontaneous degeneration at 4 weeks of age, where inflammation and 
regeneration could be thoroughly investigated. This would determine whether 
or not genetically reduced versican could affect the pathology of DMD. 
Additionally, regarding the heart data in Chapter 4, it remains unclear if the 
effects upon the increased left ventricle in the mdx-hdf mice was due to the 
reduced versican expression in the dystrophic heart, or if it was due to possible 
developmental hearts defects in the heterozygous hdf mice, as versican is crucial 
for heart development. A limitation here is that although hearts were collected, 
they were not examined further than what was documented in this chapter, 
hence the morphological differences remain unknown. 
An unexpected yet exciting result was that the reduction of versican was found 
to affect fatigability. Hence there is a need to better understand the endurance 
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phenotype by investigating the fibre types and mitochondrial markers. Chapter 4 
studied only focused upon type IIa fibres, which found no differences and hence 
highlights the importance of having a complete and thorough analysis of fibre 
types in not only the mdx and mdx-hdf diaphragm, but also in the EDL and soleus 
muscles. The muscle and age specific differences could also have been analysed 
more deeply by including studies upon mitochondria, and is hence another 
limitation for Chapters 4 and 5 of this thesis. Here it could have been beneficial 
to include gene expression analyses, or perform an oxidative stain, to observe 
any mitochondrial defects in the mdx and mdx-hdf mice. This would have 
complimented the fibre type staining, and together may have explained the 
changes in muscle strength and function of the various muscles at 6 and 26 
weeks of age. 
Another limitation for these chapters is that there are no specific stains for 
fibrosis in the mdx or mdx-hdf muscles. In chapter 4, WGA was used to view the 
area of fibrosis, which was quantified. However WGA is known to stain the cell 
membrane and is not a specific fibrotic marker, hence this is a limitation for 
fibrotic quantification. Another limitation is that no specific staining or analysis 
for fibrosis was undertaken for the 6 or 26 week old EDL or soleus muscles. It 
would have been beneficial to include specific fibrotic staining, such as Van 
Geisons stain, or even performed a hydroxyproline assay, in order to accurately 
investigate fibrotic content in all of the muscles tested in Chapters 4 and 5. 
6.4 Key findings and future directions 
Overall, this thesis found that the genetic reduction of versican had various 
differential effects on the 3 muscles types tested in this theses, namely the 
diaphragm, EDL and soleus muscles. The reduction of versican resulted in a 
major improvement in the diaphragm, whereas the majority of benefits in the 
hindlimb were observed in the young and growing 6 week mice. Interestingly, 
the improvements seen in these mice was found not to be due to the original 
hypotheses that reduced versican would attenuate inflammation, fibrosis and 
improve myogenesis. Instead as the experiments in this thesis progressed, the 
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originally proposed hypothesis were proven wrong and new mechanisms of 
action were proposed along with suggested experimental procedures and future 
directions. 
At 26 weeks of age, the genetic reduction of versican was overall beneficial. 
Indeed, mdx-hdf mice had increased spontaneous physical activity when 
compared to their mdx littermates. This was associated with a shift towards a 
more oxidative, whole body metabolism, along with increased diaphragm muscle 
strength and endurance ex-vivo. The diaphragm is one of the most severely 
affected muscle with regards to deficits in contractile function and expansion of 
the extracellular matrix (125). Follow-up studies should investigate whether 
these changes in contractile function and whole body metabolism in the 
diaphragm lead to an increase in exercise capacity and endurance in the mdx 
mice. The cellular mechanisms by which whole body metabolism shifted to more 
oxidative phenotype, as observed by the decrease in RER during the day and 
night periods, shown in Chapter 4, also requires further investigation. 
Specifically, mitochondria would need to be isolated and tested with multiple 
functional assays that measure the rate of ATP production, mitochondrial yield 
and size (473), followed by analyses using gene and protein markers of oxidative 
metabolism.  
The fact that the downregulation of a single transitional matrix protein was able 
to modulate spontaneous physical activity, whole body metabolism, and 
diaphragm contractile function, is a novel and important finding. It builds upon 
previous studies in mdx mice which targeted fibrosis in general, rather than a 
single ECM protein, and which also found improved muscle endurance and 
metabolism (551, 565). It’s worth remembering, that pathology of dystrophic 
muscles is also associated with profound metabolic abnormalities (473), and that 
the association between the ECM and mitochondria is gaining interest (517, 
566).  
Growth in skeletal muscle is associated with extensive ECM remodelling. 
Furthermore, there are differences in the matrix structure of fast and slow 
227 
 
twitch fibres. The fast twitch fibres contain more laminin (11). However, the slow 
twitch fibres contain more dystrophin, utrophin and collagen IV in their matrices 
(11, 64, 65). Therefore, Chapter 5 characterised the effects of reduced versican 
on the contractile function and pathology of fast twitch EDL muscles and slow 
twitch soleus muscles in young (6 week) and adult (26 week) mdx mice. 
At 6 weeks of age, the genetic reduction of versican increased the strength and 
endurance of soleus muscles ex-vivo. However, this improvement in strength 
was transient, as by 26 weeks of age, soleus muscles from mdx-hdf mice 
produced less force than those from age matched mdx littermates. Interestingly, 
the genetic reduction of versican in EDL muscles was associated with a transient 
improvement in muscle endurance at 6 weeks age. In contrast to observations in 
slow twitch soleus and diaphragm muscles, the ex-vivo strength did not differ 
between EDL muscles of mdx and mdx-hdf mice. 
The functional benefits of versican appear to be quite complex. Versican was 
found to be at higher levels in the 12 week old mdx diaphragm than wild type 
mice (Chapter 3). However, in an interestingly and unexpected observation, the 
21 week old mice with reduced versican (Chapter 4) had similar versican levels to 
those of the 12 week diaphragms (Chapter 3), despite the age difference and 
despite the worsening progressive fibrotic pathology at a later age (107). 
Furthermore, the reduction of versican becomes much more complicated in the 
hindlimb muscles, which appear to contain less fibrosis than that of the 
diaphragm. Interestingly through, the pathology of the soleus was found to be 
much more affected than the EDL. This could be because the soleus is a postural 
muscle and is hence used more often than the EDL muscle. This is highly 
suggestive that there are clear fibre type differences in DMD, although this is 
currently not well recognised in the literature. Furthermore, this observation is 
suggestive that any fibrotic therapies will most likely effect muscles differently, 
and therefore fibre type should be considered upon the administration of 
therapeutic treatments.  
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This increases the relevance of the model to DMD, where fibrosis is more 
extensive in the diaphragm than in hindlimb muscles from mdx mice (125). 
However, these conclusions need to be tempered with caution, as in soleus 
muscles from 26 week old mdx mice, versican reduction was associated with a 
loss of muscle strength. The underlying cellular mechanisms remain to be 
determined, but likely involve downstream effects on satellite cells and 
infiltrating inflammatory cells. Nonetheless, the findings from Chapter 5 highlight 
the importance of considering the effects of postnatal growth, fibre type, ECM 
expansion, and remodelling when testing therapeutic strategies to ameliorate 
fibrosis in dystrophic muscles. Future studies are required to investigate the 
cellular mechanism by which versican reduction affects regenerative 
myogenesis, inflammation and metabolism, to produce the observed functional 
phenotype in-vivo.  
Additionally, the lack of comprehensive fibre typing and no specific measure of 
fibrosis are obvious limitations and hence will be required in future experiments 
to better characterise the mdx and mdx-hdf diaphragm, EDL and soleus muscles 
tested within this thesis. Additional fibre type staining for all MyHC variants are 
hence required. A specific marker for fibrotic tissue, such as a hydroxyproline 
assay, as per TREAT-NMD guidelines (SOP ID number:  DMD_M.1.2.006) would 
also be necessary. Once the fibre types and fibrosis content are characterised, a 
better understanding can be had of the impact of reduced versican on the 
different muscle types tested, and can also be used to further interpret the data 
obtained in chapters 4 and 5 of this thesis, particularly upon the alterations in 
muscle strength and resistance in fatigue. 
Exercise interventions studies should be also undertaken to assess the effects of 
versican reduction on endurance and aerobic capacity. Exercise also results in 
the exacerbation of dystrophic muscle damage and degeneration (550), and 
hence can be used as a stimulus to investigate the effects of reduced versican 
upon inflammation and regeneration in mdx mice. The resultant inflammatory 
response within the muscle could be characterised through flow cytometry or 
immunohistochemical staining of inflammatory cells such as neutrophils, 
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monocytes and macrophages. Additionally, macrophages may be studied in 
further detail by investigating the populations of pro-inflammatory M1 and the 
anti-inflammatory, regenerative M2 a-c subsets.  
Similar experimental techniques could also be used to assess the effects of 
versican reduction upon myogenic processes, such as satellite cell activation, 
along with myoblast proliferation and differentiation. Perhaps the decrease in 
soleus muscle strength was mediated by a decrease in the proliferative potential 
of satellite cells, through a reduction in versican (20). Indeed, this theory is 
supported by in-vitro observations from Chapter 3, where glucocorticoid treated 
C2C12 cells were associated with a reduction in versican expression and 
increased cell fusion, and hence resulted in increased regeneration. An alternate 
approach to assess the effects of versican reduction on the proliferation and 
differentiation of satellite cells would be single fibre cell culture. For this, single 
fibres would need to be carefully harvested from muscles of interest and placed 
into culture. As satellite cells remain under the basement membrane, this would 
allow for myogenic processes such as satellite cell activation, proliferation, 
migration and differentiation, to be observed by immunohistochemically staining 
and live imaging the cells (522). 
Furthermore, the question arises whether it the effects of versican in this thesis 
are due to the entire versican protein, the core protein, or the presence or 
cleavage of the GAG regions. Any change in the form of the versican protein, 
such as a reduction in expression, an increase in GAG chain size or sulfation 
pattern could result in the modification of inflammation, myogenesis or ECM 
remodelling pathways. Hence it would be of great interest to investigate the 
synthesis, post-translation modifications and remodelling of versican (formation 
of versikine or cleavage of GAG chains) in the mdx and mdx-hdf mice in order to 
see if dystrophy, or the decrease of versican would change the form of the 
versican protein and greater results similar to what is described in this thesis. 
This would also help to further determine the role of versican in different muscle 
types and ages in a dystrophic model. 
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In addition, as the reduction in versican was only characterised in a dystrophic 
model in this thesis, it would therefore be beneficial to breed female C57BL/6 
wild type mice with male hdf mice to generate normal healthy male mice with 
genetically reduced versican. Experiments performed in thesis will need to be 
done on muscles from these mice to characterise the effects of versican in a non-
dystrophic model. Additionally, these mice could be subjected to a muscle injury, 
allowing the processes of degeneration, inflammation and regeneration to be 
studied in order to elucidate any effects of reduced versican in a normal mouse 
model. This would be a major help in understanding whether the effects in this 
thesis were because of an improvement in dystrophic pathology or due to a 
reduction in versican. 
Furthermore, in Chapter 3 of this thesis, glucocorticoids were found to supress 
versican gene and protein expression in C2C12 cells, a simplified and 
uncomplicated model of muscle regeneration. However it remains unknown if 
glucocorticoids also reduce versican within dystrophic muscles in-vivo, a highly 
intricate model which has the added complexity of cellular process such as 
inflammation, regeneration and fibrosis, and hence will need to be studied in the 
future. For this to occur, the period of glucocorticoid treatment would require 
careful consideration in an in-vivo model. For instance, a daily administration of 
glucocorticoids to mdx mice initially improved muscular strength, however the 
continuous treatment ultimately resulted in side effects, such as loss of muscle 
strength, increased cardiac fibrosis after a period of 100 days (366), and 
upregulated atrophic pathways (526). However, weekly treatment with 
glucocorticoids resulted in mdx mice having better repair of muscle membranes, 
improved the regenerative capacity of muscle, and had fewer side effects, as 
atrophic pathways were downregulated (526). Furthermore, the effects of 
glucocorticoids upon mice with genetically reduced versican currently remains 
unknown. It can be speculated that mdx-hdf mice treated with glucocorticoids 
could have minimal benefits from glucocorticoids as versican is already reduced. 
Or perhaps glucocorticoid treatments would still benefit these mice in areas 
where the reduction of versican has no effect, especially as the exact 
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mechanisms and cell signalling pathways regulated by glucocorticoids, such as 
the downstream consequences on inflammation, fibrosis and muscle function in 
DMD, are still relatively unknown. Therefore, in order to confirm versican 
downregulation in an in-vivo study, and to see if glucocorticoids have any 
benefits in mice with reduced versican, the glucocorticoid treatment of mdx and 
mdx-hdf mice must be undertaken by using a clinically relevant, intermittent 
dosing protocol. Based on findings from Chapters 4 and 5 of this thesis, most 
benefits of reduced versican were observed in mice at 6 weeks of age, therefore 
it is important to start glucocorticoid administration early, during the period of 
growth and before fibrosis becomes a problem (124). The diaphragm and the 
soleus muscle were found to be the most badly affected muscles both within this 
thesis, a finding supported by published literature (130, 567). Therefore, to 
confirm the functional benefits of glucocorticoid treatment in dystrophic mice, 
whole body metabolism, exercise capacity and skeletal muscle contractile 
function would need to be undertaken on the diaphragm and soleus muscles of 
6 week old mdx and mdx-hdf mice. This should be followed with biochemical 
analysis of transitional matrix synthesis and remodelling, including versican and 
versikine expression, and markers of regenerative myogenesis and inflammation.  
6.5 Novel pharmaceutical strategies to target excess 
versican in DMD 
Using cell culture models and mdx mice, this thesis identifies versican as a 
transitional matrix protein overexpressed in dystrophic muscles. It presents a 
comprehensive physiological characterisation of the effects of versican reduction 
on the pathology and function of diaphragm and fast and slow twitch hindlimb 
muscles from young growing, and adult mdx mice, which results being overall 
are quite favourable. Glucocorticoids may not be the only pharmaceutical 
strategy to target versican upregulation and a dysregulated transitional matrix in 
dystrophic muscles. Versican is highly decorated with chondroitin sulphate GAG 
side chains, far more than decorin and biglycan – two other highly expressed CS 
GAG proteins in dystrophic muscles (40). It should be therefore considered 
whether it is an excess of versican, or its CS GAG side chains, which are driving 
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the pathology of dystrophic muscles. If an accumulation of versican is driving 
muscle pathology, then downregulating versican expression with 
dexamethasone (Chapter 3) may be of benefit. There is an upregulation of CS 
GAG chains in muscle biopsies from patients with DMD (116). These can be 
degraded via an intramuscular injection of chondroitinase ABC, which 
ameliorated the pathology of hindlimb muscles from mdx mice, presumably 
through enhanced regenerative myogenesis (457). Furthermore, there are 
variations of versican that do not contain the CS GAG rich domain, such as the V3 
form of versican. In rabbit carotid arteries injected with cells transduced to 
express V3 versican, the V3 form was found to be beneficial in preventing 
atherosclerosis by structurally remodelling the matrix of the artery, thereby 
inhibiting macrophage infiltration and lipid deposition that bind to the GAG 
chains of versican (568). As V3 versican is found in healthy human skeletal 
muscle (569), an upregulation of the V3 form might also reduce the 
inflammation and fibrosis in dystrophic skeletal muscles, although this remains 
to be tested within future studies.  
Another important factor that could be targeted for future pharmaceutical 
therapies is versikine, the cleavage product of V1 versican. Versikine has only 
just become of great interest as a bioactive protein, and has only recently been 
identified as a DAMP (342, 343), a protein produced upon muscular injury which 
stimulates inflammatory processes. Furthermore, versikine has also been 
associated with apoptosis during the formation of the digits (334). As detailed 
within various mdx mouse muscles in Chapters 3-5 of this thesis, versikine may 
potentially drive inflammation and apoptosis in dystrophic muscles. Therefore, 
future research is required to investigate the roles and signalling pathways of 
versikine. Additionally, facilitating the faster removal of versikine may also have 
beneficial effects, potentially reducing inflammation and apoptosis within 
dystrophic muscles. As such, a better understanding of the ECM proteases which 
degrade versikine is needed. 
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6.6 Final conclusions 
Encapsulated in this thesis are data that show glucocorticoids increase 
myogenesis by reducing the ECM, and most importantly, components of the 
transitional matrix, which when modified through the reduction of versican in-
vivo in mdx mice, exerted differential effects on various muscle types, with the 
majority of benefits being in the younger 6 week old mice. Furthermore, it also 
details the importance of acknowledging patient growth, muscle type and 
progression of disease when considering the right age and type of therapeutic 
when administering treatments for DMD, and in other inflammatory diseases. 
Indeed, the ECM, once overlooked, is now rapidly becoming a major field of 
interest. However, only recently has a dysregulated transitional matrix been 
associated with disease (527, 558). Modulating the transitional matrix 
components, such as hyaluronan and versican, may therefore be of great benefit 
for regenerative medicine applications. The data contained within this thesis are 
the first to link a dysregulated and overexpressed transitional matrix with 
dystrophic pathology, and hence signifies not only a major addition to the field 
of DMD, but also to the emerging area of the transitional matrix in regeneration 
and diseased states.  
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